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ABSTRACT 
 
The therapeutic benefits of atypical antipsychotics are proposed to be 
mediated by antagonism and subsequent desensitization of 5-HT2A receptor 
signaling; however, the mechanisms underlying this desensitization response 
are not yet understood. We hypothesize that the desensitization of 5-HT2A 
receptors induced by atypical antipsychotics is dependent on activation of the 
JAK-STAT pathway. To test this hypothesis, we used a cell line, A1A1v cells, 
that natively expresses 5-HT2A receptor signaling system, and further 
confirmed the findings in rats. In A1A1v cells, we confirmed that treatment 
with both olanzapine and clozapine desensitizes 5-HT2A receptor signaling. 
Furthermore, olanzapine treatment also increased RGS7 mRNA and protein 
levels which were dependent on activation of JAK-STAT pathway. Similar 
results were found with MDL100907, a specific 5HT2A receptor antagonist; 
RGS7 protein and mRNA levels were increased along with activation of the 
JAK-STAT pathway, suggesting that antagonism of 5-HT2A receptors is 
sufficient to induce these changes. In addition, we also found an increase in 
STAT3 binding to the putative RGS7 promoter region with olanzapine 
treatment suggesting that the increase in RGS7 expression could be directly 
mediated by the JAK-STAT pathway. An increase in RGS protein could 
mediate desensitization of 5-HT2A receptor signaling by its GAP activity.  
Lastly, inhibition of the JAK-STAT pathway significantly attenuated 
olanzapine-induced desensitization of 5-HT2A receptor signaling in A1A1v 
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cells.  Similar findings were also observed in rats treated with olanzapine for 7 
days. We found a decrease in 5-HT2A receptor-stimulated PLC activity in the 
frontal cortex which was dependent on activation of JAK-STAT pathway. 
Consistent with the cell culture data, the olanzapine-induced increase in 
RGS7 proteins and mRNA levels were dependent on activation of the JAK-
STAT pathway. Olanzapine treatment significantly reduced plasma levels of 
oxytocin, adrenocorticotrophic hormone (ACTH), and corticosterone. 
Surprisingly, 5-HT2A receptor-stimulated oxytocin and corticosterone levels 
were also decreased in a dose-dependent manner by the JAK inhibitor 
whereas ACTH levels were not altered.  Further studies are needed to 
investigate the role of the JAK-STAT pathway in the regulation of hormone 
levels. Taken together, these results from experiments in cells in culture and 
in rats suggest that increases in RGS7 expression via increased activation of 
the JAK-STAT pathway are necessary for antipsychotic-induced 
desensitization of 5-HT2A receptor signaling.  
 iii
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CHAPTER I 
 
INTRODUCTION 
 
Atypical antipsychotics are widely prescribed for the treatment of 
schizophrenia. They are classified as atypical because of their ability to 
achieve antipsychotic effects with lower rates of extrapyramidal side effects 
compared with first generation antipsychotics such as haloperidol. In addition, 
selected atypical antipsychotics also improve certain aspects of cognitive 
function in schizophrenic patients, whereas typical antipsychotics may worsen 
cognition (Meltzer, 1999). Although, atypical antipsychotics have a diverse 
receptor binding profile, 5-HT-receptor-based mechanisms have been 
postulated to play a critical role in the action of the atypical antipsychotic 
drugs (Willins, et al., 1999). However, the process by which these drug-
receptor interactions translate into long-term cellular adaptive changes 
resulting in antipsychotic efficacy is unknown. Atypical antipsychotic drugs 
bind with high affinity to 5-HT2A receptors and desensitize 5-HT2A receptor 
signaling (Deutch, et al., 1991; Meltzer and Nash, 1991; Seeger, et al., 1995). 
Desensitization of 5-HT2A receptor signaling by atypical antipsychotics is 
reported to be associated with down-regulation and internalization (Willins, et 
al., 1999). The 5-HT2A receptor subtype has been implicated in various 
psychiatric disorders including depression, anxiety, and schizophrenia 
(Glennon, et al., 1984). Atypical antipsychotics as well as a specific 5-HT2A 
receptor antagonist, MDL 100,907, desensitize 5-HT2A-mediated responses 
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(Willins, et al., 1999). However, the molecular mechanisms involved in 
antagonist-induced desensitization of 5-HT2A receptor signaling are not well 
understood. By understanding the molecular mechanisms underlying the 
effects of olanzapine and other atypical antipsychotics, we hope to gain 
insight into targets for therapeutic treatment of psychiatric disorders. 
The Janus tyrosine kinase (JAK)-signal transducer and activator of 
transcription (STAT) signaling cascade has been reported to couple with 5-
HT2A receptors in skeletal muscles and vascular smooth muscle cells (Guillet-
Deniau, et al., 1997; Banes, et al., 2005). G protein-coupled receptor 
agonists, thrombin and angiotensin II, have previously been shown to activate 
the JAK-STAT signaling cascade (Bhat, et al., 1994). JAK-STAT could be one 
of the possible signaling pathways involved in mediating olanzapine-induced 
receptor desensitization. JAKs are a small family of cytoplasmic tyrosine 
kinases initially identified as a mediator of cytokine receptor signaling (Ihle, 
1995). Agonist stimulation of cytokine receptors causes phosphorylation of 
JAK, which in turn phosphorylates tyrosine residues on the receptor 
cytoplasmic tail, facilitating activation of specific STATs. Tyrosine 
phosphorylated STAT, then undergoes dimerization and translocates to the 
nucleus, where it binds to target DNA sequences (Darnell, Jr., 1998). 
Alterations in proximal components of the 5-HT2A receptor signaling system 
could mediate desensitization in response to increased activity of intracellular 
cascades such as JAK-STAT. 5-HT2A receptors are classically linked to the 
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Gαq protein family (Ivins and Molinoff, 1990). Activation of Gαq stimulates 
phospholipase C activity, which subsequently promotes the release of 
diacylglycerol and inositol triphosphate, which in turn stimulate protein kinase 
C activity and calcium release (Berg, et al., 2001). It has been extensively 
reported that increased expression of regulator of G protein signaling (RGS) 
proteins cause desensitization of several G protein-associated receptor 
systems (Koelle and Horvitz, 1996). RGS proteins reduce the duration of 
signaling of many G protein-coupled receptors by their action as GTPases, 
accelerating the hydrolysis of GTP-bound Gα proteins or by blocking the 
interaction of Gα with its target proteins through a not well understood process 
known as effector antagonism (Bramow-Newerly, et al., 2006). Expression of 
RGS7 protein in rat frontal cortex is well documented (Zhang and Simonds, 
2000;Krumins, et al., 2004) and decreased 5-HT2A receptor-mediated 
signaling via direct interaction of RGS7 protein with Gαq has been widely 
characterized in different systems (DiBello, et al., 1998;Ghavami, et al., 2004).  
 In addition, atypical antipsychotics are reported to reduce levels of 
ACTH and cortisol in schizophrenic patients (Cohrs, et al., 2006; Scheepers, 
et al., 2001; Hatzimanolis, et al., 1998; Meltzer, 1989; Markianos, et al., 
1999). Although, monoaminergic mechanisms including serotonin and 
dopamine are known to play an important role in the regulation of ACTH and 
cortisol secretion (Wilcox, et al., 1975; Fuller and Snoddy, 1984;Tuomisto and 
Mannisto, 1985; Contesse, et al., 2000), the attenuation of cortisol secretion, 
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after subchronic administration of olanzapine and clozapine to schizophrenic 
patients, has been attributed to 5-HT receptor blockade (Scheepers, et al., 
2001; Hatzimanolis, et al., 1998; Markianos, et al., 1999).  Furthermore, 5-
HT2A receptors in the hypothalamic paraventricular nucleus have been shown 
to mediate the neuroendocrine responses to a peripheral injection of DOI; 
intraparaventricular and peripheral injections of the selective 5-HT2A receptor 
antagonist MDL 100,907 dose dependently inhibit the DOI-induced increases 
in hormone secretions (Zhang, et al., 2002). These data suggest that 
decreases in hormone secretion by atypical antipsychotics may be mediated 
by 5-HT2A receptors and that plasma hormone levels can be monitored as an 
index of the function of 5-HT2A receptor signaling in the hypothalamic 
paraventricular nucleus. 
Central hypothesis 
The desensitization of 5-HT2A receptor signaling induced by chronic 
antagonist treatment is dependent on JAK-STAT signaling and subsequent 
changes in gene expression, especially an increase in RGS7 protein.  Three 
different specific aims are proposed to test this hypothesis.  
The first specific aim of this dissertation is to determine the underlying 
mechanisms of olanzapine-induced desensitization of 5-HT2A receptor 
signaling in A1A1v cells. Experiments are proposed to test whether 
olanzapine-induced desensitization is mediated by alterations in signaling 
components of 5-HT2A receptor such as RGS proteins and receptor levels. In 
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addition, we will determine the possible role of activation of the JAK-STAT 
pathway on the desensitization response and whether inhibition of this 
pathway could reduce the desensitization response caused by olanzapine. 
The second specific aim is to determine the selectivity of atypical 
antipsychotics on desensitization of 5-HT2A receptor signaling and regulation 
of RGS7 protein expression. Specifically, whether clozapine-induced 
desensitization is mediated by activation of JAK-STAT pathway and RGS7 
expression. Furthermore, we will determine if antagonism of 5-HT2A receptors 
is sufficient for desensitization of 5-HT2A receptor signaling by atypical 
antipsychotics. The third specific aim is to determine the involvement of the 
JAK-STAT signaling in the olanzapine-induced desensitization of 5-HT2A 
receptor signaling in vivo. Specifically, in this aim we will investigate the role 
of the JAK-STAT pathway in the frontal cortex (5-HT2A-mediated-PLC activity) 
and the paraventricular nucleus (hormone levels) of rats in response to 
chronic treatment with olanzapine.  
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CHAPTER II 
 
REVIEW OF RELATED LITERATURE 
 
 
Serotonin 
Discovery: 
The discovery of serotonin (5-HT) can be traced back to the late 
1940’s when it was reported that the serum of clotted blood contained a factor 
capable of causing vasoconstriction. Eventually, the indolamine 5-HT was 
discovered by Rapport et al. (1948) and was found to have vasoconstriction 
and blood clotting properties  (Rapport, et al., 1948). Independently, 
Erspamer and Ottolenghi (1950) had discovered a factor (enteramine) in gut 
mucosa that was later shown to be identical to 5-HT (Erspamer and 
Ottolenghi, 1950). Twarog and Page (1953) finally discovered that 5-HT was 
present in brain and this finding led others to establish 5-HT as a 
neurotransmitter (Twarog and Page, 1953). 5-HT is found in three major 
areas of the body; the intestinal wall (isolated as enteramine by Dr. Erspamer, 
where it causes increased gastrointestinal mobility); blood vessels (isolated 
and named as serotonin by Dr. Page’s laboratory, where it causes 
vasoconstriction); and the central nervous system (CNS) (isolated by Dr. 
Twarog).   
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Brain Distribution of 5-HT:  
The anatomical distribution of 5-HT neurons in the brain was first 
studied by fluorescence histochemical detection of the indoleamine by 
Dahlstrom and Fuxe (Dahlstrom and Fuxe, 1964). In 1964, they described 5-
HT neurons as a relatively small population of morphologically diverse 
neurons whose cell bodies are present largely within the brainstem raphe 
nuclei and particular regions of the reticular formation. Raphe clusters of 5-HT 
neurons are found rostrally from the level of the interpeduncular nucleus in 
the midbrain to the level of the pyramidal decussation in the medulla. 
 
 
Cerebral 
Cortex
Thalamus
Medial 
Central      
grey 
Median raphe 
nucleus 
(B5 &B8) 
Dorsal raphe 
nucleus 
(B6 &B7) 
Hippocampus 
Amygdala 
Striatum
Hypothalamus 
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Figure 1: Serotonergic projections in the human brain. Includes neuronal 
projections (arrow) and serotonergic nuclei in the brain stem (ovals). (Picture 
adapted from (Bear and Abraham, 1996). 
Although there are only about 20,000 serotonergic neurons in the rat 
brain (~300K in humans), the extensive axonal projection system arising from 
these neurons bears a tremendous number of collateral branches so that the 
5-HT system densely innervates nearly all regions of the CNS (Dahlstrom and 
Fuxe, 1964). The midline raphe nuclei consist of the caudal linear nucleus 
(CLi, B8), the dorsal raphe nucleus (DR, B6, B7), the median raphe nucleus 
(MnR, B5, B8), raphe magnus nucleus (RMg, B3), raphe pallidus nucleus 
(RPa, B1), and the raphe obscurus nucleus (ROb, B2) (Dahlstrom and Fuxe, 
1964; Dahlstrom and Fuxe, 1964; Fuxe and Gunne, 1964; Dahlstroem, et al., 
1964). Innervations of the ascending structures by serotonergic neurons are 
primarily derived from the dorsal raphe and median raphe (Figure 1), and 
innervate the cortex, limbic system, basal ganglia and hypothalamus. The 
cortex, striatum, and globus pallidus are predominantly innervated by dorsal 
raphe nucleus; whereas median raphe predominantly innervates medial 
septum and dorsal hippocampus. In addition, the ventral hippocampal region 
is innervated by both the dorsal raphe nucleus and the median raphe nucleus 
(McQuade and Sharp, 1997).  
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Initial 5-HT Studies: 
After the discovery of 5-HT, researchers primarily focused on defining 
the pathways for synthesis and degradation of 5-HT.  One of the first clinical 
applications of this new found understanding was the use of 5-HT synthesis 
inhibitor, parachorophenylalanine (PCPA), as a treatment to reduce excessive 
5-HT secretions from carcinoid tumors (Carrillo and Aviado, 1969). However, 
a great deal of interest soon focused on 5-HT because of its presumed 
involvement in the major psychoses (Heym, et al., 1984; Himwich and Costa, 
1960; Consbruch and Faust, 1960; Sourkes, 1956; Pelicier, 1964). The 
development of monoamine oxidase inhibitors and their effectiveness in the 
treatment of depression provided an early indication of the importance of 5-
HT in these psychiatric disorders.  
5-HT is involved in diverse physiological and behavioral functions such 
as aggression, appetite, cognition, emesis, endocrine function, 
gastrointestinal function, sex, sleep, and vascular function (Reynolds, III, et 
al., 1995; Heninger, 1997). 5-HT has been also implicated in the etiology of 
many disease states and particularly important in mental illness such as 
depression, anxiety, obsessive compulsive disorder, panic disorder, migraine, 
and eating disorders (Sjoerdsma and Palfreyman, 1990). Indeed, many 
treatments currently used for these disease states are thought to act by 
modulating serotonergic tone, highlighting the need of developing more 
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selective ligands that could lead to novel therapies with increased efficacy 
and decreased side effects.  
 
Biosynthesis and Metabolism of 5-HT:  
Considering the important and diverse role of 5-HT in the brain, one 
would assume that most of the 5-HT in the body would be present or 
synthesized in the brain. However, only 1-2% of total body 5-HT is 
synthesized in brain and is sufficient to maintain normal brain function. Most 
of the 5-HT, almost 95%, is actually found in gastrointestinal tract (GI) (90% in 
enterochromaffin cells and 5% in enteric neurons). Although a large amount 
of 5-HT is present in the periphery, it cannot cross the blood brain barrier 
therefore, it is synthesized in the brain under normal conditions (Sharma and 
Dey, 1986; Sharma, et al., 1990). Plasma L-tryptophan, which is a primary 
substrate for 5-HT synthesis, is derived mainly from diet and is actively 
transported into the brain. 5-HT can be synthesized both in the neuronal cell 
bodies and nerve terminals (Wilson and Marsden, 1996). The synthesis of 5-
HT is described in figure 2 with tryptophan hydroxylase (A) being rate limiting 
enzyme. Once released from neurons, the action of 5-HT is mainly terminated 
by re-uptake in neurons, where it is either restored in the vesicles or 
metabolized by monoamine oxidase (MAO). 
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 Figure 2: 5-HT synthesis pathway: Schematic representation of the 5-HT 
synthesis pathway with tryptophan as starting material. Tryptophan 
hydroxylase is the rate limiting enzyme.  
 
Discovery of 5-HT Receptors: 
 Neurotransmitters produce their effects as a consequence of 
interaction with appropriate receptors. Gaddum and Picarelli (1957) were the 
first to suggest the existence of more than one type of 5-HT receptor 
(Gaddum and Picarelli, 1957). Subsequently pharmacological, 
neurophysiological, and other techniques have provided evidence that 5-HT 
acts at pre-synaptic and post-synaptic sites and could be excitatory or 
Tryptophan 
A
5-hydroxytryptophan 
B   
Serotonin (5-HT) 
C 
       5-hydroxy-indole-acetic acid 
A. Tryptophan hydroxylase 
B. Amino acid decarboxylase 
C. Monoamine oxidase/ Aldehyde dehydrogenase 
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inhibitory in its action. However, more definitive evidence of 5-HT receptor 
heterogeneity began to emerge from early 1980’s.  
There is now molecular and functional evidence for the existence of 16 
different subtypes of 5-HT receptors (Hoyer, et al., 2002). Indeed, the 
multiplicity of 5-HT receptor subtypes, both within and among species, has 
exceeded most of the predictions that could have been made on the basis of 
pharmacological data in the late 1980s. While the discovery of 5-HT receptor 
subtypes advanced rapidly in the late 1980s and early 1990s, the number and 
specificity of ligands for 5-HT receptor subtypes has lagged behind. The 
existence of so many 5-HT receptors appears to be a result of more than 750 
million years of molecular evolution. Advances in molecular biological 
analysis of 5-HT receptors have made the classification procedure more 
logical (Lucas and Hen, 1995). 
 
Classification of 5-HT Receptors: 
Bradley et al. (1986) initiated a classification scheme for the subtypes 
of 5-HT receptors (Bradley, et al., 1986). His rationale was based on binding 
studies of selective pharmacological agents like methiothepin, methylsergide 
and 5-carboxymidotryptamine. The Nomenclature Committee of the Serotonin 
Club (NCSC) updated and modified this list in 1993 to include recently cloned 
receptors (Humphrey, et al., 1993).  
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The current system of classification depicted below is inclusive of new 
information obtained with both recombinant and native receptors to align the 
nomenclature with the human genome and avoid species differences (Hartig, 
et al., 1996; Hoyer, et al., 1994).  Currently, seven families of 5-HT receptors 
are recognized including 16 subtypes (multiple isoforms)(Hoyer, et al., 2002). 
 
 
Figure 3: 5-HT receptors with effector enzymes: Schematic representation 
of the 5-HT receptor family based on protein sequence and structural 
homology (Barnes and Sharp, 1999;Hoyer, et al., 2002)  
 Structurally, all 5-HT receptors, except the 5HT3 receptor (Maricq, et 
al., 1991) which is a ligand gated ion channel, related to NMDA, GABA, and 
nicotinic receptor, belong to G-protein super-family and contain the seven 
transmembrane regions. At least five 5-HT1 receptor subtypes have been 
recognized- 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E and 5-HT1F. These receptors are 
negatively linked to adenyl cyclase via the Gi family of G proteins with an 
Gi/o  GsGq
5-HT1A   5-HT1B     5-HT1D     5-HT1E   5-HT1F
 
5-HT4   5-HT6   5-HT7   5-HT5A   5-HT5B
 
5-HT2A   5-HT2B   5-HT2C  
cAMP cAMP PLC 
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overall sequence homology of about 40%. 5-HT4 - 5-HT7 are positively linked 
to adenyl cyclase via Gs. The central focus of this dissertation is on 5-HT2A 
subclass of 5-HT receptors, this receptor subtype will be described in more 
detail. 
 
5-HT2 Receptor Subfamily: 
On the basis of functional studies with agonists and antagonists, ligand 
binding affinities, molecular structure and intracellular transduction 
mechanisms, the 5-HT2 receptor family comprises three specific subtypes: 5-
HT2A, 5-HT2B, and 5-HT2C. All three are positively couple to the effector 
enzyme phospholipase C (PLC) via Gq and display an overall sequence 
homology of approx 60% (Boess and Martin, 1994; Martin and Humphrey, 
1994). Activation of these receptors results in PLC-mediated increases in 
inositol phosphate (IP3) and increases in  intracellular Ca++ levels (Berridge, 
1982; Conn and Sanders-Bush, 1984). Ullmer et al. reported that stimulation 
of 5-HT2B receptors causes intracellular calcium release via a mechanism 
independent of the phosphatidylinositol hydrolysis (Ullmer, et al., 1996).  
 
5-HT2A Receptors:  
The human 5-HT2A receptor gene is located on chromosome 13q14–
q21 (Sparkes, et al., 1991) consists of three exons separated by two introns, 
and spans over 20 kb (Liu, et al., 1991). 5-HT2A receptor subtypes have been 
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identified in both the CNS and the periphery. In periphery, they are located on 
vascular, bronchial, and urinary smooth muscle and on platelets. Their 
function includes vaso- and broncho-constriction and platelet aggregation. 5-
HT2A receptors are expressed widely throughout the CNS. They are 
expressed near most of the serotoninergic terminal rich areas, including 
neocortex (mainly prefrontal, parietal, and somatosensory cortex) and 
olfactory tubercle. There are high concentrations of this receptor on the apical 
dendrites of the pyramidal cells in layer V of the cortex suggested to modulate 
cognitive processes (Pazos, et al., 1985; Pompeiano, et al., 1994). In 
addition, 5-HT2A receptors are predominantly located in the neocortex, with a 
large density in the prefrontal cortex, which suggests its involvement in higher 
brain functions, such as working memory (Williams, et al., 2002). In the rat, 
postsynaptic 5-HT2A receptors in medial prefrontal cortex control the activity of 
the serotonergic system through changes in the activity of pyramidal neurons 
projecting to the dorsal raphe nucleus. Stimulation of central 5-HT2A receptors 
in rats causes head twitches and is suggested to mediate the effects of 
hallucinogens such as lysergic acid diethylamide (LSD) in humans (Darmani 
and Gerdes, 1995).  Abnormalities in 5-HT receptors especially 5-HT2A 
receptor-mediated signal transduction systems have been widely reported in 
various disorders like mood disorders (Ressler and Nemeroff, 2000; Akin, et 
al., 2004), and specifically depression (Rosel, et al., 2000), and bulimia 
nervosa (binge eating and inappropriate compensatory behaviors to avoid 
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weight gain) (Goethals, et al., 2004; Walsh and Devlin, 1998). One of the 
more interesting and recent findings on the 5-HT2A receptor is that it plays a 
very important role in schizophrenia. Although, the role of 5-HT2A receptors in 
the etiology of schizophrenia is still debatable, there is complete agreement 
regarding 5-HT2A receptors as an important target of atypical antipsychotics. 
The next section will discuss the progress made in over many decades of 
research on 5-HT2A receptors in various CNS disorders. 
 
5-HT2A Receptors and CNS Disorders 
5-HT2A receptors have been implicated in numerous CNS disorders 
including depression, anxiety, migraine, psychosis and schizophrenia, sleep 
disorders, and hypertension. In addition to other monoamine neurotransmitter 
receptors, 5-HT2A receptors serve as a major therapeutic target of 
antidepressant and antipsychotic drugs. The next section will highlight the 
role of 5-HT2A receptors in depression and schizophrenia. 
 
Depression and 5-HT2A receptors:  
Depression is one of the most common psychological problems.  Each 
year over 17 million American adults experience a period of clinical 
depression. A decrease in the synaptic levels of monoamines (5-HT, 
norepinephrine, and epinephrine) in the CNS may be an underlying cause of 
this disorder (Delgado, 2000). With the success of selective serotonin 
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reuptake inhibitor (SSRIs), such as fluoxetine (Prozac), the 5-HT system 
became the focus of a large body of literature implicating 5-HT 
neurotransmitter disturbances in the pathophysiology of depression. Of the 16 
different classes of 5-HT receptors identified to date, the 5-HT2A and 5-HT1A 
receptors have been most extensively investigated in psychotic disorders. 
Using positron emission tomography (PET) and a selective 5-HT2A receptor 
radioligand [18F] altanserin, a significant decrease in 5-HT2A receptor density 
was reported in hippocampus of both young and old depressed patients 
(Sheline, et al., 2004; Mintun, et al., 2004).  
In recent years, a number of open-label and placebo-controlled studies 
have suggested that atypical antipsychotic drugs augment the clinical 
response to selective serotonin reuptake inhibitors (SSRI) in treatment-
resistant patients (Ostroff and Nelson, 1999; Marangell, et al., 2002; Marek, et 
al., 2003).  One common feature of these agents is their ability to occupy 5-
HT2 receptors in the brain at clinical doses and to block 5-HT2 -mediated 
responses, in particular those mediated by 5-HT2A receptors (Marek, et al., 
2003). Studies in 5-HT2A receptor knock-out mice showed a significant 
reduction in forced-swim test immobility (test of antidepressant drug action) 
that was of equal magnitude to that produced by the antidepressant mianserin 
and to the 5-HT2A receptor antagonist, MDL100907. The lack of change in 
other behavioral tests including open-field locomotor activity, entries in the 
elevated-plus maze test, and susceptibility to pentylenetetrazole (PTZ)-
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induced seizures suggested that non-specific changes in locomotor activity or 
neuronal excitability were not responsible for the reductions in immobility 
observed in the forced swim test (Sibille, et al., 1997). Altogether, these 
observations support a role for 5-HT2A receptors in antidepressant drug 
action.  
 
Schizophrenia and 5-HT2A receptors:  
Schizophrenia is a group of illnesses that usually begins during 
adolescence or young adulthood. It is characterized by two or more of the 
following, and each present for a significant portion of time during a 1-month 
period: delusion, hallucinations, disorganized speech, grossly disorganized or 
catatonic behavior, and negative symptoms (affective flattening, alogia or 
avolution). The realization in the early 1950s, that LSD can cause psychosis 
suggests that abnormal neurotransmission at 5-HT2 receptors may be 
involved in pathophysiology of schizophrenia (Woolley and Shaw, 1954).  
Direct evidence supporting this hypothesis came primarily from post-mortem 
ligand binding studies in which a decrease in 5-HT2A receptor density in the 
prefrontal cortex of untreated schizophrenic patients was observed (bi-
Dargham, et al., 1993). Additional studies like positron emission tomography 
(PET) suggested a decrease in 5-HT2A receptor density in schizophrenic 
patients taking atypical antipsychotics (Trichard, et al., 1998). However, a 
great deal of research on 5-HT2A receptors and schizophrenia now suggests 
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that the changes in this receptor are complex and may be involved in both the 
pathology of the disorder and the effects of some antipsychotic drugs(Dean, 
2003). 
In general, the serotonergic system has an inhibitory influence on 
dopaminergic neurons and this effect appears to be mediated by 5-HT2A 
receptors at the level of midbrain (e.g. substantia niagra and ventral 
tegmental area) as well as at the terminal regions of the nigrostriatal and 
mesocortical dopaminergic pathways (Kapur and Remington, 1996). 
According to Weinberger, the primary defect in schizophrenia may be the 
diminished dopaminergic innervention of the prefrontal cortex, which results in 
mesolimbic dopaminergic hyperactivity (Weinberger, 1987) . Thus, an 
increase in subcortical dopaminergic function may account for the positive 
symptoms and a decrease in cortical dopaminergic function may underlie the 
negative symptoms of schizophrenia.  In addition, the atypical antipsychotic 
clozapine was reported to induce a sustained enhancement in dopaminergic 
tone in the medial frontal cortex (Youngren, et al., 1994), which may be 
attributed to antagonism of 5-HT2A receptors(Meltzer, et al., 1989). The ability 
of 5-HT2A receptor antagonists to modify behavioral states associated with 
excess dopaminergic activity, while having little or no effect on basal 
dopamine function, may be relevant to the lack of extra-pyramidal effects 
observed following administration of atypical antipshychotics such as 
clozapine (Meltzer, et al., 1989).  
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Furthermore, it is suggested that the atypical antipsychotic-induced 
internalization (sequestration of the receptor away from the cell surface) of 5-
HT2A receptors may be involved in the therapeutic effect of these drugs. 
Interestingly, antipsychotics devoid of 5-HT2A receptor antagonist activity had 
no effect on the regulation or subcellular distribution of 5-HT2A receptors in 
cells and in vivo. Subsequently, it is suggested that 5-HT2A receptor 
desensitization and down-regulation plays a key role in the maintenance of 
the therapeutic action of antipsychotics. These studies suggest that it is 
important to understand the molecular changes that occur with 5-HT2A 
receptor antagonist treatment and other mechanisms that result in 
desensitization of 5-HT2A receptor signaling. By discovering the molecular 
mechanisms underlying signaling and desensitization of 5-HT2A receptor, new 
targets for therapeutic intervention may be identified. 
 
Signaling Pathways of 5-HT2A receptor 
Classically, 5-HT2A receptors are coupled to Gq/11 G alpha-proteins and 
mediate physiological responses by activating PLCβ, leading to the 
generation of IP3 and diacylglycerol (DAG)(Taylor, 1990;Conn and Sanders-
Bush, 1984). IP3 mobilizes calcium from intracellular stores which then 
activates calcium-dependent kinases and various signaling pathways 
(McKune and Watts, 2001;Takuwa, et al., 1989). However, recent studies 
have revealed a rich diversity of coupling mechanisms of 5-HT2A receptors 
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suggesting that these receptors can regulate a broad array of potential 
effectors depending on cell type, receptor population, density and types of G-
proteins expressed, and the specific agonist or antagonist by which the 
receptor is activated.  
 
Activation of Phospholipase A2:  
The 5-HT2A receptor can mediate stimulation of phospholipase A2 
(PLA2); thereby generating the second messenger arachidonic acid 
(AA)(Tournois, et al., 1998). 5-HT2A receptors can couple to PLA2 activation 
through two parallel signaling cascades: (1) activation of the pertussis toxin-
sensitive G protein, namely Gαi/o, causing the release of Gβγ, which is then 
free to initiate activation of the Ras-Raf-MEK-ERK signaling cascade, 
ultimately leading to ERK-mediated phosphorylation of cytosolic PLA2 
(cPLA2); and (2) activation of receptor-coupled pertussis toxin-insensitive 
Gα12/13, which functions to activate Rho, and ultimately results in p-38 
mediated phosphorylation of PLA2 (Chambers, et al., 2003; Kurrasch-
Orbaugh, et al., 2003). In addition, because inhibition of either pathway 
caused a nearly identical reduction in AA release, it appears that the two 
pathways share a common final enzyme known as mitogen activated protein 
kinase (MAPK) prior to PLA2 activation. It was shown that only the 5-HT2A 
receptor antagonist ketanserin and the PLA2 inhibitor mepacrine were able to 
inhibit all 5-HT-induced AA release in NIH3T3 cells (Kurrasch-Orbaugh, et al., 
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2003b). Qu et al. (2003) reported that the 5-HT syndrome, characterized by 
head and body shakes, ear scratching, skin jerks, and forepaw tapping, 
involves widespread brain activation of PLA2 via 5-HT2A receptors, leading to 
the release of the second messenger, arachidonic acid (Qu, et al., 2003). 
These reports suggest that 5-HT2A receptors could differentially regulate the 
PLA2 and PLC signaling pathways depending upon the cellular environment 
(Nagatomo, et al., 2004).  
 
Activation of Extracellular Signal-Regulated Mitogen-Activated Protein 
Kinase (ERK-MAPK):  
Previously, signals generated by receptor tyrosine kinases (RTKs) and 
GPCRs were thought to be completely compartmentalized, with little or no 
cross-talk between the signaling pathways. Recently, the lines of distinction 
between signaling pathways used by GPCRs and RTKs have become less 
definite. There is a new awareness that RTKs such as the epidermal growth 
factor (EGF) receptor (EGFR) and GPCRs possess significant potential for 
cross-talk during signal initiation and propagation. The transactivation of 
EGFR-dependent signalling pathways upon stimulation of GPCRs, which are 
critical for the mitogenic activity of ligands such as lysophosphatidic acid, 
endothelin, thrombin, bombesin and carbachol, provides evidence for such an 
interconnected communication network (Prenzel, et al., 1999). 5-HT2A 
receptor-mediated activation of ERK-MAP kinases in cells with contractile 
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phenotypes and vascular smooth muscle cells require  PLC, L-type Ca2+ 
channels, and MEK1 (Florian and Watts, 1998;Watts, et al., 1998). In renal 
mesangial cells, activation of ERK-MAPK is mediated by PKC and activation 
of an NAD(P)H oxidase-like enzyme (Grewal, et al., 1999;Greene, et al., 
2000). Xu et al.(2002) reported that in sheep aortic valve interstitial cells 
(SAVIC), 5-HT-induced activation of Erk1/2 via the MAP-kinase pathway is 
mediated only in part by 5-HT2A receptor activity (Xu, et al., 2002). Both PKC 
and Src/Src-like tyrosine kinase are involved in mediating the stimulatory 
effects of 5-HT on Erk1/2 activity.  
Besides these non-neuronal cell lines, in PC12 cells (endogenously 
expressing 5-HT2A receptors) 5-HT-induced activation of ERK has been 
reported to be mediated by calcium-calmodulin and tyrosine kinases 
independent of PKC (Quinn, et al., 2002). 5-HT2A receptors are also reported 
to activate Akt in a calcium dependent manner in PC12 cells (Johnson-Farley, 
et al., 2005).  Furthermore, 5-HT2A receptors are suggested to regulate 
activity of growth factor receptors. For example, in cultured renal mesangial 
cells, stimulation of 5-HT2A receptors mediated activation of tumor necrosis 
factor-activating enzyme (TACE), the shedding of heparin-bound epidermal 
growth factor (HB-EGF), and consequent activation of EGF receptor.  
Activation of EGF receptors results in ERK activation and cell proliferation 
(Gooz, et al., 2006) 
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Taken together these reports suggest that 5-HT2A receptors mediate a 
wide variety of peripheral and central physiological effects by activation of 
other signaling pathways. Further understanding of these diverse interactions 
of 5-HT2A receptors with other signaling pathways could shed light on 
changes in gene expression observed with various psychotic drugs acting on 
5-HT2A receptors. Given the importance of 5-HT2A receptors in both 
pathological situations and regular physiological processes, the next section 
will focus on various mechanisms proposed to mediate regulation of this 
receptor. 
 
 
Regulation of 5-HT2A receptors 
 
Many GPCRs can be desensitized and down-regulated by 
overexposure to agonists.  The 5-HT2 receptor system is unique in that 
chronic exposure to either agonists or antagonists leads to receptor 
desensitization and down-regulation (Toth and Shenk, 1994;Toth and Shenk, 
1994; Blackshear, et al., 1986; McKenna, et al., 1989). Desensitization can 
occur as a result of receptor uncoupling from G protein, internalization 
(sequestration of the receptor away from the cell surface), or down-regulation 
(reduced ligand-bound receptor); each has been reported for 5-HT2A 
receptors.  
Generally, G protein-linked receptor system functioning is highly 
regulated. These receptors are regulated by transcriptional mechanisms, 
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post-transcriptional mechanism such as mRNA editing and post-translational 
modifications of the receptors, including phosphorylation (Dohlman and 
Thorner, 1997; Chuang, et al., 1996; Freedman and Lefkowitz, 1996; Burns, 
et al., 1997). Other mechanisms also influence the functioning of G protein-
linked receptor system by altering coupling of G proteins to receptors such as 
binding of inhibitory proteins to receptors (e.g. arrestins for adrenoceptors) 
(Siderowski, et al., 1996). 
This section will briefly describe the following classical mechanistic 
models of 5-HT2A receptor desensitization: I) receptor-effector uncoupling as 
the consequence of receptor phosphorylation and arrestin binding, II) receptor 
internalization that removes agonist-activated  
Cell surface receptors from the plasma membrane to a membrane-
associated intracellular compartment and, III) receptor down-regulation as the 
result of lysosomal protein degradation or reduced mRNA or protein 
synthesis. 
I) Functional uncoupling of 5-HT2A receptors:  
An essential step in the desensitization of GPCRs is phosphorylation, a 
process that can be achieved within seconds to minutes of agonist stimulation 
and leads to uncoupling GPCRs from their G-proteins (Tobin, 1997). Two 
patterns of phosphorylation-induced desensitization have been characterized 
for GPCRs: homologous and heterologous desensitization. Homologous 
desensitization is an agonist-specific process based on the phosphorylation of 
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only those receptors that were activated by a given agonist. In contrast, 
heterologous desensitization reduces the sensitivity of receptors other than 
those stimulated by a particular agonist.  
G-protein-coupled receptor kinase (GRK)-mediated desensitization: 
   
As with other GPCRs, it is generally thought that the desensitization of 
5-HT2 receptors can be induced by GRKs and arrestins. In particular for the 5-
HT2A receptor, arrestins can bind to the third intracellular loop of the 5-HT2A 
receptor and are co-localized with 5-HT2A receptors in cortical pyramidal 
neurons. Furthermore, endogenously expressed 5-HT2A receptors in C6 
glioma cells show arrestin-dependent desensitization (Gray, et al., 2001). 
However, the desensitization of 5-HT2A receptors in the heterologous HEK-
293 cell system seems to be arrestin-independent, possibly indicating that the 
underlying mechanisms of homologous 5-HT2A receptor desensitization are 
cell-type dependent (Bhatnagar, et al., 2001; Gray, et al., 2001). 
 
Desensitization mediated by other kinases: 
 
Desensitization can be mediated by second messenger-dependent 
phosphorylating proteins, e.g. protein kinase A (PKA) or C (PKC) or 
calcium/calmodulin-dependent kinase (CaMK). Based on the effects of PKC 
inhibitors (e.g., staurosporine, 1-(5-isoquinolinesulfonyl)-2-methylpiperazine 
dihydrochloride (H-7)) and activators (e.g., mezerein, phorbol 12-myristate 
13-acetate (PMA)), a PKC-mediated feedback system appears to mediate the 
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desensitization of 5-HT2A receptors (Anji, et al., 2000; Kagaya, et al., 1990; 
Marek and Aghajanian, 1995; Rahimian and Hrdina, 1995; Rahman and 
Neuman, 1993). Rahimian and Hrdina (1995) further confirmed that the 5-
HT2A receptor can be desensitized as a result of an agonist-induced increase 
in PKC activity. In C6 glioma cells, which express only the PKC α and γ 
isoforms, treatment with 5-HT increases the levels of PKC α and γ, 
suggesting that both isoforms may be involved in 5-HT2A receptor regulation 
(Anji, et al., 2000). Analogously to PKC, a second second-messenger-
dependent kinase, CaMK, seems to be involved in the pathway that 
desensitizes 5-HT2A receptors in C6 glioma cells (Akiyoshi, et al., 1993; 
Kagaya, et al., 1993; Rahman and Neuman, 1993).  
II) Internalization of 5-HT2A receptors: 
It is generally accepted that 5-HT2A receptors undergo an agonist-
induced internalization. Rapid 5-HT2A receptor internalization to endosomes 
after exposure to an agonist occurs via clathrin-coated vesicles in cells 
(Bhatnagar, et al., 2001; Berry, et al., 1996). Analogously to classical GPCR 
regulation, agonist-induced internalization of endogenously expressed 5-HT2A 
receptors mediates the receptor resensitisation (Gray, et al., 2001). However, 
the 5-HT2A receptor is differently regulated in HEK-293 cells in that 5-HT2A 
receptor internalization is not necessary for receptor resensitisation. Gray et 
al (2001) showed that inhibition of 5-HT2A receptor internalization in HEK-293 
cells results in an increased resensitisation, suggesting novel cell-type-
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specific modes of regulation for this receptor. After endosomal sorting, the 5-
HT2A receptors can be degraded or exported back to the plasma membrane. 
III) Down-regulation of the 5-HT2A receptors: 
In vivo studies have shown that 5-HT2A receptors are down-regulated 
after prolonged agonist stimulation (Eison, et al., 1989; Chaouloff, et al., 
1993; Pauwels, et al., 1990). However, reports from cell culture studies are 
not consistent, similar results have been found in some, but not all, cell 
culture studies. Agonist exposure induces a down-regulation, up-regulation or 
no change in 5-HT2A receptor density expressed in cells (Ferry, et al., 1993; 
Rinaldi-Carmona, et al., 1994). Grotewiel and Sanders–Bush (1994) have 
suggested that the cellular background in which the 5-HT2A receptor is 
expressed appears to determine the regulation of the 5-HT2A receptor density 
(Grotewiel and Sanders-Bush, 1994). They have further shown that after 
agonist pre-treatment, 5-HT2A receptors are down-regulated, unaltered or up-
regulated depending on which heterologous expression system was used. 
Although some cell culture studies showed that 5-HT2A receptors are 
desensitized and down-regulated after exposure to agonists (Ivins and 
Molinoff, 1990; Van, et al., 1993), desensitization of 5-HT2A receptors, in 
particular in heterologous expression systems, can occur without reduction in 
receptor density (Van, et al., 2003;Roth, et al., 1995). These results imply that 
5-HT2A receptor desensitization can occur with or without receptor down-
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regulation, indicating that the mechanisms of 5-HT2A receptor desensitization 
may be distinct from those involved in down-regulation and internalization. 
 Consistent with most data from cell culture and in vivo studies on 
agonist-induced regulation, agonist-induced desensitization of 5-HT2A 
receptors can be explained as a multistep phenomenon. First, the 5-HT2A 
receptors are uncoupled from the G-protein upon phosphorylation by one or 
more kinases (e.g. GRKs, PKC or CaMK) (The GRK-induced desensitization 
is completed by the binding of arrestins). Second, 5-HT2A receptors are 
internalized via clathrin-coated pits, followed by transport to endosomes. After 
endosomal sorting, 5-HT2A receptors can be shuttled back to the cell 
membrane or degraded. The occurrence of 5-HT2A receptor down-regulation 
in cells seems to depend on the cell system. Although models for agonist-
induced regulation of 5-HT2A receptors have been formulated, the underlying 
mechanisms remain poorly understood. The cellular background in which the 
5-HT2A receptor is expressed in cells appears to determine the regulation 
properties of this receptor. 
 
Paradoxical down-regulation of 5-HT2A receptors by Antagonists 
 
In vivo regulation studies showed that the adaptive changes of 5-HT2A 
receptors after administration of 5-HT2A antagonists are different from those in 
other receptor systems. Many reports demonstrated that chronic 
administration of compounds with 5-HT2A antagonistic action leads to reduced 
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5-HT2A receptor levels (i.e., the Bmax-value was reduced and the KD-value was 
unaltered after treatment with the antagonists). Studies using more selective 
5-HT2A receptor antagonists further confirmed the atypical down-regulation of 
5-HT2A receptor binding sites (Burnet, et al., 1996; Matsubara and Meltzer, 
1989; Mikuni and Meltzer, 1984). 
The consistent results obtained in vivo for antagonist-induced 
regulation of 5-HT2A receptors stand in contrast to the variable results from 
cell culture studies. In cells, the antagonist-induced regulation of the 5-HT2A 
receptor may vary depending on the antagonist used, host cell line and 
species of the receptor. Indeed, the total number of (antagonist) 5-HT2A 
receptor binding sites was found to be decreased, increased, or unaltered by 
antagonist treatment (Toth, 1996; Barker and Sanders-Bush, 1993). Grotewiel 
and Sanders–Bush stated that in cells the effects of chronic antagonist 
exposure to 5-HT2A receptors depend on the cell model system (Grotewiel 
and Sanders-Bush, 1994). In order to get a better understanding of what 
happens to the receptor population following prolonged drug treatment, it is 
important to investigate both high affinity agonist binding sites (G-protein-
coupled receptors) and the total population of antagonist-labeled receptors. 
Apparently inconsistent findings may be related to the different radioligands 
used in the different studies and the accuracy with which receptor numbers 
are quantified. Willins et al (1999) showed that antipsychotics with high affinity 
for  5-HT2A receptors induce a 5-HT2A receptor internalization, which could 
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explain the paradoxical down-regulation of 5-HT2A receptors (Willins, et al., 
1999). In contrast, antipsychotics devoid of 5-HT2A receptor antagonist activity 
had no effect on the regulation or subcellular distribution of 5-HT2A receptors 
in cells and in vivo. Consequently, it is suggested that 5-HT2A receptor 
antagonism by antipsychotics and the down-regulation of 5-HT2A receptors 
play a role in the maintenance of the therapeutic action of the drugs.  
As evident from these reports, there is no consensus model for 
antagonist-induced desensitization of 5-HT2A receptor signaling. Hence, it is 
reasonable to presume that novel cellular and biochemical mechanisms are 
responsible for antagonist-induced internalization of 5-HT2A receptors. 
Because of the pivotal role of 5-HT2A receptor in many processes and 
because of its importance in atypical antipsychotic medications, further insight 
into mechanism of 5-HT2A receptor regulation will likely have important 
ramifications for many areas of neurobiology and psychiatry. Therefore, it is 
important to understand the molecular changes that occur with 5-HT2A 
receptor antagonist treatment and other methods that result in desensitization 
of 5-HT2A receptor signaling. 
In addition to these classical mechanisms of regulation of 5-HT2A 
receptors, there are additional mechanisms which affect the downstream 
signaling pathways of 5-HT2 receptors including those that affect the ability of 
the G proteins to bind to nucleotides and activate the second messenger 
system. One mechanism is used by a group of molecules to inhibit nucleotide 
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exchange on the Gα subunit of G proteins (Dohlman and Thorner, 1997). The 
other mechanism is to accelerate the inactivation of the GTP-Gα subunit by 
increasing the rate of hydrolysis of the bound GTP. Proteins that work via this 
second mechanism are termed GTPase-activating proteins (GAPs) such as 
regulators of G protein signaling (RGS) proteins (Dohlman and Thorner, 
1997;Hepler, et al., 1997). Increased expression of RGS proteins leads to 
desensitization in several G protein-linked receptor systems (Dietzel and 
Kurjan, 1987; Druey, et al., 1996; Koelle and Horvitz, 1996). The next section 
will focus on structural and physiological aspects of RGS proteins in the 
context of their interaction with various GPCRs.  
 
RGS Proteins 
Coordinated regulation of heterotrimeric guanine nucleotide–binding 
protein (G protein) activity is critical for the integration of information from 
multiple intracellular signaling networks. The process of G protein inactivation 
is a key step that determines the duration of the signaling and therefore the 
extent of the cellular response. It is controlled by a specialized protein family -
RGS that act to speed up the inactivation (i.e. desensitization) of the signaling 
pathway by accelerating the GTP hydrolysis of the G proteins. RGS proteins 
form a large and diverse family, initially identified as GTPase activating 
proteins (GAPs) of heterotrimeric G-protein Gα. Activation of GPCR stimulates 
the exchange of GDP for GTP on Gα to initiate heterotrimer dissociation and 
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activation of effector proteins that, in turn, initiate a cascade of cellular 
signaling events. RGS proteins participate in this process by binding directly 
to the activated Gα-GTP to serve as GTPase-activating proteins (GAPs), 
which limit the lifetime of Gα-GTP and terminate signaling events.  In addition 
to terminating Gα-dependent signaling, GAP activity results in generation of 
Gα-GDP from Gα-GTP and reformation of heterotrimer and the termination of 
Gβγ -mediated signaling subunits (Berman and Gilman, 1998;Shuey, et al., 
1998; Willars, 2006).  
Although the majority of RGS are GAPs, some RGS can affect 
signaling in a non-GAP manner. For example, RGS4 and RGS19 (GAIP) 
besides acting as GAP for Gαq, can also inhibit Gαq activity through effector 
antagonism (competing with effector molecules for GTP bound Gα-subunit) 
when activated by non-hydrolysable GTP analogue, GTPγS, (Hepler, et al., 
1997)  and through inhibition of ALF4- -mediated G-protein activation of 
phospholipase C (Yan, et al., 1997). Furthermore, certain RGS proteins 
(RGS12 and RGS14) contain a GoLoco domain that selectively bind inactive 
Gα-subunits, impeding GDP release and thereby limiting G-protein activation 
known as guanine nucleotide dissociation inhibition (GDIs) (Kimple, et al., 
2001). 
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Classification of RGS Proteins: 
RGS proteins are a family of cellular proteins with a conserved RGS 
domain (also called RGS box) of about 120 amino acid residues in length. It is 
now well recognized that the RGS play essential regulatory roles in the G 
protein-mediated signal transduction. There are over 20 members in the 
mammalian RGS family (Ross and Wilkie, 2000). Based on the similarity in 
sequence and features of structural domains, they are classified into various 
subfamilies (R4, R7, R12, RA, and RZ) (Table 1). Their structural features are 
listed in Table 2. While RGS proteins by definition contain at least one RGS 
or RGS-like domain, there is considerable diversity outside this region. The 
prototype of the simplest RGS protein, RGS21 is a member of the R4 
subfamily and contains only a RGS domain (Von, et al., 2004). Other RGS 
proteins have N-and C-terminal extensions of different lengths, many of which 
contain domains that have either enzymatic activity or are involved in the 
protein-protein interactions. These domains not only influence the ability of 
RGS proteins to act as GAPs or effector antagonists, but also influence other 
aspects of the signaling mediated by GPCR activation.  
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Table 1- RGS proteins: Their Gα targets and tissue distribution (most 
recent references are listed) 
 
 
Subfamily RGS proteins Gα Protein Distribution References 
 
RZ 
RGS17(RGSZ2)
RGS19(GAIP) 
 
RGS20(RGAZ1)
Gαz 
Gαt,Gαt, 
Gαz>Gαq
 
 
Gαz>Gαi
ND 
Ubiquitous, 
low in brain 
 
 
Brain 
(de, et al., 
1999) 
(Wang, et al., 
1998) 
 
 
 
 
 
 
R4 
RGS1 
 
RGS2 
 
RGS4 
 
 
RGS5 
RGS8  
RGS13 
RGS16 
 
RGS18 
RGS21 
Gαi
 
 
 
Gαq
 
 
 
Gαi> Gαq 
 
 
 
Gαi/o, Gαq
Gαi, Gαo
 
ND 
 
Gαi 
 
 
 
Gαi/o, Gαq 
 
ND 
Lung, β- lym 
-phocyte 
 
 
Ubiquitous 
 
 
 
Brain, Heart 
 
 
 
Ubiquitous 
Brain 
 
Lung 
 
Retina, Liver, 
Pituitary  
 
 
ND 
(Druey, et al., 
1996a) 
 
(Siderovski, et 
al., 1994) 
 
 
(Seki, et al., 
1998) 
 
(Gold, et al., 
1997c) 
 
(Saitoh, et al., 
1997) 
 
Gene bank 
 
(Chen, et al., 
1997) 
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R7 
RGS6 
RGS7 
RGS9 
 
RGS11 
Gαo  
Gαi, Gαq
Gαt
 
Gαo
ND 
Brain 
 
Retina, 
Neurons 
 
Brain  
(Liang, et al., 
2000) 
 
(Gold, et al., 
1997b) 
 
(He, et al., 
1998) 
 
 
R12 
 
RGS10 
RGS12 
 
RGS14 
 
Gαi 
Gαi(Gα12/13) 
 
Gαi/o, Gα12/13
 
 
 
 
Brain 
Lung, Brain, 
Spleen 
 
ND 
 
 
 
(Hunt, et al., 
1996) 
 
(Mao, et al., 
1998) 
 
(Traver, et al., 
2000) 
 
RA 
Axin1 
Axin2 
ND 
ND 
Thymus, 
Testis 
(Zeng, et al., 
1997a) 
(Berman and 
Gilman, 
1998a) 
 
ND: not determined, associated Gα-protein coupling include reports from both 
in cells and in vivo studies, some of the information presented taken from 
gene bank report see(De and Gist, 1999) for further details). 
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Table 2- Key structural features of each subfamily and reported post-
translational modification:  
Subfamily Domain characteristics Post-Translational 
modification 
RZ 
 
*c, cysteine string,  RGS domain 
 
Palmitoylation 
R4 
 
*RGS3 has long N-terminus 
Palmitoylation 
(RGS3,4,16) 
 
Ubiquitination 
(RGS4,16) 
 
Phosphorylation 
(RGS2,3,4,16,18) 
R7 
 
*RGS9 has long C-terminus 
DEP, domain found in Dishevelled; GGL,  
Gγ-like domain;R7H, R7 homology 
Palmitoylation 
(RGS7) 
 
Ubiquitination 
(RGS7) 
 
Phosphorylation 
(RGS7,9) 
 
R12 
 
*RGS10 has only RGS domain 
*RGS14 does not have PDZ &PTB domain 
 
PDZ, post synaptic density protein 
(PSD95), Drosophila disc large tumor 
Palmitoylation 
(RGS10) 
 
Phosphorylation 
(RGS10,14) 
 
 RGS 
 RGS PTB PDZ RID GoLoco cc 
R7H GGL DEP 
C 
 RGS 
 RGS 
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suppressor (DlgA), and zonula occludens-1 
protein (zo-1); PTB, phosphotyrosine 
binding domain; CC, coiled-coiled region 
RA 
GSK3-BD, glycogen synthetase kinase 3b-
binding domain; βCat-BD, β-catenin binding 
domain; PP2A, protein phosphatase 2A 
homology domain 
Phosphorylation 
(Axin1) 
 
PP2A GSK3-BD 
 RGS 
β Cat-BD 
*For further information please refer to (Willars, 2006). 
 
In addition to well-recognized protein domains, regions or motifs, N-
and/or C-terminal extensions may well regulate their function by determining 
their sub-cellular localization.  N-terminus extensions have been proposed to 
mediate membrane localization of many RGS proteins and the C-terminus 
acts as affinity adapters increasing the affinity of RGS proteins for their 
respective Gα-proteins.   
 
Regulation of RGS Proteins: 
In addition to structural diversity, RGS proteins are subjected to a 
number of post-translational modifications including phosphorylation, 
palmitoylation, and ubiquitination (Table 2).  However, no consistent effect of 
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phosphorylation on RGS protein functions is suggested. Reports of both 
enhanced (Tang, et al., 2003;Pedram, et al., 2000) or reduced GAP activity 
(Cunningham, et al., 2001;Chen, et al., 2001;Chen and Lin, 1998), altered 
sub-cellular localization (Burgon, et al., 2001), protein stability (Derrien, et al., 
2003), and altered ability of G-protein α-subunit to enhance RhoGEF activity 
have been shown (Suzuki, et al., 2003). Several RGS proteins are 
palmitoylated on multiple sites but it is yet to be established if and how 
palmitoylation of specific residues is regulated in the cellular context and how 
this influences the function of RGS proteins (Willars, 2006). Ubiquitination, i.e. 
the addition of ubiquitin to proteins, is associated with degradation of proteins 
by 26S proteosome. Among RGS proteins, RGS7 (Kim, et al., 1999), 4, and 
16 (Davydov and Varshavsky, 2000) are reported to undergo degradation by 
this method. 
 
RGS proteins in Pathophysiology of Diseases: 
Recently, several studies have linked RGS proteins to various disease 
conditions. The following discussion will highlight the role of RGS proteins 
primarily in psychiatric disorders. Studies investigating changes in gene 
expression have extensively and consistently reported a decrease in RGS4 
mRNA in prefrontal cortex, motor cortex, and visual cortices of schizophrenic 
patient (Chowdari, et al., 2008;Levitt, et al., 2006;Mirnics, et al., 
2001;Chowdari, et al., 2002). However, similar studies in patients with major 
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depressive disorders do not show any change in mRNA levels of RGS4, 
suggesting that alteration in RGS4 expression is specific to schizophrenia. 
These findings along with reports of atypical antipsychotic-induced decreases 
in activity of 5-HT2A and D2 receptor signaling highlights the notion that RGS4 
could be a risk factor for developing schizophrenia.  
Studies specifically looking at RGS2 and RGS9 demonstrated that 
reducing the levels of these proteins have an effect on response to morphine. 
Knocking down RGS2 makes morphine less potent while decreasing RGS9 
potentiates analgesic effects of morphine(Garzon, et al., 2001). These and 
other studies have suggested that RGS proteins play an important role in 
altering effects of certain drugs of addiction because of their ability to 
modulate signal desensitization and thereby affecting potency of a compound. 
It has been proposed that small molecules that inhibit RGS protein/Gα 
interactions could be developed as novel drugs to potentiate the actions of 
endogenous neurotransmitters in various disease states such as Alzheimer's. 
 
RGS proteins as Potential Drug Target: 
Many drugs act on receptors coupled to heterotrimeric G proteins 
(GPCRs). Historically, drug discovery has focused on agents that bind to the 
receptors and either stimulate or inhibit the receptor-initiated signal. This is an 
approach that is both direct and logical, and has proven extremely fruitful in 
the past. However, as our understanding of G-protein signaling has 
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increased, novel opportunities for drug development have emerged. GTPase-
accelerating protein activity is a general feature of RGS proteins, and serves 
to facilitate the inactivation of the G protein rather than the receptor. Thus, 
agents that bind and inhibit RGS proteins could modulate endogenous 
neurotransmitter and hormone signaling, in a manner analogous to 
neurotransmitter uptake inhibitors.  
In addition, what makes many RGS proteins such attractive new drug 
targets is their unique capacity to modulate G protein signaling combined with 
their highly regionalized localization, most notably within the central nervous 
system (Gold, et al., 1997). Since their initial discovery, RGS proteins have 
been extensively studied as important new drug targets (Zhong and Neubig, 
2001; Neubig, 2002; Neubig and Siderovski, 2002).  Alternatively, such 
therapeutic agents could be used to boost the effects of existing GPCR-
directed drugs by decreasing the therapeutic dose needed while increasing 
the agonist's regional specificity, thereby reducing unwanted side effects 
(Neubig and Siderovski, 2002). The design of small molecules that block or 
mimic RGS protein/receptor interactions could become a highly specific 
therapeutic tool that is effective only in those cell types in which both the RGS 
protein and the receptor are localized.  
 
 
 
 
 
 41
Atypical Antipsychotics   
 
Schizophrenia is a debilitating disorder that affects 1% of the world’s 
population, often at an early age (Andreasen, et al., 1995; Ho, et al., 2003; 
Philip, et al., 2008). While schizophrenic patients have various abnormalities 
of perception, thought, language, or affect, many patients develop cognitive 
deficits and most show marked and long lasting impairments in social 
functioning (positive symptoms) (Prell, et al., 1996). Despite intense efforts, 
the etiology of schizophrenia has remained elusive. A promising route of 
investigation into the cause of the disease is to study how antipsychotic drugs 
alter brain function in schizophrenia. An improved understanding of how 
antipsychotic drugs convey their therapeutic effects during the treatment of 
schizophrenia can help to unravel neural mechanisms involved in the 
pathophysiology of schizophrenia. In the past, a similar approach has 
generated a prominent model of schizophrenia, the dopamine hypothesis 
(symptoms of schizophrenia (like psychoses) to a disturbed and hyperactive 
dopaminergic signal transduction) (Matthysse, 1973).  
The number of therapeutic agents available for the treatment of 
schizophrenia have grown and diversified in the last half century since the 
advent of chlorpromazine and the beginning of the pharmacologic era in 
psychiatry.  Over the past decade, much of the attention regarding the 
treatment of schizophrenia and related psychotic disorders has focused on a 
new class of antipsychotic medications (Weiden, et al., 2006;Mathews and 
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Muzina, 2007). The reintroduction of clozapine was a major step forward, and 
led to the proliferation of atypical or second generation antipsychotic drugs, 
including risperidone, olanzapine, quetiapine, ziprasidone, and sertindole 
(Lieberman, et al., 1989; Meltzer and Nash, 1991; Kane and Freeman, 1994). 
In fact, there is growing evidence that most of these drugs offer advantages 
over typical or first generation antipsychotic such as greater improvement in 
negative symptoms i.e. lack of behaviors (such as emotion, speech, social 
interaction, and action), cognitive impairment, relapse prevention, functional 
capacity and quality of life with fewer extra pyramidal side effects and tardive 
dyskinesia (Farah, 2005; Brooke, et al., 2005; Pierre, 2005; Seeman, 2002).  
Although, these improvements are substantial considering the improvement in 
overall quality of life, other distressing side effects like weight gain, 
hyperglycemia, and dyslipidemia are widely reported with atypical 
antipsychotic drugs (Roerig, et al., 2008; Henderson, 2007; Ferraioli, et al., 
2004).  Furthermore, the full clinical profile is still being studied in terms of the 
extent of therapeutic efficacy and adverse effects, on a variety of other 
outcomes including cognition, affect, subjective response, and social and 
vocational functions.  
All atypical antipsychotic drugs share a similar receptor binding profile, 
high affinity for dopamine receptors D1, D2, D4, 5-HT receptors 5-HT2A, 5-
HT2C, 5-HT3, 1-adrenergic, histamine H1, and five muscarinic receptor 
subtypes and low affinity for α2-adrenergic receptors and relatively low affinity 
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for 5HT1 subtypes, gamma aminobutyric acid A (GABAA), β-adrenergic 
receptors, and benzodiazepine binding sites (Kendrick, 1999). This binding 
profile is consistent across rat and human brain, and in cell lines. This 
receptor binding profile of atypical antipsychotic drugs is also correlated with 
the antidopaminergic, antiserotonergic, and antimuscarinic activity observed 
in animal models and predicts atypical antipsychotic activity in human 
(Bymaster, et al., 1996a;Bymaster, et al., 1996b). However, antipsychotic 
properties of atypical antipsychotics were more commonly attributed to the 
potent antagonism/inverse agonism of 5-HT2A than dopamine D2 receptors 
(Arora and Meltzer, 1994; Masellis, et al., 1995).  Since 5-HT2A receptors are 
focus of this dissertation, the following section will discuss findings suggesting 
that 5-HT2A receptors are pivotal in the action of atypical antipsychotic drugs. 
Over the years, intensive research on the new antipsychotic drugs has led to 
a greater understanding of the biochemical effects of these drugs, however, 
the pharmacological mechanisms underlying their therapeutic properties 
remain to be identified. Understanding the mode of action of the atypical 
antipsychotic drugs will be useful in exploring the pathophysiology of 
schizophrenia and other psychotic disorders and for the development of 
potential new therapeutic targets.  
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Table 3: Different classes of antipsychotic drugs and target receptors: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*
  
 
 
Drugs                  Class                Receptor affinity                     Side effects            
 
 
Haloperidol       Typical         D1 & D2,                               EPS, Prolactin 
                                              5-HT2 and α2                         Weight gain 
 
Clozapine        Atypical         D1, D2, 5-HT2, α2,                Weight gain,                        
                                              H1, M1                                Postural hypotension, 
                                                                                         Sedation,                             
                                                                                         Anti-cholinergic effect,         
                                                                                         Granulocytosis 
           
 
Olanzapine      Atypical         D1, D2, 5-HT2, H1, M1         Weight gain,     
                                                                                          Sedation, Dizziness, 
                                                                                          Transient elevation of 
                                                                                          Liver transaminases 
 
 
Risperidone      Atypical         D1, D2, 5-HT2, H1, α2          Weight gain, 
                                                                                          Seizure, Dystonia, 
                                                                                          Anxiety,    Prolactin 
 
 
Ziprasidone      Atypical         D1, D2, 5-HT2, H1                Weight gain, 
                                                                                           Seizure, Dystonia 
 
 
Sertindole        Atypical         D1, D2, 5-HT2, H1, M1          Prolonged QT interval 
 
 
Quetiapine       Atypical        D1, D2, 5-HT2, H1, M1           Anti-cholinergic effects 
                                                                                       
 
 For further information please refer to (Kendrick, 1999). 
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Mechanism of Action of Atypical Antipsychotic Drugs: 
Woolley and Shaw (1954) proposed that because hallucinogens are 
structurally related to LSD, and because schizophrenia is a disease 
exemplified by hallucination, then schizophrenia must be a disease involving 
5-HT (Woolley and Shaw, 1954). This “serotonin hypothesis of schizophrenia” 
was later discarded in favor of the ‘dopamine hypothesis of schizophrenia’ 
because of several observations that implicated dopamine (DA) in 
antipsychotic drug action (Carlsson and Lindqvist, 1963;Creese, et al., 1976). 
Additionally, clinical evidence suggested that the syndrome elicited by 
hallucinogens was quite distinct from that seen in schizophrenia (Hollister, et 
al., 1962).  Although, drugs which are developed to target dopamine D2 
receptors “typical antipsychotic drugs” are effective in treating certain core 
symptoms of schizophrenia, they also frequently induce serious side effects 
including negative symptoms, cognitive impairment, extra pyramidal side 
effects and tardive dyskinesia. 
However, the recognition that clozapine was effective without having 
motor side effects or appreciable affinity for either D1 or D2 dopamine 
receptors led to a reevaluation of dopamine hypothesis of schizophrenia and 
antipsychotic drug actions. Importantly, clozapine has a higher affinity for 5-
HT2A receptors than for either the D1 or D2 receptors. Although, clozapine 
was superior in treating psychosis, it was withdrawn after wide spread reports 
of agranulocytosis, a potentially fatal blood dyscrasia. In fact, the superior 
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efficacy and lack of motor side effects eventually led to the search for other 
atypical antipsychotic drugs without the propensity to induce agranulocytosis. 
Like clozapine, all new members of this class bind with high affinity to 5-HT2A 
receptors. These findings renewed interest in the role of 5-HT receptors in 
antipsychotic drug actions and the role of 5-HT in the pathophysiology of 
schizophrenia (Roth, et al., 1995).   
 
Role of 5-HT2A receptors in Antipsychotic Treatment: 
Altar et al. (1986) was the first to systematically examine the role of 5-
HT2A receptors in atypical antipsychotic drug actions (Altar, et al., 1986) . 
They found that several putative atypical antipsychotic drugs displaced [3H] 
spiperone binding to 5-HT2A receptors more easily than to D2 dopamine 
receptors. Additionally electrophysiological studies have also shown that 
atypical antipsychotic drugs have potent 5-HT2A receptor antagonist activity 
(Charney, et al., 1988). Further studies by Meltzer et al. (1989) demonstrated 
that a large number of atypical antipsychotic drugs were characterized by 
having higher affinities for 5-HT2A receptors than for D1 or D2 receptors 
(Meltzer, et al., 1989). These studies have led in part to the development of a 
new class of atypical antipsychotic drugs with higher affinity for 5-HT2 over D2 
receptors.  
Atypical antipsychotic drugs reduce positive symptoms by blocking 
dopamine D2 receptor in the mesolimbic systems without affecting dopamine 
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receptors in nigrostriatal system. Their effect on negative symptoms may be 
mediated through the enhancement of dopamine activity in the pre-frontal 
cortex, either by selective binding to dopamine receptor subtypes or through 
antagonism at 5-HT2 receptors. Consistent with the 5-HT2:D2 antagonism 
hypothesis of schizophrenia, numerous reports have consistently observed 
that antipsychotic effects of clozapine, olanzapine, sertindole, and quetiapine 
are mediated by their ability to block 5-HT2A receptor without excessive 
blockade of D2 receptors (Nyberg, et al., 1997; Kasper, et al., 1999; Kasper, 
et al., 1999). The strong antagonism of 5-HT2A receptor by these drugs was 
further confirmed with MDL100907 (a highly specific antagonist of 5-HT2A 
receptor) (Maixner, et al., 1998).  Furthermore, His52Tyr allele of the 5-HT2A 
receptor, which accounts for 10-20% of the schizophrenia patients is 
associated with the poor response to clozapine, again confirming role of 5-
HT2A receptor antagonism in the action of clozapine and other drugs of this 
class (Masellis, et al., 1998; Arranz, et al., 2001).  
 
Effect of 5-HT2A receptor Antagonism and D2 receptor Function:  
It had been proposed that the usefulness of 5-HT2A receptor 
antagonists in treating psychosis results from their influence on dopaminergic 
activity in mesolimbic and mesostriatal system.  Increased dopaminergic 
activity in the nucleus accumbens and other mesolimbic and possibly cortical 
regions may contribute to the positive symptoms, whereas increased 
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dopaminergic activity in the striatum would diminish extrapyramidal side 
effects (EPS).  There is considerable evidence suggesting that 5-HT2A 
receptors modulate activated but not basal mesolimbic DA activity (Gleason 
and Shannon, 1997; Martin, et al., 1998). Therefore, drugs that block the 
effect of excessive, but not basal, D2 receptor activity may be the most 
effective clinically. This hypothesis was further supported by reports that 
MDL100907 has been found to diminish the increase in DA efflux in the 
nucleus accumbens produced by either haloperidol or S-sulpiride (Liegeois, et 
al., 2002;Ichikawa and Meltzer, 1995). Therefore, it is very likely that 5-HT2A 
receptor antagonism may have antipsychotic action when dopaminergic 
activity is slightly or moderately increased.  
 
5-HT2A receptor Antagonism and Glutamate Levels: 
Besides dopamine, 5-HT2A receptors on cortical pyramidal neurons are 
also suggested to play a crucial role in psychosis by modulating intracortical 
and cortical-subcortical glutaminergic neurotransmission  (Jakab and 
Goldman-Rakic, 1998). Aghajanian and Marek have proposed a link between 
the glutamate hypothesis of schizophrenia and hallucinogen hypothesis 
based on the observation that stimulation of 5-HT2A receptors on layer V 
pyramidal cells increases the frequency of postsynaptic potentials (PSP) and 
this was blocked by  AMPA/Kinate glutaminergic antagonist LY293558 
(Marek, et al., 2000; Aghajanian and Marek, 2000).  
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Effects on Gene Expression and Cell Signaling: 
As discussed in previous sections, atypical antipsychotic drugs cause 
desensitization of 5-HT2A receptor signaling both in cell culture and in rat 
brain. These drugs also alter expression of a host of genes including 5-HT2A 
receptors (Burnet et al., 1996). However, whether changes in gene 
expression and desensitization have any cause and effect relationship is 
currently not known. The following section will review the literature reporting 
various signaling pathways activated or stimulated by these drugs.  However, 
in line with the focus of this dissertation, the following discussion will be 
limited to the change in 5-HT2A receptor expression.  
In situ hybridization and autoradiography studies reported selective 
decreses of 5-HT2A receptor mRNA and the density of [3H] ketanserin binding 
in cingulate and frontal cortex of rats injected for 14 days at the dose of 25 
mg/kg/day clozapine.  In the same study, no change was observed in 5-HT1A 
receptor expression and 5-HT2c receptor messenger RNA suggesting that 5-
HT2A receptor is the primary target of clozapine and similar drugs (Burnet et 
al., 1996). Subsequent studies by Buckland et al. (1997) in whole brain of 
animals treated with clozapine (10 mg/kg/day) for 32 days also reported a 
decrease in 5-HT2A mRNA levels in hippocampus, brainstem and midbrain. In 
contrast, 4 day treatment with clozapine increased 5-HT2A mRNA in nucleus 
accumbens (Buckland, et al., 1997).  The increase in mRNA levels after acute 
treatment may be a short-term adaptive response to the antagonistic effect of 
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these drugs. Additional studies with olanzapine using both acute (24 and 48 
h) and subchronic (16 day) treatment in rats reported a decrease in 5-HT2A 
receptor density both in frontal cortex and blood platelets without any 
changes in receptor affinity (Padin, et al., 2006).  
 
Activation of Signaling Pathways: 
Numerous reports have also suggested activation of different signaling 
pathways with atypical antipsychotic drugs in cell culture. Clozapine was 
reported to activate glycogen synthase kinase-3β( GSK-3β) in SH-SY5Y cells 
(human neuroblastoma) by specific Wnt signal pathway independent of 
AKT(Kang, et al., 2004). Other reports have suggested AKT-dependent 
activation of GSK-3β by inhibiting calcium calmodulin kinase (CaM-Kinase) 
with clozapine (Shin, et al., 2006).  Therefore, it seems that these effects are 
more likely to be cell type specific. However, no effort was made to link 
whether these effects are a consequence of clozapine or olanzapine-induced 
changes on target monoamine neurotransmitter receptors. The 
interaction/interplay of different signaling cascades has been well studied in 
various disease processes such as cancer. However, such interactions are 
relatively unknown in various neuropsychiatric and other CNS disorders.  
In addition, 5HT2A receptors are reported to mediate activation of the 
JAK-STAT pathway in multiple cell culture systems (Guillet-Deniau, et al., 
1997; Banes, et al., 2005). Activation of the JAK-STAT pathway transmits 
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information received from extracellular polypeptide signals, through 
transmembrane receptors, directly to target gene promoters in the nucleus, 
providing a mechanism for transcriptional regulation. Evolutionarily conserved 
in eukaryotic organisms from slime molds to humans, JAK-STAT signaling 
appears to be an early adaptation to facilitate intercellular communication 
(Rawlings, et al., 2004).  Thus, the JAK-STAT pathway seems to be an 
interesting prospect which might impart to atypical antipsychotics the ability to 
induce change in gene expression; however, this hypothesis needs to be 
tested. The following section will describe JAK-STAT pathway in more detail. 
 
 
JAK-STAT Pathway 
 
Characterization of the ability of interferon-α (IFN-α) to rapidly induce 
genes led to the discovery of the Janus kinase (JAK)-signal transducers and 
activators of transcription (STAT) pathway (Schindler and Darnell, Jr., 
1995;Ihle, 1995). The JAK-STAT pathway is one of a handful of pleiotropic 
cascades that transduce a multitude of signals for development and 
homeostasis in animals, from humans to flies (Heim, 1999;Pires-daSilva and 
Sommer, 2003). In mammals, the JAK-STAT pathway is the principal 
signaling mechanism for a wide array of cytokines and growth factors 
(Duncan, et al., 1997). JAK activation is reported to stimulate cell proliferation, 
differentiation, cell migration, and apoptosis (Igaz, et al., 2001; O'Shea, et al., 
2002). The JAK-STAT signaling was discovered almost 15 years ago with the 
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identification of a novel class of interferon-activated transcription factors 
(Harpur, et al., 1992; Shuai, et al., 1992).  
Although, first described as the signal-transducing pathway of 
interferons, the JAK-STAT system was soon discovered to be utilized by 
numerous cytokines and non-immune signaling pathways (growth factor, 
hormones etc). Besides cytokines, various receptors are also reported to 
activate the JAK-STAT pathways (Table 4). Since its discovery, extensive 
studies have characterized the core components of the JAK-STAT signal 
transduction pathway. It includes a wide and diverse range of extracellular 
ligands and transmembrane receptors, four genes for JAKs and seven genes 
coding for STATs (Kisseleva, et al., 2002). 
Activation of the JAK-STAT pathway requires binding of an 
extracellular ligand to a transmembrane receptor, results in the activation of 
receptor-associated JAKs. Activated JAKs then autophosphorylate and 
phosphorylate their associated receptors to generate docking sites for the 
SH2 domains of STATs. According to the established model, STATs are 
normally present in the cytoplasm as inactive monomers before being 
recruited to receptor/JAK complex. However, it has also been shown that 
STATs constitutively shuttle between the cytoplasm and nucleus before being 
retained in the nucleus following activation (Meyer and Vinkemeier, 2004). 
Once bound to the receptor/JAK complex, STAT proteins are cross-
phosphorylated and form either a hetero- or homo-dimer. Stabilized by the 
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interaction between the SH2 domain of one molecule and the phospho-Tyr of 
the other molecule, the STAT-STAT dimer translocates  to nucleus where it 
binds to a palindromic DNA sequence at the promoter of target genes  to 
modulate transcription (as shown below).  
 
Figure 4: The Model of JAK-STAT Signaling: Pre-dimerised complexes of 
a receptor and JAKs are activated following ligand binding. Phosphorylation 
of the JAKs and the receptors generate docking sites for the normally 
cytosolic STATs that are recruited to the active complex. Following 
phosphorylation of the STATs, a STAT-STAT dimer forms then translocates 
to the nucleus and binds to a palindromic DNA sequence at the promoter of a 
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target gene. Although STAT-STAT dimer formation can occur prior to 
pathway stimulation, only complexes activated by Tyr-phosphorylation appear 
to induce target gene expression (Braunstein, et al., 2003). 
Diversity of JAK-STAT Signaling:  
So far four members of JAK (JAK1-4) and seven members of STAT 
(STAT1-7) have been identified.  The JAKs range from 120-135 kDa, each of 
them contains a characteristic feature of two tandem kinase domains, referred 
to as JAK homology (JH) domains 1 and 2. Although, the most carboxy 
terminal domain, JH1, appears to be catalytically active, both JH1 and JH2 
are required for full activation.  JAKs share five additional homology domains, 
JH3-7. The most amino terminal domains JH6 and JH7 are believed to be 
important in receptor association(Schindler, 1999).  
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Structure of JAKs:  
 
Kinase 
Domain 
Pseudokinase 
    Domain  
JH7    JH6      JH5          JH4        JH3          JH2                      JH1               
   Structure of STATs: 
STAT 1,3,4,  
TAD  5A & 5B 
 
Figure 5: Structures of JAKs and STATs: The JAKs share seven regions of 
high homology, JH1-JH7. JH1 has been shown to encode the kinase. JH2 
represents a pseudokinase domain, which appears to regulate JH1 catalytic 
activity. JH3 - JH7 have been implicated in receptor association. Likewise, the 
STATs share several conserved domains, including an amino-terminal 
domain (NH2), a coiled-coil domain, the DNA-binding domain, a linker domain, 
an SH2 domain, and a tyrosine activation domain (TAD). The carboxy-
terminal transcriptional activation domain is conserved in function, but not in 
sequence.  
STAT 2&6 
Dimerization 
Domain 
DNA binding 
Domain 
   SH3  SH2 Y S 
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 Out of seven STAT members 2 & 6 are 850 amino acids long whereas 
others   are shorter, around 700 amino acids. Phosphorylation at tyrosine 
(705Y) residue facilitates dimerization with other STATs through the SH2 
domain. C-terminus contains a transcriptional activation domain (TAD) and 
also a serine residue (S) which upon phosphorylation modulates 
transcriptional activity.  DNA binding domain is localized between SH2 and 
SH3 sites.  
 
Interaction of JAK-STAT with other GPCRs:   
Recently, the interaction of various members of G-protein coupled 
receptor (GPCR) family with different JAKs and STATs has been a focus of 
investigation. Guillet-Deniau et al. (1997) reported association of JAK2 with 5-
HT2A receptor in skeletal muscle cells (Guillet-Deniau, et al., 1997).  5-HT 
stimulation of 5-HT2A receptor initiated a rapid and transient tyrosine 
phosphorylation of JAK2 kinase. They also reported association of 5-HT2A 
receptor and STAT3 with JAK2 by co-immunoprecipitation suggesting JAK-
STAT pathways could be attributed to some of the effects mediated by 5-HT2A 
receptor signaling.  
Additional studies by other groups also identified interaction of JAK2 
and activation of STAT3 with Angiotensin II (Hunt, et al., 1999) and , JAK-
STAT activation by arginine-vasopressin in vascular smooth muscle cells 
(Levy and Granot, 2006), and 5-HT stimulation of JAK-STAT in vascular 
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smooth muscle cells (Banes, et al., 2005). However, except for one report of 
involvement of small GTPases Rho and Rac for activation of JAK2 with 
thrombin and angiotensin (Pelletier, et al., 2002), not much is known about 
the mechanism of JAK activation by GPCR agonists.  Some of the other 
receptors which have shown to activate various JAKs and different STATs are 
listed below:  
Table 4: Cytokine and non cytokine receptors activate different JAKs 
and STATs: 
Receptor Ligands JAK STAT 
GPCR Chemokines-SDF, Thrombin 
AngiotensinII, Endothelin, 5-HT 
 
 
JAK1,2 , &3 STAT1,2,3,
&5 
Single 
chain-non 
kinase 
RTK 
 
EGF, PDGF, GH, PRL, CSF-1, 
EPO 
JAK1 & 2 STAT1, 3,& 
5 
Heterotrim
eric- non 
kinase 
RTK 
 
IL-2,3,6,10 and interferon JAK1,2,&3 STAT1,2,3,
&5 
 
Regulation of the JAK-STAT Signaling Pathway: 
A number of regulatory layers modulate this signaling pathway 
including both positive and negative regulators. JAK activation is dependent 
on tyrosine phosphorylation. Therefore, it is not surprising that two related 
SH2 domain containing phosphatases (as depicted in domain structure), 
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SHP1 and SHP2, are reported to negatively regulate JAK activity. Other 
reports have also suggested direct interaction and dephosphorylation of JAKs 
and STAT5 by SHP1 and SHP2 (Marrero, et al., 1998;Yu, et al., 2000). 
Besides SHPs, recent reports have also implicated membrane associated 
phosphatases like CD45 in negatively regulating JAK-STAT signaling 
stimulated by IL-3, IL-4, EPO, and IFN-γ (Irie-Sasaki, et al., 2001).  
The suppressor of cytokine signaling (SOCS) are a family of STAT 
target genes that directly antagonize STAT activation.  The founding member 
of this class CIS-1 (cytokine-inducible SH2 containing protein) is reported to 
block STAT receptor recruitment (Yoshimura, et al., 1995). Gene targeting 
studies with various STATs have reported that deletion of STAT1 & 3 is 
embryonic lethal (Naka, et al., 1998;Marine, et al., 1999a;Marine, et al., 
1999b)  and STAT2 null mice developed gigantism (Igaz, et al., 2001). Protein 
inhibitor of activated STATs (PIAS), PIAS 1 & 3 bind with activated STAT and 
blocks their ability to bind DNA (Gross, et al., 2001; Liu, et al., 1998).  
 
Biological and Clinical Significance: 
Investigation into the importance of the JAK-STAT pathway in vivo is 
hampered by the lethality of knockouts for JAK1 and JAK2; the only viable 
phenotypes is JAK3 (Nosaka, et al., 1995). However, JAK3 has only limited 
expression compared to the widely expressed JAK1 and JAK2. Thus, the role 
of JAK 1 and 2 during embryonic development is still not known. JAK3 
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knockout mice suffer from murine SCID (severe combined immune 
deficiency) that severely affects both the B- and T-cell population. These mice 
develop a phenotype which is very similar to ones lacking common γ-chain, 
suggesting it affects the same signaling pathway regulating assembly of 
various IL receptors (IL2, 4, 7, 9 &15) (Sugamura, et al., 1996; Cao, et al., 
1995).   Among STAT knockout models, all of them are viable except STAT3. 
Separate knockouts of STAT1 and STAT2 knockouts develop viral infections 
suggesting they might play a role in interferon signaling (Levy and Darnell, Jr., 
2002; Park, et al., 2000). STAT4 and STAT6 influence differentiation of T-
cells (Levy, 1999). The STAT5a knockout model does not show any severe 
abnormality except defects in mammary gland development. The STAT5b 
knockout model confirmed its role in sexually dimorphic growth hormone 
action (Liu, et al., 1996;Udy, et al., 1997).  
Most of diseases associated with malfunctioning of the JAK-STAT 
pathway were initially linked with lymphohaemopoietic neoplastic disorders 
but recently their role in myocardial hypertrophy and bronchial asthma are 
recognized. Fusion proteins of JAK2 and Tel (an Ets family transcription 
factor) were found in some acute lymphocytic leukaemias (Lacronique, et al., 
1997).  Human T-cell lymphotrophic virus 1 infected T cells (HTLV-1) sustain 
activation of the JAK-STAT pathway and is linked to malignant transformation 
(Takemoto, et al., 1997). Over activity of STAT3 was reported in multiple 
myeloma, mycosis fungoides, and in chronic myelogenous leukemia (Catlett-
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Falcone, et al., 1999; Nielsen, et al., 1999; Chai, et al., 1997). In addition to 
neoplastic diseases, the human SCID phenotype is in part also associated 
with defects of JAK-STAT pathway (Macchi, et al., 1995; Cacalano, et al., 
1999).  
De-Fraja et al extensively characterized expression and regulation of 
JAK-STAT in various brain regions (De-Fraja, et al., 1998; Cattaneo, et al., 
1998). In CNS, nitric oxide (NO) plays an important role during development 
and progression of diseases like multiple sclerosis (MS), Parkinson’s disease, 
and Alzheimer’s disease. The JAK-STAT pathway regulates inducible nitric 
oxide synthetase (iNOS) expression, which regulates NO production, and 
thereby plays an important role during pathogenesis of these disorders 
(Dell'Albani, et al., 2001;Dalton, et al., 1993;Dell'Albani, et al., 2001b). 
Berhow et al. (1996) reported that some of the effects of chronic cocaine on 
ventral tegmental area (VTA) dopaminergic neurons are mediated directly by 
the JAK-STAT pathway (Berhow, et al., 1996). Additionally, activation of the 
JAK-STAT pathway in response to IL-6 induction in spinal cord injury was 
also reported (Yamauchi, et al., 2006). In conclusion, the JAK-STAT pathway 
is now being recognized as an important regulatory mechanism in CNS 
development, function and disease progression.  
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Purpose of the Present Study 
Extensive literature now suggests that changes in 5-HT2 receptors in 
the CNS are associated with various cognitive and mood disorders including 
schizophrenia, depression, anxiety, and bipolar. Studies indicate that an 
increased function of the 5-HT2A receptor system may be associated with 
disorders such as depression (D'haenen, et al., 1992; Hrdina, et al., 1993) 
while a reduction in 5-HT2A receptors has been associated with other 
neurological and psychiatric disorders (Gurevich and Joyce, 1997; Joyce, et 
al., 1997). Additionally, it has been proposed that dysregulation of 5-HT2A 
receptor-mediated signaling may contribute to the pathogenesis of 
schizophrenia and related diseases. In fact, chronic treatments with 
antagonists that reduce 5-HT2A receptor density and/or efficacy have been 
used clinically to treat these psychiatric disorders, such as schizophrenia 
(Blier and De, 1999; Aghajanian and Marek, 2000). 
Although antipsychotics bind to their target receptors soon after 
administration, complete therapeutic benefits of antipsychotic medication take 
weeks to be realized (Agid, et al., 2003; Hyman and Nestler, 1996; 
McDermott, et al., 1991). This often results in prolonged treatment trials for 
individual patients until a particular drug is found therapeutically effective. To 
improve treatment outcome, we need to understand the mechanisms 
underlying the delay in the full clinical effects of antipsychotic drugs. The 
clinical potency of atypical antipsychotic drugs is directly correlated with their 
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ability to inhibit 5-HT2A receptors, but this relationship cannot explain their 
delayed action. With the chronic use of atypical antipsychotic drug, 5-HT2A 
receptor signaling is desensitized. Thus, it is possible that neuroadaptive 
mechanisms could possibly lead to alterations in the regulation of 5-HT2A 
receptor signaling and would be responsible for this delayed clinical 
response. Thus, it is important to investigate how 5-HT2A receptor signaling is 
regulated and discover the cellular pathways underlying desensitization after 
treatment with atypical antipsychotics such as olanzapine or clozapine.  
Atypical antipsychotic drugs are inverse agonist of 5-HT2A receptors in 
vivo in patients, and animal pharmacological studies are consistent with the 
notion that the 5-HT system may serve as one of the regulators of 
dopaminergic tone in vivo. It therefore becomes important to understand the 
molecular changes that occur with 5-HT2A receptor antagonist treatment and 
other methods that result in desensitization of 5-HT2A receptor signaling. With 
better understanding of the molecular mechanisms underlying signaling and 
desensitization of 5-HT2A receptor signaling, new targets for therapeutic 
intervention may be identified.   
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CHAPTER III 
OLANZAPINE INCREASES RGS7 PROTEIN EXPRESSION VIA 
STIMULATION OF THE JANUS TYROSINE KINASE-SIGNAL 
TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (JAK-STAT) 
SIGNALING CASCADE 
(Published in J Pharmacol Exp Therap 322(1):133-40, 2007)
 
Abstract 
 
Atypical antipsychotics such as olanzapine have high affinity for 
multiple monoamine neurotransmitter receptors and are the main stay of 
pharmacological therapy for treatment of schizophrenia.  In addition to 
blocking monoamine receptors, these drugs also affect intracellular signaling 
cascades. We now report that 24-hour treatment with 300nM olanzapine 
causes desensitization of serotonin (5-HT)2A receptors in A1A1v cells, a rat 
cortical cell line, as indicated by a reduction in inositol phosphate 
accumulation following stimulation with a 5-HT2A/2C receptor agonist [(−)-1-
(2,5-dimethoxy-4-lodophenyl)-2-aminopropane HCl] (DOI). Olanzapine 
treatment for 24 hours increased the levels of 5-HT2A receptors in both cytosol 
(234±34% of control level) and membrane fractions (206±14% of control 
levels) and RGS7 proteins in both cytosol (193±32% of control levels) and 
membrane fractions (160±18% of control levels) as measured on western 
blots. Increased phosphorylation of a tyrosine kinase JAK2, and increased 
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phosphorylation and nuclear translocation of STAT3 with 24-hour olanzapine 
treatment demonstrates activation of the JAK-STAT signaling cascade. 
Pretreatment with a JAK inhibitor, AG490, prevented the olanzapine-induced 
increase in membrane RGS7 protein levels; AG490 alone had no effect on 
RGS7 protein levels. We verified that treatment with AG490 reduced 
phosphorylation of JAK2, and inhibited the nuclear localization of phospho-
STAT3. Interestingly, treatment with the JAK inhibitor had no effect on 5-HT2A 
receptor protein levels. These data suggest that olanzapine-induced 
activation of the JAK-STAT signaling cascade causes increased expression 
of RGS7 protein, which in turn could mediate desensitization of 5-HT2A 
receptor signaling caused by olanzapine since RGS7 binds to Gαq protein 
and accelerates GTP hydrolysis. 
 
Introduction 
Atypical antipsychotics are widely prescribed for the treatment of 
schizophrenia. They are classified as atypical because of their ability to 
achieve antipsychotic effects with lower rates of extrapyramidal side effects 
compared to first generation antipsychotics such as haloperidol. In addition, 
selected atypical antipsychotics also improve certain aspects of cognitive 
function in schizophrenic patients, whereas typical antipsychotics may worsen 
cognition (Meltzer, et al., 1999). Atypical antipsychotics improved side effects 
and efficacy have been attributed to the high affinity interaction with 5-HT2A 
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receptors and lower affinity for D2 (Kasper, et al., 1999). Atypical 
antipsychotics have also been shown to block other 5-HT2 receptor subtypes 
mainly 5-HT2B and 5-HT2C (Lucaites, et al., 1996;Zhang and Bymaster, 1999). 
However, only 5-HT2C receptor antagonism is suggested in contributing to the 
atypical antipsychotic effects (Herrick-Davis, et al., 2000;Rauser, et al., 2001).  
The 5-HT2A receptor subtype has been implicated in various psychiatric 
disorders including depression, anxiety, and schizophrenia (Glennon, et al., 
1984). Olanzapine is an atypical antipsychotic, approved for the treatment of 
schizophrenia and bipolar disorder. Olanzapine has been also studied in 
treatment of disorders like substance abuse, aggression/violence, borderline 
personality disorder, and obsessive–compulsive disorder (Littrell, et al., 
2006).  
Atypical antipsychotics as well as a specific 5-HT2A receptor 
antagonist, MDL 100,907 ((+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-
fluorophenylethyl)]-4-piperidinemethanol), desensitize 5-HT2A-mediated 
responses (Willins, et al., 1999). However, the molecular mechanisms 
involved in antagonist-induced desensitization of 5-HT2A receptor signaling 
are not well understood. By understanding the molecular mechanisms 
underlying the effects of olanzapine and other atypical antipsychotics, we 
hope to gain insight into targets for therapeutic treatment of psychiatric 
disorders. It has been recently reported that olanzapine increases 
Extracellular Receptor Kinase (ERK) 1/2 phosphorylation in rat prefrontal 
 66
cortex (Fumagalli, et al., 2006).  Furthermore, changes in mRNA levels of 
both 5-HT2A/2C receptors with 5-HT2A receptor antagonists after both chronic 
and short-term treatments have been reported (Buckland, et al., 1997). These 
studies suggest that atypical antipyschotics may target intracellular pathways 
shuttling information from the receptor to the nucleus. 
The Janus kinase-signal transducers and activators of transcription 
(JAK-STAT) signaling cascade has been reported to couple with 5-HT2A 
receptors in skeletal muscles and vascular smooth muscle cells (Guillet-
Deniau, et al., 1997;Banes, et al., 2005). G-protein coupled receptor (GPCR) 
agonists, thrombin and angiotensin II, have previously been shown to activate 
JAK-STAT signaling cascade (Bhat, et al., 1994). JAK-STAT could be one of 
the possible signaling pathways involved in mediating olanzapine-induced 
receptor desensitization. Janus kinases (JAK) are a small family of 
cytoplasmic tyrosine kinases initially identified as a mediator of cytokine 
receptor signaling (Ihle, 1995).  Agonist stimulation of cytokine receptors 
causes phosphorylation of JAK, which in turn phosphorylates tyrosine 
residues on the receptor cytoplasmic tail, facilitating activation of specific 
signal transducers and activators of transcription (STAT). Tyrosine 
phosphorylated STAT then undergoes dimerization and translocates to the 
nucleus where it binds to target DNA sequences (Darnell, Jr., 1997).   
Alterations in proximal components of the 5-HT2A receptor signaling 
system could mediate desensitization in response to increased activity of 
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intracellular cascades such as JAK-STAT. 5-HT2A receptors are classically 
linked to the Gαq/11 protein family (Ivins and Molinoff, 1990). Activation of 
Gαq/11 stimulates phospholipase C (PLC) activity, which subsequently 
promotes the release of diacylglycerol and inositoltriphosphate, which in turn 
stimulate protein kinase C activity and calcium release (Berg, et al., 2001). It 
has been extensively reported that increased expression of regulators of G 
protein signaling (RGS) proteins cause desensitization of several G-protein 
associated receptor systems (Koelle and Horvitz, 1996). RGS proteins reduce 
the duration of signaling of many G-protein-coupled receptors by their action 
as GTPases, accelerating the hydrolysis of GTP bound Gα -proteins or by 
blocking the interaction of Gα with its target proteins through a not well-
understood process known as effector antagonism (Roy, et al., 2006).  
Expression of RGS7 protein in rat frontal cortex is well documented 
(Krumins, et al., 2004;Zhang and Simonds, 2000) and decreased 5-HT2A 
receptor-mediated signaling via direct interaction of RGS7 protein with Gαq 
has been widely characterized in different systems (DiBello, et al., 
1998;Ghavami, et al., 2004). We hypothesize that the increased expression of 
RGS7 protein by the JAK-STAT signaling cascade contributes to olanzapine-
induced desensitization of 5-HT2A receptor signaling. In this study, we 
examined 5-HT2A receptor and RGS7 protein levels in response to treatment 
with olanzapine and determined whether changes in these proteins are 
mediated by olanzapine-induced JAK-STAT signaling in A1A1v cells.  
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Materials and Methods 
Cell Culture:   
A1A1v cells, a cortical cell line that expresses 5-HT2A receptors, were 
used for all experiments and were generously donated by Dr. William Clarke 
and Kelly Berg (University of Texas Health Science Center, San Antonio, TX).  
Cells were grown in Dulbecco's modified Eagle's medium (DMEM) 
supplemented with 10% fetal bovine serum. Serotonin was removed from 
serum by filtration after treating with charcoal. Cells were grown in the 
serotonin-free serum media 24 hours before treatment with olanzapine. 
Olanzapine was a generous gift from Eli-Lilly. The treatment concentration 
(300nM) was obtained by dissolving olanzapine in 20% acetic acid. The pH of 
the vehicle and olanzapine was adjusted to 6.5 with 10N NaOH. A JAK 
inhibitor, α-Cyano-(3,4-dihydroxy)-N-benzylcinnamide (AG490), was 
purchased from Calbiochem, San Diego, CA. It was reconstituted with DMSO 
to obtain the desired concentration. (-)1-(2,5-dimethoxy-4-iodophenyl)-2-
aminopropane (DOI) was purchased from Sigma-Aldrich; St. Louis, MO. 
HBSS mix (1X HBSS, 20mM LiCl2, and 20mM HEPES) was used to dissolve 
DOI. Cells were treated with either vehicle (20% acetic acid) or 300nM 
olanzapine for 24 hour for various experiments.  
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Cell fractionation:   
Cells were separated into membrane and cytosol fractions using ultra 
centrifugation as previously described (Tucker, 2004). Briefly, cells were 
collected in hypotonic buffer containing 0.25M sucrose, 50mM Tris-HCl, 5mM 
EDTA, and protease inhibitor cocktail (Sigma-Aldrich; St. Louis, MO). Cell 
homogenate was prepared by sonication three times for 10 seconds. The 
homogenate was spun at 100,000xg for 45 minutes at 40C to produce a 
pellet, which is composed of membrane fraction, and a supernatant, which is 
the cytosol fraction. The pellet was reconstituted with hypotonic buffer.  The 
protein amount was assessed with bicinchoninic acid protein assay kit (Pierce 
Chemical, Rockford, IL). Cytosolic and nuclear fractions were prepared as 
previously described (Andrews and Faller, 1991) with some modification. 
Briefly, cells were washed and scrapped into ice-cold PBS containing 
phosphatase inhibitors. The pellet was collected after centrifugation at 
1,000xg for one minute and resuspended into Buffer A (10mM HEPES-KOH 
pH 7.9, 1.5mM MgCl2, 10mM KCl, 0.5mM DTT, and protease inhibitor 
cocktail) and incubated for 10 minutes on ice followed by vortex mixing for 10 
seconds. The supernatant contains the cytosolic fraction. The pellet was 
resuspended in Buffer B (10mM HEPES-KOH pH 7.9, 25% glycerol, 420mM 
NaCl, 0.2mM EDTA, 1.5mM MgCl2, 10mM KCl, 0.5mM DTT, and protease 
inhibitor cocktail) and incubated on ice for 20 min. The nuclear fraction was 
obtained as the supernatant after centrifugation at 18,000xg for 2 min. 
 70
Western Analyses:   
Equal amounts of protein were separated and transferred to 
nitrocellulose membrane as described before (Berg, et al., 1994a).  
Membranes were blocked either in TBS or PBS containing 5% (w/v) nonfat 
dry milk with 0.1% Tween 20. The following primary antibodies were used: 
anti-RGS7 (1:1000; Polyclonal antibody, Upstate Biotechnology, Inc., Lake 
Placid, NY), anti-phospho-JAK2 (1:1000; polyclonal antibody, Affinity 
Bioreagent, CO), and anti-JAK2 (1:2000; polyclonal antibody, Upstate 
Biotechnology, Inc., Lake Placid, NY). The anti-phospho- STAT1, STAT3, 
STAT5 (1:1000; polyclonal antibodies), and anti-STAT1, STAT3, STAT5 
(1:1000; polyclonal antibody) were purchased from Cell Signaling, (Danvers, 
MA). A monoclonal anti-actin antibody was from MP Biomedicals (1:10,000; 
Aurora, OH). Prior to incubation with a second primary antibody, blots were 
stripped with Restore western blot stripping buffer from Pierce (Rockford, IL) 
by incubating at 370C for 25 minutes.  After incubation blots were removed 
from stripping buffer, washed three times for 10 min each with TBS or PBS 
containing 0.1% Tween20 and blocked again. Protein bands were analyzed 
densitometrically using Scion Image software (Scion Corporation, Frederick, 
MD). The IOD for the film background was subtracted from the IOD for each 
band. Each sample was measured in triplicate. RGS7 protein and 5-HT2A 
receptor protein levels were normalized to actin protein used as a loading 
control and phosphoproteins were normalized to the corresponding total 
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protein levels. Protein levels from olanzapine-treated cells were normalized to 
vehicle-treated cells for each cell fraction.  
 
5-HT2A Receptor Antibody Production and Characterization:  
A peptide corresponding to amino acids 22 to 41 of the rat 5-HT2A 
receptor (NH2-GD PRLYHNDFNSRDANTSE-OH) was synthesized and used 
to produce antibodies by Biosynthesis, Inc. (Lewisville, TX). This sequence is 
85% identical to the mouse 5-HT2A receptor sequence and 65% identical to 
the human 5-HT2A receptor sequence as determined using the NCBI 
Sequence Viewer. The same peptide sequence was used previously by 
Garlow et al. (Garlow, et al., 1993) to produce antibodies against the 5-HT2A 
receptor. The antibodies produced were characterized using western blotting 
and ELISA assays. The antibody titer reported by Biosynthesis, Inc. was up to 
1:25,600. A1A1v cells were used to verify the specificity of the 5-HT2A 
receptor antibodies. Cells were transfected with the human 5-HT2A receptor in 
pcDNA3.1+ (Guthrie DNA Resource Center, Sayre, PA) using 3µg of DNA for 
every dish and the Lipofectamine Plus Reagent (Invitrogen, Corp., Frederick, 
MD). 
Inositol phosphate (IP) accumulation assay:  
Assays were performed as previously described (Berg, et al., 1994). 
Briefly, cells were seeded in 24 well plates at the density of 40,000/well. Cells 
were treated with vehicle or 300nM olanzapine and also at the same time 
 72
labeled with 0.5 µCi [3H] myoinositol/well for 24 hour in serum free DMEM 
media.  Cells were washed with Hank’s balanced salt solution containing 20 
mM LiCl2 and 20 mM HEPES, Ph 7.4.  PI hydrolysis was initiated with the 
addition of DOI at 370C.  Reaction was stopped after 30 min with ice-cold 10 
mM formic acid. The accumulation of 3H-labeled inositol phosphate (IP) was 
determined by ion exchange chromatography (Singh et al., 2007). 
 
Statistics:  
All statistical analyses were performed using GB-STAT School Pak 
(Dynamic Microsystems, Silver Spring, MD). Data are expressed as means ± 
SEM. For Western blots and the IP accumulation assay, data were analyzed 
using a Student's t test for equal variances.  
 
Results 
IP accumulation assay:  
Agonist-stimulated IP accumulation can be used to monitor 
desensitization of 5-HT2A receptor mediated signaling (Hanley and Hensler, 
2002). Treatment with 300nM olanzapine for 24 hours significantly decreased 
(p<0.05) DOI (10-4 M) stimulated IP accumulation by 28±1.9% compared to 
vehicle (20% acetic acid) treated cells (figure 6). This decrease suggests a 
desensitization of 5-HT2A-mediated receptor signaling by olanzapine. The DOI 
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concentration was chosen based on the previous dose-response experiments 
conducted in our laboratory (Shi, et al., 2007). 
 
Olanzapine induced phosphorylation of JAK kinase:  
Guillet-Deniau et al. (Guillet-Deniau, et al., 1997) have shown that 
serotonin stimulation of 5-HT2A receptors causes phosphorylation of JAK2 
kinase and association of the receptor with JAK2. To investigate whether 
olanzapine causes JAK2 phosphorylation, lysates of cytosol and membrane 
fractions prepared from vehicle (20% acetic acid) and olanzapine (300nM) 
treated cells were examined by western blot with anti-phospho-JAK2 
antibody, then stripped and reprobed with anti-JAK2 antibody (figure 7A). 
Tyrosine phosphorylation of JAK2 was significantly increased (p<0.05) to 
more than 232 ±15 % of the control levels in the membrane fraction of 
olanzapine-treated cells (no significant change in cytosolic levels), whereas 
total JAK2 protein levels did not show any appreciable change.  
 
Phosphorylation and nuclear translocation of STAT Proteins:   
 Phosphorylated JAK2 facilitates activation of various STAT proteins. 
Tyrosine phosphorylated STATs then undergoes dimerization, translocate to 
the nucleus and bind to the target DNA sequences. However, different STAT 
proteins mediate signaling cascades stimulated by different agonists. To 
determine which STAT protein(s) are activated in response to olanzapine, 
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lysates of cytosolic and nuclear fractions from control (20% acetic acid) and 
olanzapine (300nM) treated cells were analyzed by western blot with anti-
phospho- STAT1, STAT3, and STAT5 antibodies, then stripped and reprobed 
with corresponding anti-STAT antibodies. We found that phosphorylation and 
nuclear translocation STAT3 was significantly increased to 171±25% in the 
olanzapine-treated cells compared to vehicle-treated cells (figure 7B), where 
as phosphorylation and nuclear translocation of STAT1 and STAT5 did not 
show any change (data not shown). 
 
Olanzapine increases RGS7 protein levels:  
In order to monitor the changes in RGS7 protein levels, lysates from 
cytosol and membrane fractions of vehicle (20% acetic acid) and olanzapine 
(300nM) treated cells were analyzed by western blot with anti-RGS7 antibody 
(figure 8A). We found that RGS7 protein levels were increased in the 
membrane fraction to 160±18% of control levels and significantly increased in 
cytoplasmic fraction by 193±32% of control levels in olanzapine-treated cells 
compared to vehicle-treated control cells. 
 
Characterization of 5-HT2A receptor antibody:   
A1A1v cells were used to verify the specificity of the 5-HT2A receptor 
antibody. On western blots prepared with A1A1v cell lysates, there was a 
prominent band with a molecular mass of approximately 42 kilodaltons (figure 
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3B). This is very similar to the size of the band produced by in vitro 
transcription and translation of the human 5-HT2A receptor construct provided 
by Guthrie cDNA Resource Center (Sayre, PA). Over expression of the 
human 5-HT2A receptor construct in A1A1v cells resulted in a more intense 
protein band detected on western blots prepared with the 5-HT2A receptor 
antibody (figure 8B). Preadsorption control experiments were also performed 
to verify the specificity of the antibody. Using homogenates from rat frontal 
cortex and lysates from A1A1v cells transfected with the human 5-HT2A 
receptor, the 42 kilodalton band 5-HT2A receptor band was no longer present 
in the western blots prepared with the antibody pre-incubated with the peptide 
antigen (figure 8C). These experiments also demonstrate that the antibody 
produced using a peptide based on the sequence for rat 5-HT2A receptor, 
cross-reacts with the human 5-HT2A receptor expressed in rat cells. 
Furthermore, the 5-HT2A receptor antibody also cross-reacts with the rat 5-
HT2A receptor expressed in a rat cortical cell line. 
 
5-HT2A receptor protein levels:  
Cytosol and membrane fractions from vehicle (20% acetic acid) and 
olanzapine (300nM) treated cells were analyzed by western blot with the anti-
5-HT2A antibody we generated. We found a significant increase (p<0.05) in 
both cytoplasmic (234±32% of control level) and membrane fractions 
(206±14% of control levels) of olanzapine-treated cells compared to vehicle-
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treated cells (figure 8D). We also assessed the purity of our membrane 
fraction after stripping and reprobing the same blot with an anti-NA+-K+-
ATPase antibody. A band corresponding to NA+-K+-ATPase was mainly 
present in membrane fraction (data not shown). 
 
JAK inhibition:  
A JAK kinase inhibitor, AG490, was used to investigate whether 
inhibition of the JAK-STAT signaling cascade could reverse the increase of 5-
HT2A receptor or RGS7 protein levels observed in response to olanzapine 
treatment.  Cells were treated for one hour with 0, 15, and 30 µM of AG 490, 
before adding either vehicle or olanzapine. Twenty-four hours later, cells were 
lysed and protein levels of phospho-JAK2, RGS7, and phospho-STAT3 were 
analyzed by western blot. Olanzapine-induced phosphorylation of JAK2 was 
decreased with AG490 as shown in figure 9A. There was no change in the 
total JAK2 protein levels. With AG490 treatment, there was a similar decrease 
in olanzapine-induced STAT3 phosphorylation in the nuclear fraction as 
shown in figure 9B, and no change in STAT levels, again confirming previous 
findings that activation of JAK2 causes phosphorylation and nuclear 
localization of STAT3.   
If the JAK-STAT signaling cascade is mediating the olanzapine-
induced increase in protein levels, then inhibiting this signaling cascade 
should prevent the increase in 5-HT2A receptor and RGS7 protein levels. To 
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test this hypothesis, membrane fractions from vehicle- and olanzapine-treated 
cells, pretreated with AG490 were analyzed by western blot for 5-HT2A 
receptor and RGS7 protein levels. As in previous experiment (figure 8A) 
olanzapine treatment for 24 hours increased the levels of RGS7 protein 
(figure 10A and B). Treatment with AG490 reduced the olanzapine-induced 
increase in the RGS7 in the membrane fractions to the levels in the vehicle 
treated cells (figure 10A). Treatment with AG490 alone had no effect on the 
levels of RGS7 protein.  Although we observed a similar increase in levels of 
5-HT2A receptor protein in olanzapine-treated cells compared to vehicle-
treated cells as shown before in figure 8C, AG490 pretreatment did not alter 
protein levels of 5-HT2A receptor in cells treated with olanzapine (figure 10C 
and D) suggesting that the increase in levels are not mediated by JAK-STAT 
signaling cascade. 
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Figure 6. Olanzapine decreases DOI-stimulated IP accumulation. A1A1v cells 
were treated either with vehicle (20% acetic acid) or olanzapine (300nM) for 
24 hours, and incubated with [3H] myoinositol for same 24-hour period. Both 
vehicle- and olanzapine-treated cells were stimulated with 10-4 M DOI. Bar 
graph represents the mean DOI-stimulated IP accumulation normalized to 
DOI-stimulated IP accumulation in vehicle-treated cells from three 
independent experiments.  IP accumulation was significantly decreased in 
olanzapine-treated cells compared to vehicle-treated cells. * indicates 
significantly different from vehicle-treated cells at p < 0.05. 
 79
 (See next page for figure legend) 
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Figure 7. Olanzapine activates the JAK-STAT signaling cascade. A1A1v cells 
were treated either with vehicle (20% acetic acid) or (300nM) olanzapine for 
24 hour. (A) Cytosol (C) and membrane (M) fractions of cells were analyzed 
by western blot with an anti-phosphoJAK2 antibody, stripped and reprobed 
with anti-JAK2 and anti-actin antibodies. Bar graph represents quantification 
of phosphoJAK2 protein levels divided by JAK2 protein levels from three 
independent experiments. Phosphorylation of JAK2 was significantly 
(*p<0.05) increased with olanzapine-treatment compared to vehicle-treated 
cells. (B) Cytosol (C) and nuclear fractions (N) of cells were analyzed by 
western blot with anti-phosphoSTAT3 antibody, stripped and reprobed with 
anti-STAT3 and anti-actin antibodies. Bar graph represents quantification of 
phosphoSTAT3 protein levels divided by STAT3 protein levels from three 
independent experiments. Olanzapine treatment significantly increases the 
phospho-STAT3 in the nucleus compared to vehicle treatment. * indicates 
significantly different from vehicle-treated cells at p < 0.05. 
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(See next page for figure legend) 
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Figure 8. Olanzapine treatment increases the levels of RGS7 protein and 5-
HT2A receptor (5-HT2AR) protein levels. (A) A1A1v cells were treated with 
either vehicle (20% acetic acid) or 300nM olanzapine for 24 hour. Cytosol (C) 
and membrane (M) fractions of cells were analyzed by western blot with anti-
RGS7 antibody, stripped and reprobed with an anti-actin antibody as a 
loading control. Bar graph represents quantification of RGS7 protein levels 
divided by actin protein levels from three independent experiments. Protein 
levels of RGS7 were significantly (*p<0.05) increased in olanzapine-treated 
cells compared to vehicle-treated cells. (B) A1A1v cells transfected with 
human 5-HT2A receptor (lane 2) produced a larger band than untransfected 
cells (lane 1) probed by 5-HT2A receptor antibody. (C) Preabsorbtion of the 5-
HT2A receptor antibody blocked the production of the 42kd protein band for 5-
HT2A receptor. Western blots prepared with homogenates of rat frontal cortex 
(lanes 1 and 3) and with lysates of A1A1v cells transfected with human 5-
HT2A receptor (lanes 2 and 4) were incubated with 5-HT2A receptor antibody 
(lanes 1 and 2) or 5-HT2A receptor antibody preadsorbed with the peptide 
antigen (lanes 3 and 4). (D) A1A1v cells were treated with either vehicle (20% 
acetic acid) or 300nM olanzapine for 24 hour. Cytosol and membrane 
fractions of cells were analyzed by western blot with anti- 5-HT2A antibody, 
stripped and reprobed with anti-actin antibody as a loading control. Bar graph 
represents quantification of 5-HT2A protein levels divided by actin protein 
levels from four independent experiments. 5-HT2A protein levels in both 
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cytosol and membrane fractions were significantly increased in olanzapine-
treated cells compared to vehicle-treated cells. * indicates significantly 
different from vehicle-treated cells at p < 0.05. 
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Figure 9. AG490 pretreatment inhibited olanzapine-induced increases in JAK-
STAT signaling. A1A1v cells were pretreated for 1hour with the indicated 
concentrations of AG490 prior to treating with either vehicle (20% acetic acid) 
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or 300nM olanzapine for 24 hours. (A) Membrane fraction of cells was 
analyzed by western blot with anti-phosphoJAK2 antibody. Blots were 
stripped and reprobed with anti-JAK2 and anti-actin antibodies. Bar graph 
represents quantification of phosphoJAK2 protein levels divided by JAK2 
protein levels from three independent experiments. (B) Nuclear fractions were 
analyzed by western blot with anti-phosphoSTAT3 antibodies, stripped and 
reprobed with anti-STAT3 and anti-actin antibodies.  Bar graph represents 
quantification of phospho-STAT3 protein levels divided by STAT3 protein 
levels from three independent experiments. AG490 pretreatment decreases 
phosphoJAK2 levels and phosphoSTAT3 nuclear translocation in olanzapine 
treated cells compared to cells treated olanzapine and the AG490 vehicle. * 
indicates significantly different from vehicle-treated cells at p < 0.05. 
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Figure 10. AG490 pretreatment reduces the olanzapine-induced increase in 
RGS7 protein levels in membrane but not the levels of 5HT2A receptor protein 
(5-HT2AR). A1A1v cells were pretreated with the indicated concentrations of 
AG490 for 1hour, before treating with either vehicle (20% acetic acid) or 
300nM olanzapine for 24 hours. (A) The membrane and (B) cytosol fraction of 
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cells were analyzed by western blot with anti-RGS7 antibody, stripped and 
reprobed with anti-actin antibody; actin was used as a loading control. Bar 
graph represents quantification of RGS7 protein levels divided by actin 
protein levels from three independent experiments. (C) Membrane and (D) 
cytosol fractions of cells were analyzed by western blot with anti-5-HT2A 
receptor antibody, stripped and reprobed with anti-actin antibody as a loading 
control. Pretreatment with AG490 had no effect on the increase in 5-HT2A 
receptor protein levels induced by olanzapine. * indicates significantly 
different from vehicle-treated cells at p < 0.05. 
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Discussion 
 
This study demonstrates the involvement of an intracellular signaling 
cascade, the JAK-STAT pathway, in increasing the levels of RGS7 protein in 
response to treatment with olanzapine. The increased levels of RGS7 protein 
in turn could contribute to the desensitization of 5-HT2A receptor signaling 
induced by olanzapine in A1A1v cells by directly interacting with Gαq/11 and 
accelerating GTP hydrolysis. In contrast, we found an increase in 5-HT2A 
receptor protein levels with olanzapine treatment that was not associated with 
increased activation of the JAK-STAT signaling cascade. The increase in 5-
HT2A receptor protein levels would not likely contribute to the desensitization 
response but could conceivably counter or moderate the desensitization 
response. 
Olanzapine and other antipsychotics have been recently reported to 
stimulate other signaling cascades including increased phosphorylation of 
ERK1/2 in rat frontal cortex (Fumagalli, et al., 2006), and increased 
phosphorylation of Akt/PKB and p38 in PC12 cells (Lu, et al., 2004). The 
increased activation of signaling cascades induced by antipsychotics 
suggests that changes in gene expression regulated by these cascades could 
contribute to the positive therapeutic benefits seen in schizophrenic patients.  
Several micro-array studies have explored the effects of olanzapine 
and other antipsychotics on gene expression, reporting changes in 
expression of a host of genes including RGS proteins, and gene families 
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linked with synaptic plasticity and presynaptic neurotransmission (Feher, et 
al., 2005;Fatemi, et al., 2006). Fatemi et al. (Fatemi, et al., 2006), reported an 
increase in expression of RGS19 mRNA and a decrease in expression of 
RGS2 mRNA in the frontal cortex of rats treated for three weeks with 
olanzapine. GAP activity of RGS19 is associated with Gαz, a member of 
Gαi/o-G protein family, whereas 5-HT2A receptors are coupled with Gαq/11 
proteins. Therefore, increased RGS19 is unlikely to affect olanzapine-induced 
desensitization of 5-HT2A receptor signaling. Although RGS2 protein 
associates with Gαq protein, and could decrease the 5-HT2A receptor 
signaling; a decrease in expression of RGS2 protein could not cause the 
desensitization of 5-HT2A receptor signaling induced by olanzapine since a 
decrease in RGS protein expression would likely result in increased receptor 
signaling. Although RGS2 is expressed in frontal cortex, it is not known if it 
co-localizes with 5-HT2A receptors in frontal cortex.  
None of these microarray studies identified alterations in RGS7 protein 
or 5-HT2A receptor mRNA levels. It is important to remember that changes in 
mRNA levels may or may not result in changes in protein levels and changes 
in protein levels may not be due to changes in mRNA levels. It is also 
important to emphasize that these studies were conducted in different 
experimental settings with different time course and dose regimens than our 
study. Each study highlights important findings, further extending our 
understanding of antipsychotics mechanism of action. It is becoming evident 
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that there could be numerous pathways and alterations in gene expression 
that lead to the development of psychosis (Ko, et al., 2006) and its treatment 
with atypical antipsychotics.   
Direct association of JAK2 and STAT3 with 5-HT2A receptors, and 
activation of the JAK-STAT signaling cascade by 5-HT2A receptor agonists 
has been reported previously (Guillet-Deniau, et al., 1997).  In the present 
study, we found JAK2 activation and increased phosphorylation and nuclear 
localization of phospho-STAT3 in olanzapine-treated cells. It is interesting to 
note that phosphorylation and nuclear translocation of other isoforms of STAT 
proteins, STAT1 and STAT5, did not show any change with olanzapine 
treatment. Activation of STAT proteins, which are transcription factors, could 
bolster the previous notion that antipsychotic agents affect expression of 
various genes. 
Our experiments with a JAK kinase inhibitor, AG490, suggest that the 
increased levels of RGS7 protein are mediated by the JAK-STAT signaling 
cascade in response to olanzapine treatment. Interestingly, AG490 selectively 
targeted the membrane localized RGS7 protein and had no effect on the 
levels in cytosol fraction. The overall effect of AG490 is a decrease in the total 
levels of RGS7 protein (i.e., membrane plus cytosol), suggesting that 
olanzapine-induced JAK-STAT signaling increases the levels of RGS7 protein 
rather than causing a redistribution of the protein. We speculate that 
transcriptional activity of phospho-STAT3 could increase RGS7 mRNA 
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expression and be responsible for increased levels of RGS7 protein in the 
membrane fraction. The mechanism(s) involved in the selective decrease in 
the membrane fraction of A1A1v cells are unknown but could involve a 
chaperone protein. However, further studies are needed to test these 
hypotheses. In contrast, changes in 5-HT2A receptor protein levels seem to be 
regulated by a different mechanism, since pretreatment with AG490 fails to 
reverse the olanzapine-induce increase in receptor protein levels. 
Most atypical antipsychotics cause desensitization of 5-HT2A receptor 
signaling. The decrease in DOI stimulated IP accumulation with olanzapine 
treatment in our study is consistent with these findings and supports the use 
of A1A1v cells as a model to study the actions of olanzapine on 5-HT2A 
receptor signaling. Previous experiments in A1A1v cells using the selective 5-
HT2A receptor antagonist, MDL100907 demonstrated that IP accumulation 
stimulated by the 5-HT2A/2C selective agonist DOI is not likely due to 
stimulation of 5-HT2C receptors (Shi, et al., 2007). Numerous investigations 
have explored the mechanisms by which antipsychotics cause desensitization 
of 5-HT2A receptor signaling. This desensitization by antipsychotics could be 
mediated by receptor internalization, uncoupling of G-proteins from receptor, 
and receptor down-regulation (Roth, et al., 1995;Willins, et al., 1999) in 
addition to increases in RGS7 protein.  
Other mechanisms have been associated with desensitization of 5-
HT2A receptor signaling as a result of treatment with atypical antipsychotics. 
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Several studies specifically investigated changes in the transcript level of 5-
HT2A receptors with both short term and chronic antipsychotic treatments 
(Doat-Meyerhoefer, et al., 2005;Burnet, et al., 1996). Buckland et 
al.(Buckland, et al., 1997) reported a significant decrease in receptor mRNA 
in hippocampus, brain stem and midbrain whereas no significant change was 
observed in other brain regions after 32 days of treatment with the atypical 
antipsychotic clozapine. However, in the same study, four days of clozapine 
treatment did not produce any significant change but a trend for a decreased 
mRNA expression was observed in major brain areas. As noted previously, 
changes in mRNA levels do not necessarily result in corresponding changes 
in protein levels, so changes in 5-HT2A receptor mRNA levels are not 
necessarily inconsistent with the current findings. We found an increase in 5-
HT2A receptor protein levels in both the cytosol and membrane fractions. 
Previous studies reported a sizeable amount of 5-HT2A receptors in the 
cytosol in addition to that found in the membrane (Cornea-Hebert, et al., 
1999). Several reports suggest a decrease in Bmax with no change in Kd 
after treatment with antipsychotics (Doat-Meyerhoefer, et al., 2005;Matsubara 
and Meltzer, 1989). A decrease in the density of 5-HT2A receptors without any 
change in affinity is consistent with the receptor internalization previously 
reported (Roth, et al., 1995;Willins, et al., 1998). An increase in 5-HT2A 
receptor protein levels in the cytosol as we found with western blot analysis, 
could reflect internalized receptors. Furthermore, an increase in total 5-HT2A 
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receptor protein levels is not necessarily inconsistent with a decrease in 
receptor density. 5-HT2A receptor proteins undergo extensive post-
translational modifications that could affect ligand binding. It is difficult to 
speculate at this point about the post-translational modifications that are 
required for or inhibit ligand binding. It is likely that multiple mechanisms 
contribute to desensitization of 5-HT2A receptor signaling and that the specific 
mechanisms involved are likely tissue specific. 
In summary, our cell culture data highlight a new role of JAK-STAT 
signaling in treatment with olanzapine. Increased-activation of this pathway by 
olanzapine increases expression of RGS7 protein. Increased RGS7 protein 
could directly contribute to the desensitization of 5-HT2A receptor signaling by 
accelerating hydrolysis of GTP bound Gαq protein. Unfortunately, the JAK 
inhibitor AG490 interferes with the IP accumulation assay and therefore 
precludes our ability to determine if JAK-STAT signaling contributes to the 
desensitization of 5-HT2A receptors in our model system. We are further 
investigating whether increased RGS7 protein is the result of increased 
transcriptional activity and whether blocking membrane localization of RGS7 
protein inhibits desensitization of 5-HT2A receptor signaling cascade. Further 
studies are also needed in animal models to confirm these findings in vivo. 
Overall, the results from this study provide a further understanding of possible 
involvement of intracellular pathways in mediating the effects of atypical 
antipsychotics. 
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    CHAPTER IV 
THE ROLE OF THE JAK-STAT PATHWAY IN ATYPICAL 
ANTIPSYCHOTIC-INDUCED DESENSITIZATION OF 5-HT2A RECEPTOR 
SIGNALING IN CELL CULTURE 
 
 
Abstract 
 
We previously demonstrated that olanzapine-induced desensitization 
of 5-HT2A receptor signaling is associated with increases in RGS7 protein 
levels both in vivo and in cells in culture, and the increase in RGS7 is 
dependent on activation of the JAK-STAT pathway in cells in culture (Muma, 
et al., 2007;Singh, et al., 2007). In the current study, we found that 
desensitization of 5-HT2A receptor signaling induced by olanzapine is 
dependent on activation of the JAK-STAT pathway. Similar to olanzapine, 
clozapine-induced desensitization of 5-HT2A receptor signaling is 
accompanied by increases in RGS7 (194±11% of control levels) and 
activation of JAK2 (196±18% of control levels). Treatment with the selective 
5-HT2A receptor antagonist MDL100907 for 24 h also increased RGS7 protein 
levels (176 ±16 % of control levels) and JAK2 activation (183 ±13 % of control 
levels). Olanzapine, clozapine, and MDL100907 treatment for 24 h increased 
mRNA levels of RGS7. Olanzapine treatment for 24 h increased STAT3 
binding to the putative RGS7 promoter region. Taken together, olanzapine-
induced activation of the JAK-STAT pathway, and increases in STAT3 
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binding to the RGS7 gene could underlie the increase in RGS7 mRNA which 
could subsequently increase protein expression. Furthermore, the increase in 
RGS7 protein could play a role in the desensitization of 5-HT2A receptor 
signaling by terminating the activated Gαq/11 proteins more rapidly. Overall, 
our data suggest that the full desensitization of 5-HT2A receptor signaling by 
atypical antipsychotics requires activation of JAK-STAT pathway, which in 
turn increases RGS7 expression likely by direct transcriptional activity of 
STAT3. 
 
Introduction 
Atypical antipsychotics like clozapine and olanzapine (dibenzopyridine 
derivatives) represent a relatively new generation of antipsychotics with fewer 
incidences of negative side effects such as extrapyramidal side effects (EPS) 
(Meltzer, 1995).  Although, atypical antipsychotics have a diverse receptor 
binding profile, 5-HT-receptor-based mechanisms have been postulated to 
play a critical role in the action of the atypical antipsychotic drugs (Willins, et 
al., 1999a). However, the process by which these drug-receptor interactions 
translate into long-term cellular adaptive changes resulting in antipsychotic 
efficacy is unknown.  
Atypical antipsychotic drugs bind with high affinity to 5-HT2A receptors 
and desensitize 5-HT2A receptor signaling (Deutch, et al., 1991;Meltzer and 
Nash, 1991;Meltzer and Nash, 1991;Seeger, et al., 1995). Although, 
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desensitization of 5-HT2A receptor signaling by atypical antipsychotics is 
reported to be associated with down-regulation and internalization (Willins, et 
al., 1999); the molecular mechanisms that underlie these changes are not 
well understood. Activation of 5-HT2A receptors stimulates activation of Gαq/11, 
which in turn activates effector enzymes including phospholipase C (PLC).  
PLC catalyses release of diacylglycerol (DAG) and inositoltriphosphate (IP3) 
from phosphatidyl inositol bisphosphate (PIP2). The released IP3 can be 
measured as an index of 5-HT2A receptor signaling activity. In addition to 
these integral components of receptor signaling system, regulators of G 
protein signaling (RGS) proteins modulate signaling of several G protein 
coupled receptors (GPCR) (Koelle and Horvitz, 1996).  RGS proteins can 
regulate G-protein signaling by functioning as GTPase-activating proteins 
(GAPs). GAP activity can hasten the termination of a signal upon removal of a 
stimulus, attenuate a signal either as a feedback inhibitor or in response to a 
second input, promote regulatory association of other proteins, or redirect 
signaling within a G protein signaling network (Ross and Wilkie, 2000). RGS4 
and RGS7 are highly enriched in various brain regions including frontal cortex 
and are reported to be GAPs for Gαq/11 associated 5-HT2A receptor signaling 
(Larminie, et al., 2004). Khawaja et al. (1999) have extensively characterized 
cellular co-localization of RGS7 with Gαq/11 immunohistochemically throughout 
the adult rat brain and reported a heterogeneous and overlapping regional 
distribution (Khawaja, et al., 1999).  
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We have previously reported that desensitization of 5-HT2A receptor 
signaling with chronic treatment of olanzapine is accompanied by activation of 
STAT3 and an increase in RGS7 protein levels in rat frontal cortex (Muma, et 
al., 2007). In addition, we found that 24-h treatment with olanzapine causes 
desensitization of 5-HT2A receptor signaling and an increase in membrane-
associated RGS7 protein that is dependent on activation of the JAK2-STAT3 
pathway in A1A1v cells, a cell line endogenously expressing the 5-HT2A 
receptor signaling components (Singh, et al., 2007). However, whether 
activation of JAK-STAT is necessary for olanzapine induced desensitization 
and the mechanisms by which activation of the JAK-STAT pathway increase 
RGS7 protein are not currently known. Therefore, it is important to determine 
not only the role of the JAK-STAT pathway but also the mechanisms 
underlying up-regulation of RGS7 protein in response to antipsychotic 
treatment to help identify new targets for therapeutic intervention.  
Increases in RGS7 protein levels could be mediated by several 
mechanisms for example, RGS7 binding to Gβ5 is reported to increase 
stability of each protein (Chen, et al., 2003) such that an increase in Gβ5 could 
increase RGS7 protein levels. Another possible mechanism is a direct 
increase in transcription of RGS7 thereby increasing RGS7 mRNA levels.  
We previously reported that inhibition of activated JAK-STAT pathway, 
completely blocked the increase in RGS7 protein levels by olanzapine (Singh, 
et al., 2007). Although, transcriptional activity of STAT3 as been extensively 
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reported for various genes (Aaronson and Horvath, 2002;Kisseleva, et al., 
2002;Schindler, 2002), STAT3 has not been identified as a transcription factor 
for RGS7. STAT3-mediated regulation of gene expression is associated with 
the presence of the consensus element TTCN2-4GAA upstream of the 
transcription start site (Ehret, et al., 2001;Wrighting and Andrews, 2006). 
Genomic sequence analysis of rat RGS7 revealed that there are multiple sets 
of TTCN2-4GAA sequences. Thus, it is possible that STAT3 is a transcription 
factor for the RGS7 promoter.  
Based on our previous reports that the olanzapine-induced increases 
in RGS7 protein levels are dependent on activation of the JAK-STAT 
pathway, we hypothesize that STAT3 is a transcription factor for RGS7 and is 
directly responsible for the increase in RGS7 protein levels by olanzapine 
treatment.  In this study, we also examined whether another atypical 
antipsychotic, clozapine and a selective 5-HT2A receptor antagonist, 
MDL100907, also activate the JAK-STAT pathway and increase RGS7 
expression. Lastly, we determined whether activation of JAK-STAT pathway 
is necessary for desensitization of 5-HT2A receptor signaling by atypical 
antipsychotics.  
Materials and Methods 
Drugs: 
Olanzapine and AG490 were purchased from Torrent Research 
Chemicals Inc., ON, Canada. MDL100907 was kindly provided by Sanofi 
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Aventis, Bridgewater, NJ. Clozapine was purchased from TOCRIS, Ellisville, 
MO. Olanzapine was dissolved in 20% glacial acetic acid and the pH was 
adjusted to 6.5 with 10M NaOH as described in previous chapter. AG490, 
MDL100907 and clozapine were dissolved in 100% DMSO to obtain the 
desired concentration for individual treatments with each drug. (-)1-(2,5-
dimethoxy-4-iodophenyl)-2-aminopropane (DOI) was purchased from Sigma-
Aldrich; St. Louis, MO. HBSS mix (1X HBSS, 20mM LiCl2, and 20mM 
HEPES) was used to dissolve DOI. A stock solution of 100µM clozapine was 
prepared in DMSO. For clozapine treatment each group was added equal 
volume (10µl) in 10 ml of cell culture media of either drug or vehicle (equal 
volume of DMSO was added to each group).   
 
Cell Culture:   
A1A1 cells, a cortical cell line, that endogenously expresses 5-HT2A 
receptors and its downstream components, were used for all experiments 
(generously donated by Dr. William Clarke and Kelly Berg, University of 
Texas Health Science Center, San Antonio, TX). Cells were grown in the 
charcoal-treated serum to diminish serotonin in the media 24 h before 
treatment with olanzapine, clozapine, or MDL100907. Cells were treated with 
either vehicle or drugs for 24 h. 
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Cell fractionation:   
Cell lysates were separated into membrane and cytosol fractions using 
centrifugation as previously described (Tucker, 2004;Singh, et al., 2007). 
Briefly, cells were washed once with PBS containing phosphatase inhibitors, 
followed by incubation in hypotonic buffer containing 0.25M sucrose, 50mM 
Tris-HCl, 5mM EDTA, and protease inhibitor cocktail (Sigma-Aldrich; St. 
Louis, MO) for 15 min on ice before lifting them with a cell scrapper. Cells 
were spun at 500xg at 40C to remove cell debris and then sonicated three 
times for 10 sec to make a cell homogenate. The homogenate was spun at 
100,000xg for 45 min at 40C to produce a pellet, which is composed of 
membrane fraction, and a supernatant, which is the cytosol fraction. The 
pellet was reconstituted with hypotonic buffer.  The protein concentration was 
assessed with bicinchoninic acid protein assay kit (Pierce Chemical, 
Rockford, IL).  
 
Western Analyses:   
Equal amounts of protein from vehicle-control and drug-treated 
samples were separated on 10% SDS polyacrylamide gels. Proteins were 
transferred to nitrocellulose membrane for 2 h at 100V.  Non-specific binding 
to the membranes was blocked either with TBS containing 5% (w/v) nonfat 
dry milk with 0.1% Tween 20 (TBST) or in PBS containing 5% (w/v) nonfat dry 
milk. The following primary antibodies were used: anti-RGS7 (Polyclonal 
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antibody, Upstate Biotechnology, Inc., Lake Placid, NY), anti-phospho-JAK2 
(polyclonal antibody, Affinity Bioreagent, CO), anti-JAK2 (polyclonal antibody, 
Upstate Biotechnology, Inc., Lake Placid, NY), and anti-actin (monoclonal 
antibody MP Biomedicals, Aurora, OH). Prior to incubation with a second 
primary antibody, blots were stripped with Restore western blot stripping 
buffer (Pierce, Rockford, IL) by incubating at 370C for 25 min.  After 
incubation, blots were removed from stripping buffer, washed three times for 
10 min each with TBS or PBS containing 0.1% Tween20 (TBST or PBST) and 
blocked with 5% milk in TBST or PBST for 1 hr at room temperature. Protein 
bands were analyzed densitometrically using Scion Image software (Scion 
Corporation, Frederick, MD). The gray scale density readings were calibrated 
using a transmission step-wedge standard. The integrated optical density 
(IOD) of each band was calculated as the sum of the optical densities of all 
the pixels within the area of the band outlined. The IOD for the film 
background was subtracted from the IOD for each band. Each sample was 
measured in triplicate. RGS7 protein was normalized to actin protein and 
phosphoproteins were normalized to the corresponding total protein levels. 
Protein levels from treated cells were normalized to vehicle-treated cells for 
each western blot analysis.  
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Inositol phosphate (IP) accumulation assay:  
The assay was performed as previously described (Singh, et al., 
2007b). Briefly, cells were seeded in 24 well plates at a density of 40,000 
cells/well. Cells were treated with vehicle or different concentrations of 
clozapine for 24 hr in serum-free DMEM media during the same 24-hr period; 
cells were labeled with 0.5 µCi [3H] myoinositol/well. Following treatment and 
labeling, cells were washed 4 times with HBSS mix containing 20mM LiCl2, 
and 20 mM HEPES, then incubated with 500 µL of same buffer at 370C for 15 
min. Following the incubation, cells were challenged with 100 µM DOI for 30 
min. Media was removed with 10mM ice-cold formic acid after the challenge 
treatment, and incubated on ice for 1 hr. AG1-X8 (Bio-Rad) resin columns 
were prepared as follows: columns were washed once with 3 ml of 3 M-
ammonium formate/100 mm formic acid, twice with 5 ml of 10 mm formic 
acid/10 mm inositol. Once the columns were drained out completely, samples 
were loaded into the column and allowed to enter into the resin. Columns 
were then washed once with 5 ml of 10 mM formic acid/10 mM inositol, twice 
with 5 ml of 60 mM sodium formate/ 5 mM borax. After washing, samples 
were eluted with 5 ml of 1 M ammonium formate/ 100 mM formic acid into 
scintillation vials, 12 ml of scintillation cocktail was added into each vial, 
mixed thoroughly and counted in a scintillation counter.  
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PLC Assay:   
Since preincubation with AG490 interferes with [3H] myoinositol 
incorporation into A1A1v cells, we used an alternative, ex vivo, method to 
isolate membranes from control and treated cells and incubate the membrane 
fraction with [3H] myoinositol.  This method involves testing the enzymatic 
activity of PLC present in isolated membranes thereby avoiding any problems 
with incorporation of [3H] myoinositol in presence of AG490. To harvest cells, 
culture plates were washed twice with Tris buffer (25 mM Hepes-Tris, 1mM 
EGTA, pH 7.4, containing protease inhibitor cocktail). Cells were harvested by 
scraping cells off the plates, and then cells were centrifuged at 20,000g for 20 
min at 4°C. The pellet was resuspended in Tris buffer and stored at -80°C. 
Homogenates were thawed on the day of the PLC assay and homogenized 
by hand with five up-and-down strokes with a glass on glass homogenizer 
and then centrifuged at 20,000g for 20 min. After centrifugation, the pellet was 
resuspended in 50 mM Tris buffer and centrifuged at 20,000g for 10 min. The 
resultant pellet was washed 3X and resuspended in assay buffer (25 mM Tris 
pH 7.4, 3 mM EGTA, and 10 mM LiCl).  
5-HT- and GTP S-stimulated PLC activity in cell membranes were 
measures as described previously (Damjanoska, et al., 2003;Wolf and 
Schutz, 1997). Protein concentrations were determined using a bicinchoninic 
acid protein assay kit (Pierce Chemical). The membrane protein was diluted 
to an approximate concentration of 30 µg/100 µl with  buffer containing 25 
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mM HEPES-Tris, 3 mM EGTA, 10 mM LiCl, 12 mM MgCl2, 1.44 mM sodium 
deoxycholate with 0.5 µM GTP S (a nonhydrolyzable form of GTP), 100 nM 
free Ca2+, 1mM unlabeled phosphatidylinositol, and 100 µM [3H] 
phosphatidylinositol (PerkinElmer Life and Analytical Sciences). A 
concentration of 100 µM 5-HT or 1 µM of bradykinin was used to stimulate 
PLC activity. 5-HT-stimulated PLC activity is a selective measure of 5-HT2A 
receptor function in A1A1v cells as previously demonstrated using selective 
antagonists (Shi, et al., 2007). Bradykinin was used to investigate the 
selectivity of olanzapine-induced desensitization of 5-HT2A receptor signaling.  
 
RNA Isolation and Reverse Transcription:  
Total RNA was isolated using the RNeasy Mini Kit (Qiagen Sciences, 
Valencia, CA) according to the manufacturer’s protocol. Total RNA was 
quantitated using a spectrophotometer and optical density (OD) 260/280 nm 
ratios were determined. Quality of the RNA was further accessed with a 
formaldehyde-agarose gel. First strand cDNA was synthesized using random 
hexamers and Superscript II Reverse Transcriptase from Invitrogen according 
to the manufacturer’s protocol. Reactions were incubated at 250C for 2 min, 
250C for 10 min, and 420C for 50 min and inactivated by heating at 700C for 
15 min in an M J Mini, personal thermal cycler (BIO-RAD).  
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Real-Time PCR:  
The GAPDH (sense 5’-tggagtctactggcgtcttcac-3’; antisense 5’-
ggcatggactgtggtcatga-3’) and RGS7 (sense 5’-gaagatgagttgcaccgacaga-3’; 
antisense 5’-ggtctttcagtgcctcatccat-3’) primer sets were synthesized by IDT, 
Inc (Coralville, IA).  PCR amplification was performed with 7500 Real-Time 
PCR System using SYBR green PCR master mix (Applied Biosystems, 
Foster city, CA). The PCR parameters used were a 10 min denaturation cycle 
at 95°C, 40 cycles of amplification at 95°C for 15 sec, and 
annealing/extension at 60°C for 1 min. Real-Time PCR was performed with 
25 µL reaction mixture of cDNA, primers and SYBR green master mix. 
 
RNA Data Analysis:  
Comparative Ct (∆∆CT) method was used for analysis of all real-time 
PCR data.  ∆CT values were calculated by normalizing CT values of RGS7 to 
GAPDH from vehicle and antagonist-treated groups. The extent of the 
response is determined by 2mean(∆∆CT), and the relative degree of response is 
calculated by 2−mean (∆∆CT). Results are expressed as fold change in RGS7 
mRNA levels for clozapine, MDL100907 or olanzapine-treated cells with 
respect to vehicle-treated cells. Data presented are from four independent 
experiments performed in triplicate. 
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Chromatin Immunoprecipitation Assay (ChIP):  
The chromatin immunoprecip -itation (ChIP) assay was performed using a kit 
(Millipore, Billerica, MA) according to the manufacturer’s protocol. Following 
crosslinking, the DNA/protein complexes were sheared by sonication. One 
percent of sheared DNA/protein complex was kept and used as an input DNA 
sample. Anti-STAT3 rabbit polyclonal antibody (Sigma, Saint Louis, MO), or 
normal rabbit IgG (Millipore, Billerica, MA) was used for immunoprecipitation. 
Immunoprecipitated DNA/protein complexes were analyzed using polymerase 
chain reaction (PCR) with following primer sets flanking the five potential 
STAT3 binding sites (site 1-site 5): 
F1 5’-GAAGTCAGGAGTCAGTCAAAGC-3’,  
R1 5’- ACTCCTTGGCTTCAACTAT GG-3’ 
F2 5’-AAGCTGGGTACGTTTCAGG-3’, R2 5’-AATTTGGAGGCCTGGACC-3’ 
F3 5’-ATCCTTGGCACTGGACACC-3’, R3 5’-GGGCTAAGATAATGGGAGG-3’  
F4 5’-GATGGTTTGCCACTTGTGC-3’, R4 5’- CTACTCTGCAGCCATCTGC-3’ 
F5 5’- ACATTCCAACAGGACCGG-3’, R5 3’-ATCGGTCATGGCATCTCACC-3’ 
A previously identified STAT3 binding region from the hepcidin gene was 
used as a positive control (F 5’- GAGGGTGACACAACCCTGTT-3’, R 5’-
ACCGAGTGACA GTCGCTTTT-3’) (Wrighting and Andrews, 2006). Two 
microliter of precipitated DNA was amplified using Taq polymerase (New 
England, Biolabs, Ipswich, MA). The conditions for PCR amplification were as 
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follows: 40 cycles of 940C for 15 s, 550C for 15 s, 720C for 45 s, and the 
amplimers were resolved on 1% agarose gels containing ethidium bromide. 
 
Statistics:   
All statistical analyses were performed using GB-STAT School Pak 
(Dynamic Microsystems, Silver Spring, MD). Data are expressed as means ± 
SEM. For Western blots and IP accumulation assay, data were analyzed 
using a using a one-way analysis of variance, followed by a Newman–Keuls' 
post hoc analysis. RT-PCR and PLC activity assay was analyzed using a two-
way analysis of variance, followed by a Newman–Keuls' post hoc analysis.  
 
Results 
IP3 accumulation assay:  
Agonist-stimulated IP3 accumulation can be used to monitor 
desensitization of 5-HT2A receptor signaling (Singh, et al., 2007). Treatment 
with different concentrations of clozapine for 24 h significantly decreased 
(F(4,14) = 104.43, p < 0.0001) DOI (10-4 M) stimulated IP3 accumulation in a 
dose dependent manner compared to vehicle (DMSO) treated cells (figure 
11). A post-hoc analysis revealed a decrease in IP3 accumulation by 39% 
with 5 µM (p < 0.01), 53% with 20µM (p < 0.01), 64% with 30µM (p < 0.01), 
and 80% with 40 µM (p<0.01) treatment. This decrease suggests a 
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desensitization of 5-HT2A-mediated receptor signaling in A1A1v cells by 
clozapine.  
 
Clozapine and MDL100907 treatment increase phosphorylation of JAK2:  
We have shown that the 5-HT2A receptor inverse agonist, olanzapine 
causes phosphorylation of JAK2 kinase (Singh, et al., 2007). In order to 
investigate whether the effect is specific to olanzapine or is a general effect of 
atypical antipsychotics and more specifically 5-HT2A receptor antagonists, we 
treated A1A1v cells for 24h with either clozapine, MDL100907 or drug 
vehicles. Membrane fractions prepared from vehicle, clozapine (20µM), and 
MDL100907 (1µM) treated cells were analyzed by western blot with an anti-
phospho-JAK2 antibody, then stripped and reprobed with an anti-JAK2 
antibody (figure 12). Tyrosine phosphorylation of JAK2 was significantly 
increased (F(2,8) = 39.57, p < 0.001). A post-hoc analysis revealed that pJAK 
levels were increased to 183 ±13 % of the control levels with MDL100907 and 
196±18% of the control levels with clozapine treated cells, whereas total 
JAK2 protein levels did not show any appreciable change.  
 
Clozapine and MDL100907 increase RGS7 protein levels:  
Next, we wanted to determine whether this increase in JAK2 
phosphorylation with both clozapine and MDL100907 is also accompanied by 
increases in RGS7 protein levels as previously observed with olanzapine 
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(Singh, et al., 2007). In order to monitor the changes in RGS7 protein levels, 
membrane fractions of vehicle, clozapine, or MDL100907-treated cells were 
analyzed by western blot with anti-RGS7 antibody (figure 13). We found that 
RGS7 protein levels were significantly increased (F(2,8) = 95.99, p < 0.001) by 
drug treatments.  A post-hoc analysis revealed that RGS7 protein levels were 
increased to 176 ±16 % of the control levels with MDL100907 and 194±11 in 
clozapine treated cells.  
 
JAK2 inhibitor partially reversed the olanzapine-induced desensitization 
of 5-HT2A receptor signaling:  
We have previously shown that olanzapine-induced activation of the 
JAK2-STAT3 pathway is necessary for the increase in RGS7 protein levels; 
next we wanted to determine if activation of the JAK2-STAT3 pathway is 
necessary for olanzapine-induced desensitization of 5-HT2A receptor 
signaling. However, AG490 interfered with the measurements of IP3 
accumulation in vivo. Therefore, we decided to use an alternative ex vivo 
method in which we isolated membranes from AG490 pretreated, control and 
olanzapine-treated cells and then incubated them with [3H] myoinositol. This 
method involves measuring the enzymatic activity of PLC present in isolated 
membranes thereby avoiding any interference of preincubation of AG490 on 
incorporated [3H] myoinositol. Olanzapine-induced changes in PLC activity 
were monitored in response to stimulation with 5-HT, bradykinin, or GTPγS. 5-
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HT stimulation measures the ability of 5-HT2A receptors to stimulate PLC 
activity via Gαq/11 activation where as GTPγS directly binds to Gαq/11 to 
activate PLC. Bradykinin was used to investigate the specificity of olanzapine-
induced desensitization response by examining the effects on another Gq/11 
linked receptor system. Olanzapine treatment significantly decreased (by 
55%, p<0.01). PLC activity stimulated with serotonin. AG490 alone had no 
effect on PLC activity (figure 14A).  However, pretreatment with AG490 
significantly attenuated the olanzapine-induced decreases in PLC activity 
(p<0.05) suggesting that the JAK-STAT pathway is necessary for the full 
olanzapine-induced desensitization of 5-HT2A receptor signaling. Two-way 
ANOVA indicates a main effect of olanzapine on PLC activity (F(1,19) = 41.18, 
p < 0.001),  a main effect of AG490 (F(1,19) = 4.23, p < 0.05), but no significant 
interaction was observed between olanzapine and AG490 (F(1,19) = 2.92, 
p < 0.391). In addition, olanzapine or AG490 treatment had no effect on 
GTPγS-stimulated PLC activity (figure 14B). When olanzapine-treated cells 
were stimulated with bradykinin (figure 14C); olanzapine treatment had no 
effect on bradykinin-stimulated PLC activity confirming that olanzapine 
treatment specifically desensitizes 5-HT2A receptor signaling. 
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Olanzapine, Clozapine and MDL100907 increase mRNA levels of RGS7 
protein:  
To investigate whether the increase in RGS7 protein levels is 
associated with an increase in RGS7 mRNA levels, cells were treated in a 
similar fashion as in previous experiments for 24h with vehicle, olanzapine, 
clozapine, or MDL100907. Total RNA was isolated from each sample and 
reverse transcribed with random hexamers to make cDNA. Using that cDNA, 
a real-time PCR analysis was performed with specific primers for RGS7 and 
GAPDH.  The vehicle and drug-treated RGS7 mRNA levels were normalized 
to GAPDH. We found a statistically significant (F(1,15) = 43.43; p < 0.001) 
increase in RGS7 mRNA levels. A post-hoc analysis revealed that RGS7 
mRNA levels were increased to 153±11% with olanzapine (figure 15A), 
175±14 % with clozapine, and 144±17 % with MDL100907 treatment (figure 
15B) over their respective vehicle-treated cells.  
 
STAT3 binds to the putative RGS7 promoter region:  
To determine if STAT3 binds to potential STAT3 consensus site in cells, we 
used a ChIP approach. A bioinformatic analysis of the 10 kb promoter region 
of rat RGS7 identified five potential STAT3 binding sites based on the 
consensus sequence-TTCN2-4GAA.  Specific primers were designed that 
flank each of these consensus sites and were named site number one 
through five (figure 6). A1A1v cells were treated with vehicle (20% acetic 
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acid) or olanzapine (300nM) for 24h as previously described. 
Immunoprecipitates isolated from either vehicle or olanzapine-treated cells 
were used to perform ChIP analysis. Of the five potential STAT3 binding sites 
identified, only site 2 tested positive in this analysis (Figure 6).  Moreover, 
treatment with olanzapine produced increased STAT3 binding at this site. Site 
2 begins 2.34kb upstream of the RGS7 transcription start site. The primers 
specific for hepcidin, used as a positive control, also tested positive using 
STAT3 immunoprecipitates.  In contrast, when the beads alone or pre-
immune IgG was used to produce chromatin no amplimer was detected. 
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 Figure 11. Clozapine decreases DOI-stimulated IP accumulation. A1A1v cells 
were treated with either vehicle (DMSO) or with various concentrations of 
clozapine for 24 h, and incubated with [3H]-myoinositol for same 24 h period. 
Both vehicle- and clozapine-treated cells were stimulated with 10-4 M DOI. 
Bar graph represents DOI-stimulated IP accumulation normalized to DOI-
stimulated IP accumulation in vehicle-treated cells from four independent 
experiments.  IP accumulation was significantly decreased in clozapine-
treated cells compared to vehicle-treated cells. * indicates significantly 
different from vehicle-treated cells at p < 0.01. 
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 Figure 12.  Clozapine and MDL100907 stimulate JAK2 phosphorylation. 
A1A1v cells were treated either with vehicle (DMSO) or 20 µM clozapine or 
1µM MDL100907 for 24 h. Membrane fractions of cells were analyzed by 
western blot with anti-phosphoJAK2 antibody, stripped and reprobed with 
anti-JAK2 and anti-actin antibodies. Bar graph represents quantification of 
phosphoJAK2 protein levels divided by JAK2 protein levels from five 
independent experiments. Phosphorylation of JAK2 was significantly 
increased (p<0.05) with both clozapine and MDL100907 treatment compared 
with vehicle treated cells. * indicates significantly different from vehicle-treated 
cells at p < 0.05. 
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 Figure 13. Clozapine and MDL100907 treatment increases RGS7 levels. 
A1A1v cells were treated either with vehicle (DMSO) or 20 µM clozapine or 
1µM MDL100907 for 24 h. Membrane fractions of cells were analyzed by 
western blot with an anti-RGS7 antibody, stripped and reprobed with an anti-
actin antibody as a loading control. Bar graph represents quantification of 
RGS7 protein levels divided by actin protein levels from four independent 
 116
experiments. RGS7 protein levels were significantly increased (p<0.05) with 
clozapine and MDL100907 compared to vehicle-treated cells. * indicates 
significantly different from vehicle-treated cells at p < 0.05. 
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 (See next page for figure legend) 
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Figure 14. A JAK inhibitor partly attenuated the olanzapine-induced decrease 
in PLC activity.  A1A1v cells were pretreated for 1h with the 30µM AG490 
prior to treating with either vehicle (20% acetic acid) or 300nM olanzapine for 
24 h. (A) 5-HT-stimulated PLC activity was significantly (p<0.01) reduced by 
olanzapine treatment  compared to vehicle-treated control (*indicates 
significantly different from vehicle-treated control at p < 0.01). AG490 alone 
did not have any effect on PLC activity. However, in cells pretreated with 
AG490, the olanzapine-induced decrease in PLC activity was significantly 
attenuated (p<0.05) (B) GTPγS-stimulated-PLC activity was not altered either 
by the olanzapine or AG490 treatments. (C). Olanzapine treatment had no 
effect on Bradykinin-stimulated PLC activity, whereas 5-HT-stimulated PLC 
activity was significantly reduced suggesting olanzapine treatment selectively 
affect 5-HT2A receptor mediated-PLC activity. 
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 (See next page for figure legend) 
 120
 Figure 15. Olanzapine, clozapine and MDL100907 increase RGS7 mRNA 
levels. A1A1v cells were treated either with vehicle (20% acetic acid), 300nM 
olanzapine, vehicle (DMSO), 20 µM clozapine or 1µM MDL100907 for 24 h. 
Total RNA was isolated from vehicle-treated control or drug-treated cells, and 
equal amounts of cDNA were reverse-transcribed. Bar graph represents 
quantification of RGS7 mRNA levels normalized to GAPDH levels from five 
independent experiments and represents the fold change over control. RGS7 
mRNA levels were significantly increased in olanzapine, clozapine and 
MDL100907-treated compared to vehicle-treated cells (p<0.05). * indicates 
significantly different from vehicle-treated cells at p<0.05. 
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Figure 16. STAT3 binds to the putative RGS7 promoter region at site 2. ChIP 
assays were performed as described in “Materials and Methods” with an anti-
STAT3 antibody, non-immune IgG, or with beads alone.  DNA samples were 
amplified using primer pairs that flanked all five potential STAT3-binding sites 
(site1 – site 5). Primers that amplify the STAT3 binding site previously 
identified in the hepcidin gene were used as a positive control. Non-
precipitated genomic DNA (input) was used as a positive control. 
Amplification was not observed in lanes loaded with samples 
immunoprecipitated with beads alone, i.e., without the STAT3 antibody, and 
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non-specific IgG in place of the STAT3 antibody confirming specificity of the 
reaction with the STAT3 antibody.  For brevity, only site 2 and site 3 results 
are shown. 
 123
Discussion 
 
Atypical antipsychotics have been previously reported to act as inverse 
agonist and to induce desensitization of 5-HT2A receptor signaling (Egan, et 
al., 1998;Egan, et al., 2000;Herrick-Davis, et al., 1998;Rauser, et al., 2001). 
Internalization and down-regulation have been proposed as mechanisms of 
desensitization, (Roth, et al., 1995;Willins, et al., 1998) however, subsequent 
studies provided evidence supporting both internalization- and down-
regulation- dependent and independent desensitization of 5-HT2A receptor by 
atypical antipsychotics (Kuoppamaki, et al., 1995;Hanley and Hensler, 2002). 
It is likely that internalization and down-regulation can contribute to the 
desensitization process but whether they are necessary and sufficient for the 
full desensitization process is not known.  In addition, studies were 
inconclusive regarding the role for transcriptional regulation of 5-HT2A 
receptor down-regulation with antipsychotics (Gray and Roth, 2001). Both, a 
decrease in receptor mRNA in hippocampus, brain stem, and midbrain and 
no change in mRNA levels are reported previously with atypical 
antipsychotics (Burnet, et al., 1996;Doat-Meyerhoefer, et al., 2005).  Thus, 
transcriptional regulation of 5-HT2A receptor by atypical antipsychotics does 
not appear to be responsible for down-regulation leading to the 
desensitization of 5-HT2A receptor signaling.  
Consistent with previous reports that atypical antipsychotics induce 
desensitization of 5-HT2A receptor signaling, (Gray and Roth, 2001) we find 
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that olanzapine and clozapine induce desensitization of 5-HT2A receptor 
signaling in A1A1v cells. Olanzapine, clozapine, and MDL100907 increase 
RGS7 mRNA and protein levels as well as the activation of the JAK-STAT 
pathway. We previously found that the increase in RGS7 protein expression 
in response to olanzapine treatment is dependent of JAK-STAT signaling 
(Singh, et al., 2007). We now further report that the desensitization response 
on the 5-HT2A receptor signaling, induced by these atypical antipsychotics is 
dependent on JAK-STAT signaling. Olanzapine-induced decreases in PLC 
activity, monitored as an index of 5-HT2A receptor responsiveness (i.e., 
desensitization), were significantly attenuated by pretreatment with a JAK2 
kinase inhibitor. These data suggest that activation of the JAK-STAT pathway 
is necessary for atypical antipsychotics-induced 5-HT2A receptor-mediated 
PLC activity. 
In addition to 5-HT2A receptors, atypical antipsychotics also have high 
affinity for other GPCRs for example, other 5-HT receptors (e.g., 5-HT1A, 5-
HT2C, 5-HT6, and 5-HT7) (Meltzer, et al., 1989;Roth, et al., 1992;Meltzer, 
1999;Seeger, et al., 1995), the dopamine D4 receptor (Van Tol, et al., 
1991;Roth, et al., 1995), all five muscarinic receptors (m1-m5) (Peroutka and 
Synder, 1980;Zeng, et al., 1997), and several adrenergic and histamine 
receptors (Peroutka and Synder, 1980). MDL100907 initially characterized as 
a selective antagonist of 5-HT2A receptor, has been used to delineate 
antipsychotic responses mediated specifically by 5-HT2A receptor (Olijslagers, 
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et al., 2005;Wolff and Leander, 2000;Bhagwagar, et al., 2006) and 
desensitizes 5-HT2A receptor signaling (Rauser, et al., 2001;Shi, et al., 2007). 
In this study, we report that MDL100907 stimulated activation of the JAK-
STAT pathway and increased RGS7 protein and mRNA levels suggesting 
that antagonism of 5-HT2A receptors is sufficient to induce these changes 
caused by atypical antipsychotics.  
RGS proteins reduce G-protein-mediated signaling by acting as guanosine 
triphosphatase (GTPase)-accelerating proteins (GAPs) for Gα subunits 
(Hollinger and Hepler, 2002;Dohlman and Thorner, 1997). Expression of 
RGS7 protein in rat frontal cortex is well documented (Zhang and Simonds, 
2000c;Krumins, et al., 2004) and decreased 5-HT2A receptor signaling via 
direct interaction of RGS7 protein with Gαq has been characterized in different 
systems (DiBello, et al., 1998;Ghavami, et al., 2004). Furthermore, an 
increase in RGS7 protein following both olanzapine and clozapine treatment 
would increase the termination rate of 5-HT2A receptor- Gαq/11 protein 
signaling by more rapidly hydrolyzing GTP, and could thereby produce or 
contribute to the desensitization response. When GTPγS, a non-hydrolysable 
GTP analog is used to activate G proteins, PLC activity is not affected by 
RGS proteins, since RGS proteins are not able to hydrolyze GTPγS. 
Therefore, the differential effects of olanzapine on receptor versus G-protein 
activation of PLC activity are consistent with an increase in RGS7 protein as 
an underlying mechanism for olanzapine-induced desensitization. The 
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increased levels of RGS7 could reduce 5-HT-stimulated PLC activity as we 
found in olanzapine treated cell membranes; however, GTPγS stimulated-
PLC activity was not altered by olanzapine consistent with increase RGS 
proteins underlying the change in response. 
Numerous studies have reported a significant decrease in RGS4 
expression in the prefrontal cortex of schizophrenic subjects (Mirnics, et al., 
2001;Erdely, et al., 2006;Bowden, et al., 2007;Gu, et al., 2007). Expression of 
RGS4 and RGS7 have been previously noted to be independent (Krumins, et 
al., 2004). Like RGS7 proteins, RGS4 also regulates 5-HT2A receptor 
signaling. Atypical antipsychotic-induced increases in RGS7 levels observed 
in our studies might restore the 5-HT2A receptor signaling duration to 
physiological levels by substituting for the diminished RGS4 protein.  
Atypical antipsychotics could increase RGS7 levels by either increased 
stability of RGS7 protein or by increased transcription of RGS7 mRNA. RGS7 
binding to Gβ5 is reported to increase the stability of each protein (Chen, et al., 
2003). In addition, RGS7 phosphorylation and subsequent binding to 14-3-3 
sequesters RGS7 in the cytoplasm (Burchett, 2003). Therefore, an increase 
in phosphorylation of RGS7 or increased expression of 14-3-3 or Gβ5 could 
increase the levels of RGS7 in the cytoplasm. Our real-time PCR data 
suggest that the increase in RGS7 levels by olanzapine, clozapine and 
MDL100907 could be directly mediated by an increase RGS7 mRNA via 
activation of the JAK-STAT pathway. STAT3 regulates a variety of biological 
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processes, functioning at both transcriptional and non-transcriptional levels to 
influence cell growth, survival and metabolism (Inghirami, et al., 
2005;Leeman, et al., 2006).  From a genomic sequence analysis of rat RGS7, 
we have identified multiple sets of the STAT3 consensus binding element, 
TTCN2-4GAA, (Decker, et al., 1997;Ehret, et al., 2001), suggesting that 
STAT3 could be a possible transcription factor for the RGS7 promoter.  Using 
a ChIP analysis, we found one of the STAT3 consensus binding elements 
located at 2.34kb upstream of transcription start site strongly binds with 
STAT3 in response to olanzapine treatment. STAT3 binding to the RGS7 
gene along with an increase in mRNA levels of RGS7 suggests the possibility 
that STAT3 is a transcription factor for RGS7. The promoter region of RGS7 
is not yet identified, however,  it is usually present upstream of the 
transcription start site consistent with our identified STAT3 binding site 2.34kb 
upstream from the transcription initiation site. Taken together, these results 
are consistent with our hypothesis that activation of JAK-STAT pathway by 
atypical antipsychotics and the subsequent increase in RGS7 expression is 
an underlying mechanism for desensitization of 5-HT2A receptor signaling.  
In our previous studies (Singh, et al., 2007;Muma, et al., 2007) we have 
reported olanzapine-induced activation of the JAK-STAT pathway.  In this 
study we demonstrate that activation of the JAK-STAT pathway is necessary 
for full desensitization of 5-HT2A receptor signaling by atypical antipsychotics 
in A1A1v cells. While the precise mechanism of JAK-STAT activation by 
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atypical antipsychotics is not determined, it has been reported that 5-HT2A 
receptor associates in a complex with JAK2 and STAT3 (Guillet-Deniau, et 
al., 1997). Other studies have reported that 5-HT activates JAK2, JAK1, and 
STAT1 via the 5-HT2A receptors (Banes, et al., 2005). Furthermore, atypical 
antipsychotics have also been reported to activate other signaling cascades 
for example, activation of ERK1/2 pathways in the rat frontal cortex 
(Fumagalli, et al., 2006), Akt/PKB and P38 pathways in PC12 cells (Lu, et al., 
2004), and GSK3α/β in the rat frontal cortex (Kang, et al., 2004;Roh, et al., 
2007). Although, atypical antipsychotics have been extensively characterized 
as an inverse agonist/antagonist of 5-HT2A receptor, activation of JAK-STAT 
in our studies clearly indicates that besides being an antagonist, atypical 
antipsychotics are agonist for the JAK-STAT pathway. Our studies 
demonstrate that agonist activity as demonstrated by activation of JAK-STAT 
pathway and antagonist effects at the PLC enzyme occur simultaneously. 
Previous studies have demonstrated selective agonism, where one agonist 
stimulates one pathway preferentially over another (Kenakin, 2007).  Our 
studies extend the diversity of signaling by a single receptor suggesting that a 
ligand like olanzapine or clozapine can be an agonist for one 5-HT2A receptor 
mediated pathway, JAK-STAT, and simultaneously an antagonist at the Gq/11-
PLC pathway.  
Overall, our data suggest that desensitization of 5-HT2A receptor 
signaling by atypical antipsychotics requires activation of the JAK-STAT 
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pathway. In addition, activation of the JAK-STAT pathway and increases in 
RGS7 expression by transcriptional activity of STAT3 is likely to contribute to 
the full desensitization response of 5-HT2A receptors signaling. However, 
further studies are needed to confirm the transcriptional activity of STAT3 on 
putative promoter site of RGS7.  
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        CHAPTER V 
JAK-STAT PATHWAY IN OLANZAPINE-INDUCED 
DESENSITIZATION OF 5-HT2A RECEPTOR SIGNALING IN RAT BRAIN 
 
Abstract 
We previously demonstrated that chronic treatment with olanzapine 
causes desensitization of 5-HT2A receptor signaling in the rat frontal cortex 
and this desensitization response is associated with increases in RGS7 
protein levels and activation of STAT3 (Muma, et al., 2007). We now report 
that desensitization of 5-HT2A receptor signaling induced by olanzapine is 
dependent on activation of the JAK-STAT pathway. Pretreatment with a JAK2 
inhibitor significantly attenuated 5-HT2A stimulated-PLC activity. In the current 
study, we found that olanzapine treatment increased RGS7 protein levels 
(211±19% of control levels), RGS7 mRNA levels (188±13%), and activation of 
JAK2 (198±14% of control levels) in rat frontal cortex. Furthermore, inhibition 
of JAK activation also prevented the olanzapine-induced increases in RGS7 
mRNA and protein levels. We verified that treatment with AG490 reduced 
phosphorylation of JAK2. The functional status of the 5-HT2A receptor 
pathway in the hypothalamic paraventricular nucleus (PVN) was examined 
using 5-HT2A receptor-stimulated increases in plasma hormone levels. 
Plasma oxytocin, adrenocorticotrophic hormone (ACTH) and corticosterone 
measurements showed that olanzapine injections for 7 days caused 
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desensitization of 5-HT2A receptor signaling (oxytocin response decreased 
81.63±4.37%; ACTH response decreased 38.68±12.43%; corticosterone 
response decreased 54 ± 6.41%). Surprisingly, oxytocin and corticosterone 
levels were also decreased in a dose-dependent manner by the JAK2 
inhibitor whereas ACTH levels were not altered. Taken together, these results 
suggest that the olanzapine-induced increase in RGS7 expression is 
mediated by activation of JAK-STAT and is necessary for olanzapine-induced 
desensitization of 5-HT2A receptor signaling in the frontal cortex. Although, 
decreases in plasma hormone levels confirmed olanzapine-induced 
desensitization of 5-HT2A receptor signaling in the hypothalamus, the precise 
role of the JAK-STAT pathway in 5-HT2A-stimulated hormonal release 
requires further investigation.   
 
Introduction 
 
Evidence implicates involvement of serotonin 5-HT2A receptors in a 
number of psychiatric disorders, including schizophrenia, depression, and 
anxiety(Nichols, et al., 1994;Naughton, et al., 2000). Furthermore, atypical 
antipsychotics are reported to bind with high affinity at 5-HT2A receptors as 
determined in cell culture (Meltzer, et al., 1989) and in vivo (Zhang and 
Bymaster, 1999). Although, atypical antipsychotics bind to diverse population 
of receptors (Meltzer, et al., 1989;Altar, et al., 1986;Zhang and Bymaster, 
1999;Roth, et al., 2004), therapeutic benefits associated with atypical 
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antipsychotics are attributed, in part, to their ability to antagonize (i.e. 
desensitize) 5-HT2A receptor signaling  (Goyer, et al., 1996). In addition, 
further evidence for the involvement of 5-HT2A receptors in the mechanisms of 
action of atypical antipsychotics came from reports of polymorphisms in the 
promoter and coding regions of the 5-HT2A receptor gene. Schizophrenics 
with this polymorphism were reported to respond poorly to clozapine 
treatment suggesting that genetic variation at 5-HT2A receptors may influence 
clozapine response and strengthens the candidacy of these receptors as 
important therapeutic targets (Yu, et al., 2001;Arranz, et al., 1996;Masellis, et 
al., 1998).  
Several studies have reported the desensitization and down-regulation 
of central 5-HT2A receptor signaling by antagonist in the brain (Blackshear and 
Sanders-Bush, 1982;Gandolfi, et al., 1985;Hensler and Truett, 
1998),however, molecular mechanisms underlying these changes are not 
understood.  In addition, atypical antipsychotics are reported to reduce levels 
of ACTH and cortisol in schizophrenic patients (Cohrs, et al., 
2006;Scheepers, et al., 2001;Hatzimanolis, et al., 1998;Meltzer, et al., 
1989;Hatzimanolis, et al., 1998). Although, monoaminergic mechanisms 
including serotonin and dopamine are known to play an important role in the 
regulation of ACTH and cortisol secretion (Wilcox, et al., 1975;Fuller and 
Snoddy, 1984;Tuomisto and Mannisto, 1985;Lefebvre, et al., 1998), the 
attenuation of cortisol secretion, after subchronic administration of olanzapine 
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and clozapine to schizophrenic patients, has been attributed to 5-HT receptor 
blockade(Scheepers, et al., 2001;Meltzer, et al., 1989;Hatzimanolis, et al., 
1998;Hatzimanolis, et al., 1998).  Furthermore, 5-HT2A receptors in the 
hypothalamic paraventricular nucleus have been shown to mediate the 
neuroendocrine responses to a peripheral injection of DOI, 
intraparaventricular and peripheral injections of the selective 5-HT2A receptor 
antagonist MDL 100,907 dose-dependently inhibit the DOI-induced increases 
in hormone secretions (Zhang, et al., 2002). These results suggest that 
alterations in hormone secretions by atypical antipsychotics may be mediated 
by 5-HT2A receptors and that plasma hormone levels can provide an index of 
the function of 5-HT2A receptor signaling in the hypothalamic paraventricular 
nucleus.  
5-HT2A receptors are coupled through Gq/11 proteins to phospholipase 
C (PLC) (Hide, et al., 1989;Roth, et al., 1998). Upon activation of PLC, 
hydrolysis of phosphatidylinositol 4,5-bisphosphate generates diacylglycerol 
and inositol 1,4,5-trisphosphate (Berridge, 1986). Gαq/11 proteins stimulate 
PLC activity until the bound GTP is hydrolyzed to GDP. The intrinsic GTPase 
activity of Gαq/11 proteins is enhanced by regulators of G protein signaling 
proteins type 4 and 7 (RGS4 and RGS7)(Hepler, et al., 1997;Xu, et al., 1999).  
Activation of various GPCRs like angiotensin ΙΙ, bradykinin, thrombin, 
and 5-HT2A have been reported to induce activation of the JAK-STAT 
pathway under different cellular milieu and in different cell types (Ju, et al., 
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2000;Marrero, et al., 1995;Guillet-Deniau, et al., 1997). Although, the exact 
mechanism by which 5-HT2A receptors activate the JAK-STAT pathway is not 
known, 5-HT2A  receptors associate with JAK and STAT and rapid activation 
of JAK and STAT via phosphorylation in response to serotonin was previously 
reported (Guillet-Deniau, et al., 1997). In addition, chronic exposure to 
cocaine, an inhibitor of serotonin reuptake, was reported to activate JAK2 in 
the rat ventral tegmental area (VTA)(Berhow, et al., 1996). Previously, we 
have reported that daily treatment with olanzapine for 7 days causes 
desensitization of 5-HT2A receptor signaling accompanied by activation of the 
JAK-STAT pathway and increases in RGS7 protein levels (Muma, et al., 
2007). The JAK-STAT pathway regulates expression of a number of genes 
including c-Fos, c-Jun and c-Myc (Burysek, et al., 2002;Cattaneo, et al., 
1999), transcription factors which can then stimulate expression of select 
genes. Consistent with these reports, we have also shown that olanzapine 
treatment in cells in culture causes JAK-STAT dependent desensitization and 
increases in membrane-associated RGS7 protein levels (Singh, et al., 2007). 
The increased membrane-associated RGS7 protein can then increase 
hydrolysis of activated Gαq/11 and could contribute to the desensitization of 5-
HT2A receptor signaling. However, whether olanzapine-induced activation of 
JAK-STAT pathway has any direct impact on desensitization of 5-HT2A 
receptor signaling in vivo is currently unknown.  
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Based on our previous studies, we hypothesized that olanzapine 
induces activation of the JAK-STAT pathway, and subsequent activation and 
translocation of STAT3 to the nucleus increases RGS7 transcription and 
mRNA thereby increasing RGS7 protein levels in the membrane. The 
increased membrane-associated RGS7 protein can then increase hydrolysis 
of activated Gαq/11 and result in desensitization of 5-HT2A receptor signaling. 
We began to test this hypothesis by investigating the impact of blocking the 
JAK-STAT pathway with a specific JAK2 inhibitor, AG490, on olanzapine-
induced desensitization of 5-HT2A receptor signaling in the frontal cortex and 
hormone release in the hypothalamus. Furthermore, we also monitored the 
effect of AG490 on olanzapine-induced increases in RGS7 protein levels and 
the impact of activated STAT3 on levels of RGS7 mRNA and protein in the 
frontal cortex.   
 
Materials and Methods 
 
Animals: 
Male Sprague-Dawley rats (250–275 g; Harlan, Indianapolis, IN) were housed 
two per cage in an environment controlled for temperature, humidity, and 
lighting (7:00 AM–7:00 PM). Food and water was provided ad libitum. Eight 
rats were used per experimental group. All procedures were conducted in 
accordance with the National Institutes of Health Guide for the Care and Use 
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of Laboratory Animals as approved by the Loyola University Institutional 
Animal Care and Use Committee. 
Drugs:
Olanzapine and AG490 were purchased from Torrent Research 
Chemicals Inc., ON, Canada. Olanzapine was dissolved in 20% glacial acetic 
acid and the pH was adjusted to 6.0 with 10M NaOH as described previously 
(Singh et al., 2007). Olanzapine was injected at a dose of 10 mg/kg i.p. 
AG490 was dissolved in 50% DMSO and injected at 2 mg/kg and 10 mg/kg 
s.c. DOI was purchased from Sigma/RBI (Natick, MA) and dissolved in 0.9% 
saline and injected at a dose of 1 mg/kg i.p. for the challenge injections. 
Experimental procedures: 
Rats were randomly assigned to the various experimental groups with 
cage mates being placed within the same experimental groups. The body 
weight of each rat was recorded every alternate day. They were kept in a 
quiet environment to minimize stress and prevent plasma hormones from 
exceeding basal levels. Rats were first injected with 50% DMSO or one dose 
of AG490 (2 mg/kg or 10 mg/kg s.c.). One hr later these rats were injected 
with either the vehicle 20% glacial acetic acid or 10 mg/kg olanzapine. These 
injections were repeated for 7 days.  Twenty-four hr after the last injection of 
AG490 or olanzapine, eight rats from each group received either a challenge 
injection of (-)-DOI (1 mg/kg s.c.) or a 0.9% saline (1 ml/kg s.c.) 30 min before 
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sacrifice. The trunk blood was collected in centrifuge tubes containing 0.5 ml 
of 0.3 M EDTA (pH 7.4) solution. The plasma samples for 
radioimmunoassays were stored at -80°C. Whole brains were removed, 
frozen on dry ice, and stored at -80°C for biochemical and molecular 
analyses.   
PLC activity assay:   
The membrane fraction prepared from frontal cortex of animals 
challenged with saline was used for the measurement of PLC activity. PLC 
activity was measured by the amount of inositol 1,4,5 trisphosphate produced 
by PLC, as described previously (Damjanoska, et al., 2004;Wolf and Schutz, 
1997a). Briefly, 30 µg of membrane protein from frontal cortex was diluted into 
100 µl of total volume with a buffer containing 25 mM Hepes-Tris, 3 mM 
EGTA, 10 mM LiCl, 12 mM MgCl2, 1.44 mM sodium deoxycholate with 1 µM 
GTPγS, 300 nM free Ca2+,  1 µM 5-HT, and 1 mM unlabeled phosphatidyl 
inositol. The reaction tubes were kept on ice until the incubation period (20 
min at 37°C) was started with the addition of 100 µM [3H] phosphatidyl 
inositol. The reaction was stopped by addition of 0.9 ml of CHCl2/MeOH (1:2) 
and 0.3 ml of chloroform. The tubes were shaken vigorously for 90 seconds 
and centrifuged at room temperature for 90 seconds at 13,600Xg. Then, 0.3 
ml of the upper aqueous phase was mixed with 4 ml of scintillation cocktail 
and counted by a scintillation counter for 5 min. Protein concentrations in 
 138
these membrane preparations were measured using the BCA protein assay 
kit (Pierce Chemical, Rockford, IL). 
 
Radioimmunoassay of hormones: 
Plasma concentrations of oxytocin, ACTH, and corticosterone were 
determined by radioimmunoassays as described previously (Li, et al., 1993;Li, 
et al., 1997;Li, et al., 1999). 
Immunoblot analyses of RGS7, pJAK2, and JAK2 proteins 
Tissue preparation: 
Frontal cortex from the treatment groups that received 1 mg/kg DOI 
challenge was used for the measurement of pJAK2, JAK2 and RGS7 
proteins. Tissue was homogenized in 20 volume of ice-cold homogenization 
buffer which contained 25 mM HEPES-Tris, pH 7.4 at 25 °C, 1 mM EGTA and 
protease inhibitor cocktail (1:1000) from Sigma-Aldrich (St. Louis, MO) by 
using a Tekmar Tissumizer (Cincinnati, OH). The homogenate was 
centrifuged at 20,000 × g for 10 minutes at 4 °C. After centrifugation, the 
supernatant was collected as the cytosolic fraction. The tissue pellet was 
resuspended in 20 volumes homogenization buffer and centrifuged again. 
The final membrane pellet was resuspended and sonicated in 25 mM 
HEPES-Tris buffer containing 3 mM EGTA and 10 mM LiCl. Protein 
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concentrations were determined by using a bicinchoninic acid protein assay 
kit (Pierce Chemical, Rockford, IL).  
Western analyses:  
Equal amounts of protein from vehicle-control and drug-treated 
samples were separated on 10% SDS polyacrylamide gels. Proteins were 
transferred to nitrocellulose membrane for 2 hr at 100V.  Non-specific binding 
was blocked either in TBS containing 5% (w/v) nonfat dry milk with 0.1% 
Tween 20 (TBST) or in PBS containing 5% (w/v) nonfat dry milk. The 
following primary antibodies were used: anti-RGS7 (Polyclonal antibody, 
Upstate Biotechnology, Inc., Lake Placid, NY), anti-phospho-JAK2 (polyclonal 
antibody, Affinity Bioreagent, CO), anti-JAK2 (polyclonal antibody, Upstate 
Biotechnology, Inc., Lake Placid, NY) and anti-actin (monoclonal antibody MP 
Biomedicals, Aurora, OH). Prior to incubation with a second primary antibody, 
blots were stripped with Restore western blot stripping buffer (Pierce, 
Rockford, IL) by incubating at 370C for 25 minutes.  After incubation, blots 
were removed from stripping buffer, washed three times for 10 minutes each 
with TBS or PBS containing 0.1% Tween20 (TBST or PBST) and blocked 
with 5% milk in TBST or PBST for 1 hr at room temperature. Protein bands 
were analyzed densitometrically using Scion Image software (Scion 
Corporation, Frederick, MD). The gray scale density readings were calibrated 
using a transmission step-wedge standard. The integrated optical density 
(IOD) of each band was calculated as the sum of the optical densities of all 
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the pixels within the area of the band outlined. The IOD for the film 
background was subtracted from the IOD for each band. Each sample was 
measured in triplicate. RGS7 protein was normalized to actin protein and 
phosphoproteins were normalized to the corresponding total protein levels. 
Protein levels from treated cells were normalized to vehicle-treated cells for 
each western blot analysis.  
 
RNA Isolation and Reverse Transcription: 
  Total RNA was isolated using the RNeasy Mini Kit (Qiagen Sciences, 
Valencia, CA) according to the manufacturer’s protocol. Total RNA was 
quantitated using a spectrophotometer and optical density (OD) 260/280 nm 
ratios were determined. Quality of RNA was determined with a formaldehyde-
agarose gel. First strand cDNA was synthesized using random hexamers and 
Superscript II Reverse Transcriptase from Invitrogen (Carlsbad, CA) 
according to the manufacturer’s protocol. Reactions were incubated at 250C 
for 2 minutes, 250C for 10 minutes, and 420C for 50 minutes and inactivated 
by heating at 700C for 15 minutes in an M J Mini, personal thermal cycler 
(BIO-RAD, Hercules, CA ).  
 
Real-Time PCR: 
 The GAPDH (sense 5’-tggagtctactggcgtcttcac-3’; antisense 5’-
ggcatggactgtggtcatga-3’) and RGS7 (sense 5’-gaagatgagttgcaccgacaga-3’; 
antisense 5’-ggtctttcagtgcctcatccat-3’) primer sets were synthesized by IDT, 
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Inc (Coralville, IA).  PCR amplification was performed with 7500 Real-Time 
PCR System using SYBR green PCR master mix (Applied Biosystems, 
Foster City, CA). The PCR parameters used were a 10 minute denaturation 
cycle at 95°C, 40 cycles of amplification at 95°C for 15 seconds, and 
annealing/extension at 60°C for 1 minute. Real-Time PCR was performed 
with 25 µL reaction mixture of cDNA, primers and SYBR green master mix. 
 
RNA Data Analysis: 
  Comparative Ct (∆∆CT) method was used for analysis of all real-time 
PCR data.  ∆CT values were calculated by normalizing CT values of RGS7 to 
GAPDH from vehicle and drug-treated animal groups. The extent of the 
response is determined by 2mean(∆∆CT), and the relative degree of response is 
calculated by 2−mean (∆∆CT). Results are expressed as fold change in RGS7 
mRNA levels for AG490, olanzapine, AG490 and olanzapine-treated cells 
with respect to vehicle-treated cells. Data presented are from four 
independent experiments performed in triplicate. 
 
Statistical analyses:  
All statistical analyses were performed using GB-STAT School Pak 
(Dynamic Microsystems, Silver Spring, MD). Data are expressed as means ± 
SEM. For RT-PCR, western blots data, and PLC activity assay was analyzed 
using a two-way analysis of variance, followed by a Newman–Keuls' post hoc 
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analysis.  Hormone levels were analyzed using a three-way analysis of 
variance, followed by Newman-Keuls’ post hoc analysis.  
 
Results 
 
Inhibition of the JAK-STAT pathway attenuated the olanzapine-induced 
inhibition of 5-HT2A receptor-mediated PLC activity:  
We previously reported that olanzapine treatment for 7 days caused a 
significant decrease in 5-HT-stimulated PLC activity in the rat frontal cortex 
(Muma, et al., 2007). Consistent with our previous report, 10mg/kg olanzapine 
treatment for 7 days caused a significant decrease (*p<0.01) in 5-HT-
stimulated PLC activity (Figure 17A) in the frontal cortex. Olanzapine 
treatment decreased PLC activity by 68%. PLC activity was not affected by 
AG490 treatment alone. However, PLC activity was significantly attenuated 
(*p<0.05) in rats injected with AG490 at 10 mg/kg, before olanzapine 
injections, suggesting activation of the JAK-STAT pathway is necessary for 
the desensitization response induce by olanzapine treatment. Two-way 
ANOVA indicates a main effect of olanzapine (F(1,19) = 5.91, p<0.05), a main 
effect of AG490 (F(1,19) = 46.18, p<0.001), but no significant interaction was 
observed between olanzapine and AG490 (F(1,19) = 1.27, p=.275).  
Furthermore, AG490 or olanzapine treatment has no effect on GTPγS-
stimulated PLC activity suggesting that the desensitization response is 
occurring at 5-HT2A receptor or 5-HT2A receptor-Gαq/11 interface (figure 17B).  
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Phosphorylation of JAK2 was blocked by AG490 treatment:  
Treatment with olanzapine for 7 days significantly increased (*p<0.05) 
phosphorylation of JAK2 in the membrane fraction of the frontal cortex as 
shown in figure 18. The total JAK2 protein level was not significantly altered 
with olanzapine treatment. The olanzapine-induced increases in 
phosphorylation of JAK2 were significantly reduced to basal levels by pre-
injections of AG490 at 10 mg/kg. AG490 alone had no effect on JAK2 
phosphorylation. Two way ANOVA indicates a main effect of olanzapine 
(F(1,15) = 19.88, p < 0.001), a main effect of AG490 (F(1,15) = 37.41, p < 0.001), 
and a significant interaction between olanzapine and AG490 was also 
observed (F(1,15) = 31.28, p = 0.001). 
 
Increase in RGS7 mRNA and protein levels by olanzapine treatment was 
blocked by pre-treatment with AG490:  
Olanzapine injections for 7 days significantly increased mRNA 
(*p<0.05) and protein (*p<0.05) levels of RGS7 as shown in figure 19A and 
19B.  Both message and protein levels of RGS7 were not affected by AG490 
treatment alone. In rats pre-injected with AG490 at 10 mg/kg, the olanzapine-
induced increases in RGS7 expression were significantly attenuated to basal 
levels. Two-way ANOVA for mRNA measurement indicates a main effect of 
olanzapine (F(1,15)=43.43, P<0.001), a main effect of AG490 (F(1,15)=155.96, 
P<0.001), and a significant interaction between olanzapine and AG490 
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(F(1,15)=69.51, P<0.001). Two-way ANOVA for protein levels indicate a main 
effect of olanzapine (F(1,15)=10.30, P<0.01), a main effect of AG490 
(F(1,15)=12.30, P<0.01), and a significant interaction between olanzapine and 
AG490 (F(1,15)=12.40, P<0.01). 
Effect of olanzapine on plasma levels of oxytocin, ACTH, and 
corticosterone 
Basal plasma ACTH, corticosterone, and oxytocin levels were not 
significantly altered after seven daily injections of AG490 and olanzapine. An 
acute dose (i.e., a challenge dose) of DOI was administered 30 minutes 
before the measurement of plasma hormone levels. 
  
Oxytocin response to DOI: 
DOI-challenge produced a significant (*p<0.01) increase in plasma 
oxytocin levels (1257%) in vehicle-pretreated rats, in 2 mg/kg AG490 injected 
rats increase (853%) (*p<0.01), and in 10 mg/kg AG490 injected rats (449%) 
(*p<0.01) compared to saline-challenged rats. However, there were significant 
differences in the DOI-stimulated increases in plasma oxytocin, suggesting a 
dose-dependent inhibition on oxytocin release with AG490 treatment. 
Olanzapine treatment completely blocked the DOI-induced increases in 
oxytocin release as compared to vehicle-treated rats (Figure 20A). Although, 
a trend towards reversal of olanzapine-inhibited oxytocin level was observed 
at high dose of AG490 (10 mg/kg), it was statistically insignificant. Three-way 
ANOVA indicates a main  effect of DOI challenge on oxytocin levels (F(1,81)= 
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44.62, P<0.0001), a main effect of olanzapine (F(1,81)= 5.36, P<0.05), and a 
main effect of AG490 (F(2,81)= 9.94, P<0.001). Significant interactions  
between DOI X olanzapine (F(1,81)= 28.12, P<0.0001) , DOI X AG490 (F(2,81)= 
63.57, P<0.0001), and olanzapine X AG490 (F(2,81)= 165.69, P<0.0001)  were 
also observed. Finally, there was significant interaction among DOI X 
olanzapine X AG490 (F(2,81)= 65.83, P<0.0001).   
 
ACTH response to DOI:   
DOI-challenge produced a significant (*p<0.01) increase in plasma 
ACTH levels (1279%) in control rats, in 2 mg/kg AG490 injected rats 
(*p<0.01) (1296%), and in 10 mg/kg AG490 injected rats (*p<0.01) (1032%) 
compared to vehicle-treated rats. Olanzapine treatment significantly 
(38%,*p<0.01) attenuated the DOI-stimulated increase in ACTH release as 
compared to vehicle treated rats (Figure 20B). However, AG490 treatment 
had no significant effect on ACTH levels in rats treated with olanzapine 
compared to vehicle-treated rats. Three-way ANOVA indicates a main effect 
of DOI challenge on ACTH levels (F(1,66)= 118.44, and a main effect of AG490 
(F(2,66)= 22.32, P<0.0001). A significant interaction between DOI X olanzapine 
(F(1,66)= 16.46, P<0.001) , DOI X AG490 (F(2,66)= 99.68, P<0.0001), and 
olanzapine X AG490 (F(2,66)= 1897.87, P<0.0001)  was also observed. There 
was also a significant interaction among DOI X olanzapine X AG490 (F(2,66)= 
155.32, P<0.0001).   
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Corticosterone response to DOI:   
DOI-challenge produced a significant (*p<0.01) increase in plasma 
corticosterone levels (685%) in vehicle-pretreated rats, in rats treated with 2 
mg/kg AG490 (524%) (*p<0.01), and in 10 mg/kg AG490 injected rats (406%) 
(*p<0.01) compared to saline-challenged rats. Olanzapine treatment 
significantly (54%,*p<0.01) attenuated the DOI stimulated increase in 
corticosterone release as compared to vehicle treated rats (Figure 20C). 
However, AG490 pretreatment had no significant effect on corticosterone 
levels in rats treated with olanzapine. Three-way ANOVA indicates a main 
effect of DOI challenge on ACTH (F(1,82)= 43.57, P<0.0001), a significant 
effect of olanzapine (F(1,82)= 5.96, P<0.001), a main effect of AG490 (F(2,82)= 
10.55, P<0.0001). A significant interaction between DOI X olanzapine (F(1,82)= 
29.63, P<0.001) , DOI X AG490 (F(2,82)= 62.98, P<0.0001), and olanzapine X 
AG490 (F(2,82)= 164.50, P<0.0001)  was also observed. Finally, there was a 
significant interaction between DOI X olanzapine X AG490 (F(2,82)= 68.01, 
P<0.0001).   
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(See next page for figure legend) 
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Figure 17. PLC activity in the frontal cortex. (A): 5-HT-stimulated PLC activity 
in the frontal cortex is significantly decreased with 7 days of daily olanzapine 
injections compared to vehicle-treated control rats (*p < 0.01). AG490 
injections alone had no effect on the PLC activity whereas the olanzapine-
induced decrease in PLC activity was significantly (*p<0.05) attenuated by 
pre-injections of AG490 (10 mg/kg). (B) GTPγS-stimulated-PLC activity was 
not altered by either the AG490 or olanzapine treatments. 
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Figure 18. Olanzapine treatment significantly increased (* p<0.05) 
phosphorylation of JAK2 in the frontal cortex. AG490 treatment alone had no 
effect on phosphorylation of JAK2, however, inhibition of the JAK-STAT 
pathway with AG490 pre-treatment significantly attenuated phosphorylation of 
JAK2. Total JAK2 protein levels were not altered. (* indicate significantly 
different from olanzapine treated rats p<0.05), whereas AG490 alone had no 
effect on JAK2 levels. 
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(See next page for figure legend) 
 151
Figure 19. Olanzapine treatment significantly (* p<0.05) increased RGS7 
mRNA in the frontal cortex (A) and membrane-bound RGS7 protein levels (B) 
over vehicle-treated control rats. AG490 pre-treatment completely blocked the 
olanzapine-induced increase in mRNA levels of RGS7. Olanzapine-induced 
increase in protein levels were also blocked by AG490 pretreatment.  (* 
indicate significantly different from olanzapine treated rats p<0.05), whereas 
AG490 alone had no effect on RGS7 levels.  
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(See next page for figure legend) 
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Figure 20. Chronic treatment with olanzapine significantly attenuated DOI- 
stimulated hormone responses. Oxytocin (A), ACTH (B) and corticosterone 
(C) responses to a challenge with DOI 1 mg/ml at 30 min post-injection. The 
data represent the mean ± S.E.M. of eight rats per group. Basal plasma 
oxytocin, ACTH and corticosterone levels were not significantly different 
among vehicle, AG490 and olanzapine injected rats. DOI-challenge induced a 
significant increase of plasma oxytocin, ACTH and corticosterone levels 
compared with saline-challenge groups. A significant difference amongst DOI-
challenged control and treated rats is indicated by * for p < 0.001. A 
significant effect of chronic olanzapine and AG490 treatment compared with 
vehicle treatment is indicated by δ δ, p < 0.01. 
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Discussion 
Although, atypical antipsychotics bind to diverse population of receptors 
(Meltzer, et al., 1989;Altar, et al., 1986;Zhang and Bymaster, 1999;Roth, et 
al., 2004), the therapeutic benefits associated with atypical antipsychotics are 
attributed, in part, to their ability to antagonize 5-HT2A receptor signaling (i.e. 
desensitization) (Goyer, et al., 1996). Previous studies have shown atypical 
antipsychotics induced desensitization of 5-HT2A receptor signaling both in 
vivo and in cells (Gray and Roth, 2001;Hanley and Hensler, 2002). 
Internalization and down-regulation are suggested to be involved in the 
desensitization response; however, the underlying molecular mechanisms 
necessary for desensitization are not yet identified.  Previously, we reported 
that both in rat frontal cortex and in cells in culture, olanzapine causes 
desensitization of 5-HT2A receptor signaling,  increases RGS7 expression and 
activates the JAK-STAT pathway (Muma, et al., 2007;Singh, et al., 2007).  
Consistent with our previous findings in cultured A1A1v cells, we now find 
that the olanzapine-induced decrease in 5-HT2A receptor mediated-PLC 
activity in the rat frontal cortex is dependent in part on activation of the JAK-
STAT pathway. Olanzapine treatment increases RGS7 mRNA and protein 
levels. We previously reported that increased RGS7 protein expression in 
response to olanzapine treatment is dependent on JAK-STAT signaling in 
A1A1v cells (chapter I). Consistent with this report, increases in RGS7 mRNA 
and protein levels are blocked by inhibition of JAK-STAT pathway in frontal 
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cortex. The olanzapine-induced desensitization of 5-HT2A receptor signaling 
was significantly attenuated with pretreatment with a JAK2 kinase inhibitor. 
These data suggest that activation of the JAK-STAT pathway is necessary for 
olanzapine-induced desensitization of 5-HT2A receptor signaling.  
RGS proteins can reduce G-protein-mediated signaling by their ability to 
increase the intrinsic guanosine triphosphatase (GTPase) activity of 
heterotrimeric G proteins. This GTPase accelerating protein (GAP) activity 
enhances G protein deactivation and promotes desensitization (Hollinger and 
Hepler, 2002;Dohlman and Thorner, 1997). RGS7 protein is primarily 
expressed in the brain (Koelle and Horvitz, 1996;Saitoh, et al., 1999). The 
expression of RGS7 mRNA in the brain is widespread and abundant. An 
increase in RGS7 protein following olanzapine treatment would increase the 
termination rate of 5-HT2A receptor-Gαq/11 protein signaling by more rapidly 
hydrolyzing GTP, and could thereby produce or contribute to the 
desensitization response. When GTPγS, a non hydrolysable GTP analogue, 
is used to activate G-proteins, PLC activity is not affected by RGS proteins, 
since RGS proteins are not able to hydrolyze GTPγS bound to G proteins. 
Therefore, the differential effects of olanzapine on receptor versus G-protein 
activation of PLC activity are consistent with an increase in RGS7 protein as 
an underlying mechanism for olanzapine-induced desensitization. The 
increased levels of RGS7 proteins could reduce 5-HT-stimulated PLC activity 
as we found in olanzapine-treated cell membranes; however, GTPγS 
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stimulated-PLC activity was not altered by olanzapine consistent with 
increased RGS proteins underlying the desensitization response. These 
results are consistent with our previous report where AG490 pretreatment 
significantly attenuated the olanzapine-induced decrease in 5-HT2A receptor-
mediated PLC activity in A1A1v cells but GTPγS stimulated-PLC activity was 
not altered by olanzapine. 
Previous studies have reported down-regulation of RGS4 expression in 
the frontal cortex of schizophrenic patients (Mirnics et al., 2001; Gu et al., 
2007). Although, none of these studies have identified alterations in RGS7 
expression. Since RGS7 and RGS4 are independently regulated  (Krumins et 
al., 2004), the olanzapine-induced increase in RGS7 protein might replace the 
diminished RGS4 levels and thereby restore the 5-HT2A receptor signaling 
duration to more physiological levels.  
The olanzapine-induced increase in RGS7 levels could be mediated by 
either increased stability of RGS7 proteins and/or increased transcription of 
RGS7 mRNA. Interaction of RGS7 with Gβ5 (Zhang and Simonds, 2000) and  
polycystine (Kim, et al., 1999) is reported to increase the stability of RGS7. In 
addition, interaction of RGS7 with 14-3-3  is reported to control its GAP 
activity (Benzing, et al., 2000). However, our real-time PCR data suggest that 
the increase in RGS7 levels by olanzapine is mediated by a direct increase in 
RGS7 mRNA via activation of JAK-STAT pathway.  In addition, previous 
reports have suggested that  activation of JAK-STAT by tumor necrosis factor 
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α (TNFα) (Guo, et al., 1998) decreases the inhibitory interaction of RGS7 with 
14-3-3 thereby increasing its GAP function (Benzing, et al., 2002). Thus, it is 
possible that activation of JAK-STAT pathway by olanzapine treatment could 
increase GAP activity of RGS7 by inhibiting its interaction with 14-3-3.  
In our previous studies we identified a STAT3 consensus binding 
elements located 2.34kb upstream of transcription start site that binds 
strongly with STAT3 in response to olanzapine treatment. Thus, STAT3 
binding to the RGS7 gene along with an increase in mRNA levels of RGS7 
suggest the possibility that STAT3 could be a transcription factor for RGS7. 
Taken together, these results are consistent with our hypothesis that atypical 
antipsychotics increase RGS7 expression via activation of the JAK-STAT 
pathway.  
While the precise mechanism of JAK-STAT activation by atypical 
antipsychotics is not determined, it has been reported that the 5-HT2A 
receptor associates in a complex with JAK2 and STAT3 (Guillet-Deniau, et 
al., 1997). Other studies have reported that 5-HT activates JAK2, JAK1, and 
STAT1 via the 5-HT2A receptors (Banes, et al., 2005). Furthermore, atypical 
antipsychotics have also been reported to activate other signaling cascades 
for example, activation of ERK1/2 pathways in the rat frontal cortex 
(Fumagalli, et al., 2006), Akt/PKB and P38 pathways in PC12 cells (Lu, et al., 
2004), and GSK3α/β in the rat frontal cortex (Kang, et al., 2004;Roh, et al., 
2007).  It is also important to emphasize that these studies were conducted in 
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different experimental settings with different time course and dose regimens 
than our study. Each study highlights important findings, further extending our 
understanding of the mechanisms of action of antipsychotics. It is becoming 
evident that there could be numerous pathways and alterations in gene 
expression that lead to the development of psychosis and its treatment with 
atypical antipsychotics. We found almost 50% recovery of the olanzapine-
induced reductions in PLC activity with inhibition of the JAK-STAT pathway, 
suggesting one of these other signaling cascades together with the JAK-
STAT pathway could participate in mediating desensitization of 5-HT2A 
receptor signaling by atypical antipsychotics. Similarly, we previously found 
that inhibition of the JAK-STAT pathway reduced by the olanzapine-induced 
desensitization response by approximately half in A1A1v cells. These results 
produced by inhibition of the JAK-STAT pathway suggest that activation of 
the JAK-STAT pathway is necessary but not sufficient to induce complete 
desensitization of 5-HT2A receptor signaling by atypical antipsychotics and 
may involve other signaling cascades.  
A wide range of studies have suggested a link between hypothalamic-
pituitary-adrenal (HPA)-axis dysfunction and psychiatric disorders particularly 
negative symptomatology in schizophrenia (Shirayama, et al., 2002;Walker, 
et al., 2002). Subsequent studies have demonstrated that the atypical 
antipsychotic- induced decrease in cortisol levels is associated with an 
improvement in psychopathology (Meltzer, 1989;Hatzimanolis, et al., 
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1998;Markianos, et al., 1999). The olanzapine-induced decrease in 5-HT2A 
receptor stimulated plasma levels of oxytocin, ACTH, and corticosterone in 
this study are consistent with previous reports (Scheepers, et al., 2001;Wik, 
1995;Tepavcevic, et al., 1994)  . However, unlike in the frontal cortex where 
preinjections of AG490 significantly attenuated the olanzapine-induced 
decrease in 5-HT2A receptor-mediated PLC activity, olanzapine-induced 
desensitization of 5-HT2A receptor stimulated plasma hormone release was 
not affected by inhibition of JAK-STAT pathway. 
 We did however find a selective dose-dependent inhibitory effect of 
AG490 on 5-HT2A receptor stimulated oxytocin and corticosterone levels 
whereas ACTH levels were not affected. Previous studies have reported that 
corticotropin releasing hormone (CRH) and oxytocin-containing neurons in 
the PVN, are directly innervated by 5-HT containing nerve terminals 
originating in the dorsal raphe nucleus (Liposits, et al., 1987;Sawchenko, et 
al., 1983;Kawano, et al., 1992;Saphier, 1991). Subsequent reports have 
further demonstrated the presence of 5-HT2A receptors on the oxytocin and 
CRH neurons in the PVN. Treatment with MDL100907, a specific antagonist 
of 5-HT2A receptor, inhibited release of oxytocin and ACTH in response to 
DOI, a 5-HT2A/2C agonist (Damjanoska, et al., 2003;Zhang, et al., 2004). 
However, it is not clear how inhibition of the JAK-STAT pathway 
independently regulates release of oxytocin and corticosterone. Previous 
studies investigating effect of clozapine on inhibition of CRH gene 
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transcription, suggested involvement of various kinases like PI3K, PKA, PKC, 
CaMK, and MAPK, Akt (Basta-Kaim, et al., 2006). This is consistent with the 
ability of atypical antipsychotics to induce alterations in gene expression 
probably by activation of various signaling cascades (Feher, et al., 
2005;Fatemi, 2006). Thus, olanzapine-induced activation of JAK-STAT 
pathway together with other signaling cascades may affect the gene 
expression of oxytocin and CRH thereby decreasing their plasma levels 
independent of the olanzapine response. Furthermore, as we have previously 
noted for PLC activity in A1A1v cells (Singh, et al., 2007), AG490 may 
interfere with the release of these hormones in the blood stream.  
Taken together, this study further confirmed that olanzapine-induced 
desensitization of 5-HT2A receptor-mediated PLC activity in frontal cortex is 
dependent in part on increased expression of RGS7 via activation of the JAK-
STAT pathway. Our plasma hormone data confirmed that olanzapine causes 
desensitization of 5-HT2A receptors in the hypothalamus but further studies 
are needed to determine the role of JAK-STAT pathway in the regulation of 
hormone levels.   
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CHAPTER VI 
                   CONCLUSIONS 
Our results suggest that atypical antipsychotics desensitize 5-HT2A 
receptor signaling both in cells and in vivo by activation of the JAK-STAT 
pathway. Phosphorylated and activated STAT3 forms a homodimer and 
translocates to the nucleus (figure 21), as suggested by increased phospho-
STAT3 levels in the nucleus. In the nucleus, phospho-STAT3 binds to its 
consensus element (TTCN2-4GAA) on the RGS7 putative promoter region at 
2.34kb upstream from the transcription start site. Treatment with atypical 
antipsychotics also increased RGS7 mRNA and proteins levels, which were 
blocked by pretreatment with a selective JAK2 inhibitor, AG490, suggesting 
that the increase in RGS7 expression is dependent on activation of the JAK-
STAT pathway. Furthermore, an increase in RGS7 protein following atypical 
antipsychotic treatment could increase the termination rate of 5-HT2A 
receptor- Gαq/11 protein signaling by more rapidly hydrolyzing GTP, and could 
thereby produce or contribute to the desensitization response.  In addition, 
inhibition of the JAK-STAT pathway also significantly reduced the 
desensitization response induced by atypical antipsychotics as measured by 
5-HT2A receptor-mediated PLC activity, suggesting that desensitization is 
dependent on activation of the JAK-STAT pathway. Although atypical 
antipsychotics bind with high affinity to a number of receptors, MDL100907 
also increased RGS7 mRNA and protein levels and activation of the JAK-
 162
STAT pathway in our cell culture model suggesting that antagonism at 5-HT2A 
receptors is sufficient for induction of these changes. The results of the 
present studies support our hypothesis that atypical antipsychotic-induced 
desensitization of 5-HT2A receptor signaling is dependent on activation of the 
JAK-STAT pathway and subsequent increases in RGS7 expression. 
In the present study, we found almost 50% recovery of the olanzapine-
induced reductions in PLC activity with inhibition of the JAK-STAT pathway, 
suggesting that activation of the JAK-STAT pathway is necessary but not 
sufficient for olanzapine-induced desensitization. It has been reported that 
another tyrosine signaling pathway ERK1/2 and serine/threonine signaling 
proteins like (GSK)-3β are activated by stimulation of 5-HT2A receptors and 
atypical antipsychotics like olanzapine (Browning, et al., 2005;Quinn, et al., 
2002;Roh, et al., 2007). Thus, it is likely that atypical antipsychotic-induced 
desensitization of 5-HT2A receptor signaling could be in part mediated by 
these other signaling pathways. This can be tested by monitoring 5-HT2A 
receptor-mediated PLC activity in the presence of a selective ERK1/2 
pathway inhibitor SB386023 and/or (GSK)-3β inhibitor SB-216763 separately 
and along with AG490. If the PLC activity is completely restored by a 
combination of these inhibitors with AG490, this would confirm that 
desensitization of 5-HT2A receptor signaling is mediated by activation of the 
JAK-STAT pathway together with other signaling pathways. 
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Figure 21: Proposed model for desensitization of 5-HT2A receptor 
signaling by atypical antipsychotics: Treatment with atypical 
antipsychotics causes desensitization of 5-HT2A-Gαq/11 pathway as measured 
by either production of inositol phosphate in cells or PLC activity in brain 
tissue. We hypothesized that atypical antipsychotics through 5-HT2A receptor 
antagonism activate the JAK-STAT pathway causing phosphorylated STAT3 
to dimerize and translocate to the nucleus, stimulate immediate early genes 
and subsequently increase RGS7 transcription and RGS7 protein levels in the 
membrane. An increase in RGS7 proteins following atypical antipsychotics 
treatment would increase the termination rate of 5-HT2A receptor-Gαq/11 
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protein signaling by more rapidly hydrolyzing GTP, and could thereby produce 
or contribute to the desensitization response.   
 
Our results are consistent with the notion that there could be numerous 
pathways and alterations in gene expression that are altered by treatment 
with atypical antipsychotics (Ko, et al., 2006).  We also found that treatment 
with atypical antipsychotics increased RGS7 mRNA and protein levels in cells 
and in vivo is dependent on activation of the JAK-STAT pathway. We 
proposed that increases in membrane bound RGS7 protein can accelerate 
hydrolysis of activated Gαq/11 that results in desensitization of 5-HT2A receptor 
signaling. RGS7 like other regulatory proteins is an unstable protein and is 
rapidly degraded by the ubiquitin−proteasome pathway.  Thus, it would be 
important to measure the GAP activity and half-life of RGS7 proteins to 
further confirm that the atypical antipsychotic-induced increase in RGS7 
expression is indeed occurs. The GAP activity of RGS7 can be measured by 
multiple mechanisms as reported in literature such as an in vitro GAP assay 
using radioisotope ([γ-32P] GTP) (Shuey, et al., 1998) and a direct 
fluorescence-based assay for RGS domain GAP activity (Willard, et al., 
2005).  In addition, it has been extensively reported that interaction with 
proteins such as polycystin, Gβ5, and 14-3-3 regulate the stability and activity 
of RGS7 proteins.  RGS7 contains a putative coiled-coil structure flanked by 
two potential PEST sequences (Rechsteiner, 1990) that contain minimal 
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consensus phosphorylation sites necessary for degradation. Polycystin by 
directly binding to a PEST sequence-containing domain of RGS7 inhibits the 
phosphorylation-dependent ubiquitination and subsequent degradation of 
RGS7 and thereby modulate its functional activity. It has also been suggested 
that polycystin may relocalize RGS7 to a subcellular compartment away from 
ubiquitin-protein ligases responsible for recognition and targeting of RGS7 to 
the proteasome (Kim, et al., 1999).  In addition, association of RGS7 with Gβ5 
is reported to stabilize the protein and enhance the GAP function of RGS7 on 
acceleration of GIRK channel kinetics (Kovoor, et al., 2000).  
Furthermore, RGS7 contains a functional 14-3-3-binding site within the 
RGS domain and a significant fraction of RGS7 normally exists bound to 
endogenous 14-3-3. The binding of RGS7 to 14-3-3 is phosphorylation-
dependent; the primary 14-3-3-binding site in RGS7 involves serine 434, a 
region implicated in interactions with Gα  subunits. It has been reported that 
phosphorylation and subsequent interaction with 14-3-3 results in a 
progressive decline in the GAP activity of RGS7 proteins (Benzing, et al., 
2000). Interestingly, previous reports have suggested that  tumor necrosis 
factor α (TNF)  by binding to its receptor TNFR1  induces activation of the 
JAK-STAT pathway (Guo, et al., 1998). Additionally, it has been 
demonstrated that treatment of mice with TNF-α inhibits the phosphorylation 
of serine 434 and completely abrogated the interaction of RGS7 with 14-3-3. 
In fact, RGS-mediated deactivation kinetics of G protein-coupled inwardly 
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rectifying K+ channels (GIRKs) in a Xenopus co-expression system was 
slowed by microinjections of 14-3-3 protein (Benzing, et al., 2002).   
Thus, it would be interesting to know if atypical antipsychotic-induced 
activation of the JAK-STAT pathway affects interactions of RGS7 with any of 
these proteins thereby affecting its GAP activity and stability. Although, a 
RGS7 knock-out animal model is not available, using a siRNA approach to 
decrease RGS7 expression, it can be determined whether increased RGS7 is 
necessary for atypical antipsychotics-induced desensitization of 5-HT2A 
receptors signaling in cells. This can be further examined in animals using a 
viral vector to deliver siRNA in the brain.   
In the present study, we reported that treatment with olanzapine 
increases STAT3 binding to its consensus element at 2.34kb upstream from 
transcription start site on the putative RGS7 promoter region. STAT3 binding 
to the putative RGS7 promoter region can be further verified with electro-
mobility shift assay (EMSA). The advantages of studying DNA: protein 
interactions by EMSA are that the source of the DNA-binding protein may be 
a crude nuclear or whole cell extract rather than a purified preparation. Gel 
shift assays can be used qualitatively to identify sequence-specific DNA-
binding proteins (such as STAT3) in crude lysates. Although, transcriptional 
activity of STAT3 has been extensively reported for various genes (Aaronson 
and Horvath, 2002;Kisseleva, et al., 2002;Schindler, 2002), STAT3 has not 
been identified as a transcription factor for RGS7. STAT3-mediated regulation 
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of gene expression is associated with the presence of the consensus element 
TTCN2-4GAA upstream of the transcription start site (Ehret, et al., 
2001;Wrighting and Andrews, 2006). Genomic sequence analysis of rat 
RGS7 revealed that there are multiple sets of TTCN2-4GAA sequences. Thus, 
it is possible that STAT3 is a transcription factor for the RGS7 promoter. The 
promoter region of RGS7 is not yet identified, however, it is usually present 
upstream of the transcription start site consistent with our identified STAT3 
binding site 2.34kb upstream from the transcription initiation site. We can 
further confirm the transcriptional activity of STAT3 on RGS7 promoter by 
using a reporter gene assay. This can be done by linking the identified 
putative promoter sequence to an easily detectable reporter gene such as 
that encoded for the firefly luciferase. Although, STAT3 knock-out is lethal, a 
conditional knock-out can be used to further confirm the role of STAT3 in 
regulating RGS7 expression.  
A previous study has examined the impact of olanzapine on changes in 
gene expression in the frontal cortex of rats treated with olanzapine (2 mg/kg 
per day for 21 days) (Fatemi, et al., 2006). In this study, 31 genes were down-
regulated and 38 genes were found to be upregulated including one RGS 
protein, RGS19. RGS7 was not identified as one of the upregulated genes in 
this study as expected since in our previous study, we did not find a 
significant increase in RGS7 protein levels with the 2 mg/kg dose of 
olanzapine (Muma, et al., 2007). Thus, a microarray study with a higher dose 
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of olanzapine (10mg/kg) based on our previous results (chapter V) can be 
useful in identifying changes in gene expression with chronic olanzapine 
treatment. The use of a higher dose of olanzapine is also supported by its 
half-life which in  rat brain is 2.5 to 5.1 hours,  much longer than the 20 to 54 
hour half-life of olanzapine in humans (Aravagiri, et al., 1999). Based on our 
present findings, we may identify alterations in one or more proteins in the 5-
HT2A receptor signaling pathway by olanzapine and possibly regulated by 
STAT3. 
In the present study, we found that treatment with olanzapine did not 
affect the basal levels of oxytocin, ACTH and corticosterone but decreased 
DOI-stimulated release of oxytocin, ACTH, and corticosterone which is  
consistent with previous reports (Scheepers, et al., 2001;Wik, 
1995;Tepavcevic, et al., 1994). However, unlike in the frontal cortex where 
preinjections of AG490 significantly attenuated the olanzapine-induced 
decrease in 5-HT2A receptor-mediated PLC activity, olanzapine-induced 
desensitization of 5-HT2A receptor stimulated plasma hormone release was 
not affected by inhibition of the JAK-STAT pathway. We did however find a 
selective dose-dependent inhibitory effect of AG490 on 5-HT2A receptor- 
stimulated oxytocin and corticosterone release whereas ACTH release was 
not affected. Although, JAK2 expression in the frontal cortex is almost twice 
the levels in the hypothalamus as reported previously (Berhow et al., 1996), 
dose-dependent inhibition of oxytocin and corticosterone release by AG490 
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suggests that JAK2 expression was not a factor in its inability to attenuate the 
desensitization response in the release of various hormones. Furthermore, 
the effect of JAK-STAT inhibition on 5-HT2A receptor-stimulated release of 
oxytocin and corticosterone suggests that the JAK-STAT may be directly 
involved in release of these hormones. Since, in the present study we injected 
AG490 systemically (s.c), a direct injection locally in  the PVN would provide 
further details of JAK-STAT impact on release of these hormones.  
In addition, antipsychotic drugs are reported to regulate gene 
expression, including those involved in regulation of hypothalamic-pituitary-
adrenal (HPA) axis, whose activity is frequently disturbed in schizophrenic 
patients. Recently, it has been reported that a clozapine-induced decrease in 
basal activity of the CRH promoter in Neuro-2A cells stably transfected with 
hCRH-CAT reporter construct is dependent on the activation of  PI3-K/Akt 
pathway (Basta-Kaim, et al., 2006). Although, this report does highlight a role 
of signaling cascades on CRH promoter activity, it is not yet understood how 
treatment with atypical antipsychotics decrease cortisol levels in 
schizophrenic patients (Scheepers, et al., 2001;Wik, 1995;Tepavcevic, et al., 
1994). Furthermore, in contrast to this study, we did not find any effect of 
JAK-STAT activation on ACTH release, which is regulated by CRH. In fact, 
we found a dose-dependent inhibitory effect of AG490 on oxytocin and 
corticosterone release. Since STAT3 has been extensively characterized as 
transcription factor for variety of genes, it would be interesting to investigate if 
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oxytocin and corticosterone regulating genes also contain STAT3 consensus 
elements. Since, both clozapine and olanzapine have similar chemical 
structure (thienobenzodiazepine), it would also be important to determine the 
role of activation of the JAK-STAT pathway in the desensitization response 
induced by atypical antipsychotics, by using a compound with a different 
chemical structure such as risperidone which contains benzisoxazole and 
piperidine functional groups. 
Overall, these results suggest that atypical antipsychotic 
(thienobenzodiazepine) treatment desensitizes 5-HT2A receptor function and 
increases expression of RGS7 mRNA and protein levels. Antagonism of 5-
HT2A receptors mediates the activation of the JAK-STAT pathway and is 
sufficient for subsequent increase in RGS7 mRNA and protein levels.  
Treatment with olanzapine increased STAT3 binding to its consensus 
element at 2.34kb upstream from transcription start site of RGS7 putative 
promoter region. Thus, STAT3 binding to the RGS7 gene along with an 
increase in mRNA levels of RGS7 suggest the possibility that STAT3 could be 
a transcription factor for RGS7. 
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